Fixation and Revision of 923 Scheduled Formulations and Retail prices of 65 formulations approved in 122 Authority meeting

रजिस्ट्री स.ं डी.एल.- 33004/99 REGD. No. D. L.-33004/99 सी.जी.-डी.एल.-अ.-30032024-253444 CG-DxLx-xEG-I3D0H0x3x2x0 24-253444 xxxGIDExxx असाधारण EXTRAORDINARY भाग II—खण् ड 3—उप-खण्ड (ii) PART II—Section 3—Sub-section (ii) प्राजधकार स ेप्रकाजित PUBLISHED BY AUTHORITY स.ं 1478] नई दिल्ली, मगं लवार, मार् च26, 2024/र्त्रै 6, 1946 No. 1478] NEW DELHI, TUESDAY, MARCH 26, 2024/CHAITRA 6, 1946 ( ) ( ) नई दिल्ली, 26 मार्,च 2024 का. आ. 1547(अ).— , नवम्बर 4, 6, 10, 11, 14, 16, 17 18 a b 2263 GI/2024 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] @ 0.00551% बढाकर (0.00551% (1) (2) (3) (4) (5) (6a) (6b) 1 मर्कैपटॉप्यरू िन गोली 50 मिलीग्राि 1 गोली 5.26 4663(अ) 25-10-23 2 अबार्कवीि गोली 300 मिलीग्राि 1 गोली 48.59 1574(अ) 31-03-23 अबार्कवीि (ए) + गोली 600 मिलीग्राि (ए) 4663(अ) 3 1 गोली 72.32 25-10-23 +300 मिलीग्राि (बी) लाममवडु ाइन (बी) 4 एमिटाजोलामाइड गोली 250 मिलीग्राि 1 गोली 4.06 4663(अ) 25-10-23 5 dSIlwy 250 fexzk- 1 dSIlwy 5.05 4663(अ) 25-10-23 ,afVªd dksfVM xksyh 75 6 1 xksyh 0.35 4663(अ) 25-10-23 fexkz- dkWuosu'kuy@bQsjoslsVa 4663(अ) 7 @fMLijflcy@,afVªd 1 xksyh 0.71 25-10-23 dksfVM xksyh 150 fexkz- पाउडर फोर इजं ेक्शन 0.5 4663(अ) 8 एक्टटनोमाइमिन डी 1 वाइल 331.03 25-10-23 मिलीग्राि 9 ऐिीटलोववि गोली 400 मिलीग्राि 1 गोली 13.66 4663(अ) 25-10-23 10 ऐिीटलोववि गोली 200 मिलीग्राि 1 गोली 7.61 1574(अ) 31-03-23 पाउडर फोर इजं ेक्शन 250 4663(अ) 11 ऐिीटलोववि 1 वाईल 426.40 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 500 4663(अ) 12 ऐिीटलोववि 1 वाईल 528.45 25-10-23 मिलीग्राि 13 ऐिीटलोववि गोली 800 मिलीग्राि 1 गोली 37.66 1574(अ) 31-03-23 14 ऐिीटलोववि ओइटं िटें 3% 1 ग्राि 11.67 1574(अ) 31-03-23 vksjy fyD;bw ZM 400 15 1 fefy- 1.36 4663(अ) 25-10-23 fexkz-@5 fefy- 16 एडने ोिाइन इजं ेक्शन 3 मिलीग्राि/मि.ली. 1 मि.ली. 92.86 4663(अ) 25-10-23 17 एड्रने ालाईन इजं ेक्शन1मिलीग्राि/मि.ली. 1 मि.ली. 12.23 1574(अ) 31-03-23 vksjy fyD;bw ZM 200 18 1 fefy- 1.79 1577(अ) 31-03-23 fexkz-@5 fefy- 19 xksyh 400 fexzk- 1 xksyh 7.04 1577(अ) 31-03-23 20 च्बेवेबल xksyh 400 1 xksyh 8.13 4663(अ) 25-10-23 fexkz- 21 एलोप्यूररनॉल गोली 300 मिलीग्राि 1 गोली 5.63 4663(अ) 25-10-23 22 एलोप्यूररनॉल गोली 100 मिलीग्राि 1 गोली 1.89 1574(अ) 31-03-23 इजं ेक्शन 0.5 1574(अ) 23 अलप्रोस्ट्टैजडल 1 मि.ली. 6106.75 31-03-23 मिलीग्राि/मि.ली. इंजेटशन 250 4663(अ) 24 एजमकाजसन 1 मम.ली. 54.17 25-10-23 ममलीग्राम /मम.ली.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 3 25 ऐजमयोडैरोन गोली 200 मिलीग्राि 1 गोली 11.51 1574(अ) 31-03-23 26 ऐजमयोडैरोन गोली 100 मिलीग्राि 1 गोली 6.14 1574(अ) 31-03-23 इजं ेक्शन 50 1574(अ) 27 ऐजमयोडैरोन 1 मि.ली. 21.13 31-03-23 मिलीग्राि/मि.ली. 28 ऐजमररजप्टलाइन गोली 50 मिलीग्राि 1 गोली 5.99 4663(अ) 25-10-23 29 ऐजमररजप्टलाइन गोली 75 मिलीग्राि 1 गोली 5.45 4663(अ) 25-10-23 30 ऐजमररजप्टलाइन गोली 25 मिलीग्राि 1 गोली 2.49 4663(अ) 25-10-23 31 ऐजमररजप्टलाइन गोली 10 मिलीग्राि 1 गोली 2.39 4663(अ) 25-10-23 32 अम्लोजडजपन गोली 2.5 मिलीग्राि 1 गोली 1.79 1574(अ) 31-03-23 33 अम्लोजडजपन गोली 5 मिलीग्राि 1 गोली 2.50 1574(अ) 31-03-23 34 अम्लोजडजपन गोली 10 मिलीग्राि 1 गोली 5.45 4663(अ) 25-10-23 35 एमोजससजसजलन कैप्सूल 250 मिलीग्राि 1 कैप्सूल 2.44 1574(अ) 31-03-23 36 एमोजससजसजलन कैप्सूल 500 मिलीग्राि 1 कैप्सूल 7.36 4663(अ) 25-10-23 vksjy fyD;bw ZM 250 4663(अ) 37 1 fefy- 1.56 25-10-23 fexkz-@5 fefy- (पी) इंजेटशन र्के मलए 38 एमोजससजसजलन पाउडि 250 1 वाईल 24.79 1578(अ) 31-03-23 ममलीग्राम इंजेटशन र्के मलए 39 एमोजससजसजलन पाउडि 500 1 वाईल 54.65 4663(अ) 25-10-23 ममलीग्राम ओिल मलक्टवड 40 एमोजसससीजलन 125 ममलीग्राम 1 मम.ली. 1.02 1579(अ) 31-03-23 /5 मम.ली. (पी) एमोजससजसजलन (ए) पाउडर फोर इजं ेक्शन 1 ग्राि 41 +सलैवुलाजनक एजसड (ए) +200 मिलीग्राि 1 वाईल 140.66 4663(अ) 25-10-23 (बी) (बी) पाउडर फोर इजं ेक्शन 500 एमोजससजसजलन (ए) + 42 मिलीग्राि (ए) + 100 1 वाईल 101.35 4663(अ) 25-10-23 सलैवुलाजनक एजसड (बी) मिलीग्राि (बी) ड्राई मसरप 125 मिलीग्राि एमोजससजसजलन (ए) + 43 (ए) + 31.25 1 मि.ली. 2.05 1574(अ) 31-03-23 सलैवुलाजनक एजसड (बी) (बी)/5मिली..(पी) एमोजससजसजलन (ए) गोली 500 मिलीग्राि (ए) 44 +सलैवुलाजनक एजसड 1 गोली 18.30 4663(अ) 25-10-23 + 125 मिलीग्राि (बी) (बी) ओरल मलमक्वड 200 एमोजससजसजलन (ए) + मिलीग्राि (ए) + 28.5 45 1 मि.ली. 2.02 4663(अ) 25-10-23 सलैवुलाजनक एजसड (बी) मिलीग्राि (बी)/5 मि.ली.(पी) ,EQksVsfjflu ch&dkWuous 'kuy 46 batSD'ku 50 fexkz-/ 1 वाईल 227.40 1577(अ) 31-03-23 वाईल4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] पाउडर फोर इजं ेक्शन 500 1574(अ) 47 एम्पीजसलीन 1 वाईल 14.25 31-03-23 मिलीग्राि आटेमेडर (ए) + गोली 40 मिलीग्राि (ए) + 1574(अ) 48 1 गोली 18.04 31-03-23 ल्यूमेफैंररन (बी) 240 मिलीग्राि (बी) आटेमेडर (ए) + गोली 80 मिलीग्राि (ए) + 4663(अ) 49 1 गोली 25.51 25-10-23 ल्यूमफैंररन (बी) 480 मिलीग्राि (बी) आटेमेडर (ए) + गोली 20 मिलीग्राि (ए) + 4663(अ) 50 1 गोली 12.65 25-10-23 ल्यूमफैंररन (बी) 120 मिलीग्राि (बी) पाउडर फोर इजं ेक्शन 60 4663(अ) 51 आर्टचसुनेट 1 वाईल 244.73 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 120 4663(अ) 52 आर्टचसुनेट 1 वाईल 454.44 25-10-23 मिलीग्राि कोम्बी पैक (ए + बी) 1 आटेसुनेट (ए) + गोली 50 मिलीग्राि (ए) + 1 53 सल्फैडॉजससन - 1 कोम्बी पकै 22.55 4663(अ) 25-10-23 गोली (500 मिलीग्राि + 25 पाइररमेथामाइन (बी) मिलीग्राि) (बी) 54 xksyh 100 fexzk- 1 xksyh 0.24 4663(अ) 25-10-23 55 xksyh 500 fexzk- 1 xksyh 1.48 1577(अ) 31-03-23 गोली 300 मिलीग्राि (ए) एटाजानवीर (ए) + 56 + गोली 100 मिलीग्राि 1 गोली 99.83 1574(अ) 31-03-23 ररटोनवीर (बी) (बी) 57 एटोरवास्ट्टेरटन गोली 40 मिलीग्राि 1 गोली 19.30 4663(अ) 25-10-23 58 एटोरवास्ट्टेरटन गोली 20 मिलीग्राि 1 गोली 12.56 4663(अ) 25-10-23 59 एटोरवास्ट्टेरटन गोली 10 मिलीग्राि 1 गोली 4.94 1574(अ) 31-03-23 60 एटोरवास्ट्टेरटन गोली 80 मिलीग्राि 1 गोली 40.58 4663(अ) 25-10-23 batSD'ku 10 fexkz- 61 1 fefy- 16.98 4663(अ) 25-10-23 @fefy- 62 एरोजपन ड्रोप 1% 1 मि.ली. 3.94 4663(अ) 25-10-23 63 एरोजपन ओइटं ्िटें 1% 1 ग्राि 4.71 4663(अ) 25-10-23 इजं ेक्शन 0.6 1574(अ) 64 एरोजपन 1 मि.ली. 4.57 31-03-23 मिलीग्राि/मि.ली. 65 अजैजथयोप्राइन गोली 50 मिलीग्राि 1 गोली 11.26 4663(अ) 25-10-23 गोली 25 ममलीग्राम 1578(अ) 66 अजैजथयोप्राइन 1 गोली 7.24 31-03-23 (पी) पाउडर फोर इजं ेक्शन 500 1574(अ) 67 एजजथ्रोमाइजसन 1 वाईल 204.72 31-03-23 मिलीग्राि 68 एजजथ्रोमाइजसन गोली 250 मिलीग्राि 1 गोली 11.65 4663(अ) 25-10-23 69 एजजथ्रोमाइजसन गोली 500 मिलीग्राि 1 गोली 23.57 4663(अ) 25-10-23 ओरल मलमक्वड 200 4663(अ) 70 एजजथ्रोमाइजसन 1 मि.ली. 3.41 25-10-23 मिलीग्राि/5 मि(पी) .ली. 71 dSIlwy 250 fexzk- 1 dSIlwy 10.62 4663(अ) 25-10-23 गोली 1000 4663(अ) 72 एजजथ्रोमाइजसन 1 गोली 57.78 25-10-23 ममलीग्राम 73 एजजथ्रोमाइजसन र्कैप्िलू 500 1 कैप्सूल 19.03 2124(अ) 04-05-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 5 ममलीग्राम 74 बैसलोफेन गोली 20 मिलीग्राि 1 गोली 16.28 1574(अ) 31-03-23 75 बैसलोफेन गोली 10 मिलीग्राि 1 गोली 11.90 4663(अ) 25-10-23 76 बैसलोफेन गोली 5 मिलीग्राि 1 गोली 6.37 4663(अ) 25-10-23 बेंडामुस्ट्टाइन इजं ेक्शन 100 मिलीग्राि / 1574(अ) 77 1 वाईल 4946.80 31-03-23 हाइड्रोसलोराइड वाईल 78 बेंजोइल पेरोससाइड जेल 2.5 1 ग्राि 3.62 1574(अ) 31-03-23 79 बेंजोइल पेरोससाइड जेल 5 % 1 ग्राि 7.97 1574(अ) 31-03-23 80 बेंजोइल पेरोससाइड जेल 3.5% 1 ग्राम 10.11 1578(अ) 31-03-23 batSD'ku 4 fexzk- 81 1 fefy- 4.74 1577(अ) 31-03-23 @fefy- 82 बेटामेथासोन वैलेरेट क्रीि 0.05% 1 ग्राि 0.67 1574(अ) 31-03-23 83 बेटामेथासोन वैलेरेट क्रीि 0.1% 1 ग्राि 1.04 1574(अ) 31-03-23 84 बाइकलुटामाइड गोली 50 मिलीग्राि 1 गोली 43.30 1574(अ) 31-03-23 85 जबसकॉडल गोली 5 मिलीग्राि 1 गोली 1.17 4663(अ) 25-10-23 86 जबसकॉडल सपोमसटरी 5 मिलीग्राि 1 सपोमसटरी 9.98 4663(अ) 25-10-23 पाउडर फोर इजं ेक्शन 15 1574(अ) 87 ब्लोमाइजसन 1 वाईल 677.41 31-03-23 यूमनट्स पाउडर फोर इजं ेक्शन 2 4663(अ) 88 बोटेजोजमब 1 वाईल 5260.50 25-10-23 मिलीग्राि jls fijVs kWjh lksyq'ku 4663(अ) 89 QkWj ;wt bu uscyq kbtj 1 fefy- 11.90 25-10-23 0-5 fexkz-@fefy- jls fijVs kWjh lksyq'ku 1577(अ) 90 QkWj ;wt bu uscyq kbtj 1 fefy- 13.14 31-03-23 1 fexkz-@fefy- batSD'ku 0-5% ds lkFk 91 1 fefy- 7.39 4663(अ) 25-10-23 7-5% Xywdkst 92 batSD'ku 0-50% 1 fefy- 4.42 4663(अ) 25-10-23 93 batSD'ku 0-25% 1 fefy- 2.83 4663(अ) 25-10-23 94 बुप्रेनॉर्फचन गोली (सब(मलंग िं ल- 0.4 1 गोली 9.43 4663(अ) 25-10-23 मिलीग्राि गोली (मलंग िं ल-सब) 2 4663(अ) बुप्रेनॉर्फचन (ए) 95 मिलीग्राि + (ए) 0.5 1 गोली 36.98 25-10-23 +नालॉससोन (बी) मिलीग्राि (बी) गोली 0.4 )मलंग िं ल-सब) 4663(अ) बुप्रेनॉर्फचन (ए) 96 मिलीग्राि (ए) + 0.1 1 गोली 11.82 25-10-23 +नालॉससोन (बी) मिलीग्राि (बी) ओरल मलमक्वड 20 1574(अ) 97 कैफीन 1 मि.ली. 245.68 31-03-23 मिलीग्राि/मि.ली. batSD'ku 20 fexkz- 98 1 fefy- 250.50 1577(अ) 31-03-23 @fefy- yks'ku ¼vkbZih ds 99 1 fefy- 0.95 1577(अ) 31-03-23 vulq kj½ 100 कैजल्ियम फोजलनेट गोली 15 मिलीग्राि 1 गोली 47.54 4663(अ) 25-10-23 101 कैपेजसटाबाइन गोली 500 मिलीग्राि 1 गोली 112.73 4663(अ) 25-10-23 िोडीफाइड ररलीज – गोली 4663(अ) 102 काबाचमेिापाइन 1 गोली 2.40 25-10-23 200 मिलीग्राि6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] िोडीफाइड ररलीज– गोली 1574(अ) 103 काबाचमेिापाइन 1 गोली 4.66 31-03-23 400 मिलीग्राि 104 काबाचमेिापाइन गोली 400 मिलीग्राि 1 गोली 3.55 1574(अ) 31-03-23 105 काबमच ेजपाइन गोली 200 मिलीग्राि 1 गोली 1.57 4663(अ) 25-10-23 ओरल मलमक्वड 100 1574(अ) 106 काबचमेजपाइन 1 मि.ली. 0.31 31-03-23 मिलीग्राि/5मि.ली. (पी) 107 काबचमेजपाइन गोली 100 मिलीग्राि 1 गोली 1.07 4663(अ) 25-10-23 108 कार्बचमाजोल गोली 10 मिलीग्राि 1 गोली 4.26 1574(अ) 31-03-23 109 कार्बचमाजोल गोली 5 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23 110 कार्बचमाजोल गोली 20 मिलीग्राि 1 गोली 13.87 4663(अ) 25-10-23 इजं ेक्शन 10 4663(अ) 111 काबोप्लैरटन 1 मि.ली. 59.07 25-10-23 मिलीग्राि/मि.ली. काबोजससजमथाइल 4663(अ) 112 ड्रोप 0.5% 1 मि.ली. 12.30 25-10-23 सेलुलोि काबोजससजमथाइल 1574(अ) 113 ड्रोप 1% 1 मि.ली. 16.58 31-03-23 सेलुलोि 114 सेफैड्रोजसल गोली 500 मिलीग्राि 1 गोली 4.47 1574(अ) 31-03-23 ओरल मलमक्वड 125 1574(अ) 115 सेफैड्रोजसल 1 मि.ली. 0.68 31-03-23 मिलीग्राि/5मि.ली. (पी) 116 सेदफजससम गोली 400 मिलीग्राि 1 गोली 22.10 4663(अ) 25-10-23 117 सेदफजससम गोली 200 मिलीग्राि 1 गोली 9.78 4663(अ) 25-10-23 ओरल मलमक्वड 50 4663(अ) 118 सेदफजससम 1 मि.ली. 1.63 25-10-23 मिलीग्राि/5 मि.ली. (पी) ओरल मलमक्वड 100 4663(अ) 119 सेदफजससम 1 मि.ली. 2.39 25-10-23 मिलीग्राि/5मि.ली.(पी) 120 dSIlwy 200 fexzk- 1 dSIlwy 14.68 4663(अ) 25-10-23 पाउडर फोर इंिेसिन 4663(अ) 121 सेफोटाजससम 1 वाईल 17.72 25-10-23 250 जमलीग्राम पाउडर फोर इजं ेक्शन 500 4663(अ) 122 सेफोटाजससम 1 वाईल 24.38 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 1000 1574(अ) 123 सेफोटाजससम 1 वाईल 39.96 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 1000 1574(अ) 124 सेफ्टाजजडाइम 1 वाईल 227.02 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 250 4663(अ) 125 सेफ्टाजजडाइम 1 वाईल 79.07 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 500 4663(अ) 126 सेजफ्रयाससोन 1 वाईल 50.28 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 250 1574(अ) 127 सेजफ्रयाससोन 1 वाईल 28.34 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 1000 1574(अ) 128 सेजफ्रयाससोन 1 वाईल 62.38 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 2000 1574(अ) 129 सेजफ्रयाससोन 1 वाईल 138.12 31-03-23 मिलीग्राि गोली 500 1578(अ) 130 सेफ्यूरोजससम 1 गोली 51.43 31-03-23 ममलीग्राम[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 7 इंजेटशन 1500 1579(अ) 131 सेफ्रॉजससम 1 वाईल 338.76 31-03-23 ममलीग्राम 132 सेटीररजजन गोली 10 मिलीग्राि 1 गोली 1.88 1574(अ) 31-03-23 ओरल मलमक्वड 5 1574(अ) 133 सेटीररजजन 1 मि.ली. 0.66 31-03-23 मिलीग्राि/5 मि(पी).ली. 134 सलोरोदिन गोली 150 मिलीग्राि 1 गोली 1.17 4663(अ) 25-10-23 ओरल मलमक्वड 50 4663(अ) 135 सलोरोदिन 1 मि.ली. 0.34 25-10-23 मिलीग्राि/5मि.ली. 136 कॉलेकैजल्सफेरॉल गोली 1000 आईय ू 1 गोली 4.31 4663(अ) 25-10-23 ओरल मलमक्वड 400 1574(अ) 137 कॉलेकैजल्सफेरॉल 1 मि.ली. 2.61 31-03-23 आईय ू/मि.ली. सॉमलड ओरल डोज़ फॉि म 1574(अ) 138 कॉलेकैजल्सफेरॉल 1 गोली 22.50 31-03-23 60000 आईयू गोली 139 dSIlwy 60000 vkbZ;w 1 dSIlwy 30.78 4663(अ) 25-10-23 140 dSIlwy 1000 vkbZ;w 1 dSIlwy 4.89 4663(अ) 25-10-23 ििै े ग्रेनअु ेि/ 141 कॉलेकैजल्सफेरॉल पाउडि/60000 1 ग्राम 33.98 1578(अ) 31-03-23 आईय ू 142 जसप्रोफ्लोससाजसन गोली 250 मिलीग्राि 1 गोली 2.20 4663(अ) 25-10-23 143 जसप्रोफ्लोससाजसन गोली 500 मिलीग्राि 1 गोली 4.25 4663(अ) 25-10-23 144 जसप्रोफ्लोससाजसन ड्रॉप 0.3 % 1 मि.ली. 1.54 4663(अ) 25-10-23 इजं ेक्शन 200 1574(अ) 145 जसप्रोफ्लोससाजसन 1 मि.ली. 0.20 31-03-23 मिलीग्राि/100मि.ली. vksjy fyD;bw ZM 250 1577(अ) 146 1 fefy- 0.74 31-03-23 fexkz-@5 fefy- (पी) 147 जसप्रोफ्लोससाजसन ओइटं िटें 0.3% 1 ग्राि 1.29 4663(अ) 25-10-23 148 जसस्ट्प्लैरटन इजं ेक्शन 1 मिलीग्राि/मि.ली. 1 मि.ली. 7.09 4663(अ) 25-10-23 149 सलैररथ्रोमाइजसन गोली 250 मिलीग्राि 1 गोली 23.89 1574(अ) 31-03-23 150 सलैररथ्रोमाइजसन गोली 500 मिलीग्राि 1 गोली 39.84 4663(अ) 25-10-23 ओरल मलमक्वड 125 4663(अ) 151 सलैररथ्रोमाइजसन 1 मि.ली. 4.61 25-10-23 मिलीग्राि/5 मि.ली. (पी) 152 कसलंडामाइजसन कैप्सूल 150 मिलीग्राि 1 कैप्सूल 16.36 4663(अ) 25-10-23 153 कसलंडामाइजसन कैप्सूल 300 मिलीग्राि 1 कैप्सूल 28.37 4663(अ) 25-10-23 154 कसलंडामाइजसन गोली 300 मिलीग्राि 1 गोली 18.97 1574(अ) 31-03-23 इंजेटशन 150 155 जसलन्डामाईजसन 1 मम.ली. 60.60 1579(अ) 31-03-23 ममलीग्राम / मम.ली. 156 सलोबाजम गोली 5 मिलीग्राि 1 गोली 5.73 4663(अ) 25-10-23 157 सलोबाजम गोली 10 मिलीग्राि 1 गोली 9.84 1574(अ) 31-03-23 158 सलोफाजजमाइन कैप्सूल 100 मिलीग्राि 1 कैप्सूल 3.98 2540(अ) 08-06-238 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 159 सलोफाजजमाइन कैप्सूल 50 मिलीग्राि 1 कैप्सूल 2.11 2540(अ) 08-06-23 160 सलोमीफीन साइरेट कैप्सूल 50 मिलीग्राि 1 कैप्सूल 27.37 2124(अ) 04-05-23 161 सलोमीफीन साइरेट कैप्सूल 100 मिलीग्राि 1 कैप्सूल 51.14 2124(अ) 04-05-23 162 सलोमीफेनेजसरेट गोली 100 मिलीग्राि 1 गोली 13.95 4663(अ) 25-10-23 163 सलोमीफेनेजसरेट गोली 50 मिलीग्राि 1 गोली 8.84 4663(अ) 25-10-23 164 xksyh 10 fexkz- 1 xksyh 2.85 4663(अ) 25-10-23 165 xksyh 25 fexkz- 1 xksyh 6.22 1577(अ) 31-03-23 166 xksyh 75 fexkz- 1 xksyh 16.46 4663(अ) 25-10-23 167 सलोनाजेपम गोली 0.25 मिलीग्राि 1 गोली 2.02 4663(अ) 25-10-23 168 सलोनाजेपम गोली 0.5 मिलीग्राि 1 गोली 3.45 1574(अ) 31-03-23 169 सलोनाजेपम गोली 1 मिलीग्राि 1 गोली 4.77 4663(अ) 25-10-23 170 सलोजपडोग्रेल गोली 75 मिलीग्राि 1 गोली 6.66 1574(अ) 31-03-23 171 सलोजपडोग्रेल गोली 150 मिलीग्राि 1 गोली 20.48 1574(अ) 31-03-23 172 yks'ku 1% 1 fefy- 3.89 1577(अ) 31-03-23 173 isljh 100 fexzk- 1 isljh 10.01 1577(अ) 31-03-23 174 MªksIl 1% 1 fefy- 3.37 1577(अ) 31-03-23 175 Øhe 1% 1 xkze 3.00 1577(अ) 31-03-23 176 सलोजापाइन गोली 25 मिलीग्राि 1 गोली 2.78 1574(अ) 31-03-23 177 सलोजापाइन गोली 50 मिलीग्राि 1 गोली 5.19 1574(अ) 31-03-23 178 सलोजापाइन गोली 100 मिलीग्राि 1 गोली 8.45 1574(अ) 31-03-23 179 कोल्सीजसन गोली 0.5 मिलीग्राि 1 गोली 3.26 1574(अ) 31-03-23 xksyh 400 fexkz- ¼,½ $ 4663(अ) 180 1 xksyh 0.90 25-10-23 80 fexzk- ¼ch½ को-ररमोससाजोल गोली 800 मिलीग्राि (ए) 181 [सल्फामेथोससाजोल 1 गोली 2.30 4886(अ) 10-11-23 (ए)+राइमेथोजप्रम (बी)] + 160 मिलीग्राि (बी) vksjy fyD;bw ZM 200 4663(अ) 182 fexzkz-¼,½ $ 40 fexkz- 1 fefy- 0.35 25-10-23 ¼ch½@5 fefy- पाउडर फोर इजं ेक्शन 500 1574(अ) 183 साईसलोफॉस्ट्फोमाईड 1 वाईल 73.48 31-03-23 मिलीग्राि 184 xksyh 50 fexkz- 1 xksyh 3.73 1577(अ) 31-03-23 185 साइसलोसेरीन कैप्सूल 250 मिलीग्राि 1 कैप्सूल 59.19 4663(अ) 25-10-23 186 xksyh 250 fexzk- 1 xksyh 46.01 1577(अ) 31-03-23 187 साइसलोस्ट्पोररन कैप्सूल 25 मिलीग्राि 1 कैप्सूल 28.04 1574(अ) 31-03-23 ओरल मलमक्वड 100 1574(अ) 188 साइसलोस्ट्पोररन 1 मि.ली. 80.58 31-03-23 मिलीग्राि/मि.ली. (पी) 189 साइसलोस्ट्पोररन कैप्सूल 50 मिलीग्राि 1 कैप्सूल 55.11 4663(अ) 25-10-23 190 साइसलोस्ट्पोररन कैप्सूल 100मिलीग्राि 1 कैप्सूल 103.12 4663(अ) 25-10-23 इजं ेक्शन 1000 4663(अ) 191 साइटोजसनएराजबनोसाइड 1 वाईल 1130.33 25-10-23 मिलीग्राि/वाईल 192 साइटोजसनएराजबनोसाइड इजं ेक्शन 100 मिलीग्राि / 1 वाईल 139.59 1574(अ) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 9 वाईल इजं ेक्शन 500 मिलीग्राि/ 1574(अ) 193 साइटोजसनएराजबनोसाइड 1 वाईल 536.33 31-03-23 वाईल 194 डबीगारान कैप्सूल 110 मिग्रा. 1 कैप्सूल 31.81 2822(अ) 28-06-23 195 डबीगारान कैप्सूल 150 मिग्रा. 1 कैप्सूल 35.59 2822(अ) 28-06-23 पाउडर फोर इजं ेक्शन 200 4663(अ) 196 डकारबाजीन 1 वाईल 381.75 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 500 4663(अ) 197 डकारबाजीन 1 वाईल 518.83 25-10-23 मिलीग्राि 198 डेकलाटसवीर गोली 60 मिलीग्राि 1 गोली 199.97 4663(अ) 25-10-23 199 डापसोन गोली 100 मिलीग्राि 1 गोली 0.41 2540(अ) 08-06-23 200 िारुनवीर गोली 600 मिलीग्राि 1 गोली 154.44 4663(अ) 25-10-23 201 डेससामेथासोन गोली 0.5 मिलीग्राि 1 गोली 0.22 1574(अ) 31-03-23 202 डेससामेथासोन गोली 4 मिलीग्राि 1 गोली 4.62 4663(अ) 25-10-23 इजं ेक्शन 4 मिलीग्राि / मि.ली. 203 डेससामेथासोन 1 मि.ली. 5.09 2124(अ) 04-05-23 (2 मि.ली.) 2125(अ) इजं ेक्शन 4 मिलीग्राि / मि.ली. 204 डेससामेथासोन 1 मि.ली. 2.57 04-05-23 (5 मि.ली.) batSD'ku 4 fexkz- 4663(अ) 205 @fefy- ¼izfr iSd 10 1 fefy- 1.57 25-10-23 fefy-½ batSD'ku 4 fexkz- 4663(अ) 206 @fefy- ¼izfr iSd 20 1 fefy- 1.35 25-10-23 fefy-½ batSD'ku 4 fexkz- 4663(अ) 207 @fefy- ¼izfr iSd 30 1 fefy- 0.90 25-10-23 fefy-½ 208 डायिेपाम गोली 5 मिलीग्राि 1 गोली 1.63 4663(अ) 25-10-23 209 डायिेपाम इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 5.54 4663(अ) 25-10-23 210 xksyh 2 fexzk- 1 xksyh 1.44 4663(अ) 25-10-23 211 lIqiksftVªh 5 fexkz- 1 lIqiksftVªh 6.19 4663(अ) 25-10-23 212 डाईसलोफेनाक गोली 50 मिलीग्राि 1 गोली 2.05 1574(अ) 31-03-23 इजं ेक्शन 25 1574(अ) 213 डाईसलोफेनाक 1 मि.ली. 1.69 31-03-23 मिलीग्राि/मि.ली. batSD'ku 10 fexkz- 4663(अ) @fefy-¼10 fefy- iSd 214 1 fefy- 3.32 25-10-23 िे र्कम½ batSD'ku 10 fexkz- 4663(अ) 215 @fefy-¼10 fefy- औि 1 fefy- 2.10 25-10-23 अधिर्क iSd½ डायथाइलकाबाचमाजीन 1574(अ) 216 गोली 100 मिलीग्राि 1 गोली 1.67 31-03-23 (डी ई सी) डायथाइलकाबाचमाजजन 1574(अ) 217 गोली 50 मिलीग्राि 1 गोली 0.56 31-03-23 (डीईसी) डायथाइलकाबाचमाजजन ओरल मलमक्वड 120 1574(अ) 218 1 मि.ली. 0.48 31-03-23 (डीईसी) मिलीग्राि/ 5 मि.ली.(पी)10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 219 जडिोजससन गोली 0.25मिलीग्राि 1 गोली 1.33 1574(अ) 31-03-23 vksjy fyD;bw ZM 0-05 220 जडिोजससन 1 fefy- 1.47 4663(अ) 25-10-23 fexkz-@ fefy- batSD'ku 0-25 fexkz- 221 जडिोजससन 1 fefy- 3.87 4663(अ) 25-10-23 @fefy- 222 जडजल्टयाजेम गोली 60 मिलीग्राि 1 गोली 5.46 1574(अ) 31-03-23 223 xksyh 30 fexkz- 1 xksyh 2.68 4663(अ) 25-10-23 batSD'ku 5 fexzk- 224 1 fefy- 3.50 4663(अ) 25-10-23 @fefy- 225 डाइनोप्रोस्ट्टोन जेल 0.5 मिलीग्राि 1 ग्राि 84.72 4663(अ) 25-10-23 batSD'ku 50 fexkz- 226 1 fefy- 9.03 4663(अ) 25-10-23 @fefy- पाउडर फोर इजं ेक्शन 20 1574(अ) 227 डॉसीटेससेल 1 वाईल 2868.39 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 80 1574(अ) 228 डॉसीटेससेल 1 वाईल 10333.69 31-03-23 मिलीग्राि 229 डॉlलूटेग्रेजवर गोली 50 मिलीग्राि 1 गोली 112.79 1574(अ) 31-03-23 230 डोमपररडोन गोली 10 मिलीग्राि 1 गोली 2.31 4663(अ) 25-10-23 ओरल मलमक्वड 1 1574(अ) 231 डोमपररडोन 1 मि.ली. 1.24 31-03-23 मिलीग्राि/मि.ली. 232 डोनेपेजजल गोली 10 मिलीग्राि 1 गोली 17.46 4663(अ) 25-10-23 233 डोनेपेजजल गोली 5 मिलीग्राि 1 गोली 12.11 4663(अ) 25-10-23 इजं ेक्शन 40 4663(अ) 234 डोपामाइन 1 मि.ली. 4.77 25-10-23 मिलीग्राि/मि.ली. batSD'ku 2 fexzk- 235 1 fefy- 31.75 1577(अ) 31-03-23 @fefy- 236 डॉससीसाइजसलन कैप्सूल 100 मिलीग्राि 1 कैप्सूल 3.08 1574(अ) 31-03-23 237 डॉससीसाइजसलन xksyh 100 fexzk- 1 xksyh 1.22 1577(अ) 31-03-23 इजं ेक्शन के मलए पाउडर 100 238 डॉससीसाइजसलन मिलीग्राि 1 वाईल 502.64 4663(अ) 25-10-23 239 डी- पेजनजसलमाइन कैप्सूल 250 मिलीग्राि 1 कैप्सूल 15.65 1574(अ) 31-03-23 izfr 0-1 240 लाइसेंस के नसिं ार 75.65 4663(अ) 25-10-23 fefy- 241 इफावरेन्ि गोली 600 मिलीग्राि 1 गोली 70.59 1574(अ) 31-03-23 242 xksyh 200 fexzk- (पी) 1 xksyh 22.54 4663(अ) 25-10-23 र्कैप्िलू 200 243 1 कैप्सूल 21.98 2124(अ) 04-05-23 ममलीग्राम 244 एनालाजप्रल गोली 5 मिलीग्राि 1 गोली 3.70 1574(अ) 31-03-23 245 एनालाजप्रल गोली 2.5 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23 batSD'ku 40 fexkz-@0-4 fefy- 246 0-1 fefy- 111.99 4663(अ) 25-10-23 batSD'ku 60 fexkz-@0-6 fefy- 247 एंटेकावीर गोली 1 मिलीग्राि 1 गोली 130.24 4663(अ) 25-10-23 248 एंटेकावीर गोली 0.5 मिलीग्राि 1 गोली 84.44 4663(अ) 25-10-23 249 एररथ्रोपोइटीन इजं ेक्शन 2000 1 मि.ली. 549.58 1574(अ) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 11 आईय/ूमि.ली. इजं ेक्शन 10000 आईय ू 1574(अ) 250 एररथ्रोपोइटीन 1 मि.ली. 1969.11 31-03-23 /मि.ली. 251 एजस्ट्सटालोप्राम गोली 5 मिलीग्राि 1 गोली 5.02 1574(अ) 31-03-23 252 एजस्ट्सटालोप्राम गोली 10 मिलीग्राि 1 गोली 9.00 1574(अ) 31-03-23 253 एजस्ट्सटालोप्राम गोली 20 मिलीग्राि 1 गोली 14.36 1574(अ) 31-03-23 batSD'ku 10 fexkz- 254 1 fefy- 26.38 1577(अ) 31-03-23 @fefy- 255 एथेमब्युटोल गोली 600मिलीग्राि 1 गोली 4.08 1574(अ) 31-03-23 256 एथेमब्युटोल गोली 800 मिलीग्राि 1 गोली 4.96 4663(अ) 25-10-23 257 एथेमब्युटोल गोली 400 मिलीग्राि 1 गोली 2.61 1574(अ) 31-03-23 258 xksyh 200 fexzk- 1 xksyh 1.14 1577(अ) 31-03-23 गोली 0.03 मिलीग्राि (ए) एजथजनलएस्ट्राजडयोल (ए) 259 + गोली 0.15 मिलीग्राि 1 गोली 3.17 1574(अ) 31-03-23 + लेवोनोगेस्ट्रेल (बी) (बी) 260 एजथओनामाइड गोली 250 मिलीग्राि 1 गोली 14.81 1574(अ) 31-03-23 261 एटोपोसाइड कैप्सूल 50 मिलीग्राि 1 कैप्सूल 56.63 1574(अ) 31-03-23 इजं ेक्शन 20 1574(अ) 262 एटोपोसाइड 1 मि.ली. 34.51 31-03-23 मिलीग्राि/मि.ली. 263 दफल्ग्राजस्ट्टम इजं ेक्शन 300 एिसीजी 1 वाइल 1159.97 1574(अ) 31-03-23 264 फ्लुकोनाजोल गोली 400 मिलीग्राि 1 गोली 29.75 4663(अ) 25-10-23 265 फ्लूकोनाजोल गोली 200 मिलीग्राि 1 गोली 17.46 4663(अ) 25-10-23 266 फ्लूकोनाजोल गोली 100 मिलीग्राि 1 गोली 7.62 1574(अ) 31-03-23 267 फ्लुकोनाजोल गोली 150 मिलीग्राि 1 गोली 12.06 1574(अ) 31-03-23 268 फ्लुकोनाजोल गोली 50 मिलीग्राि 1 गोली 9.68 4663(अ) 25-10-23 269 dSIlwy 200 fexzk- 1 dSIlwy 40.11 4663(अ) 25-10-23 270 dSIlwy 150 fexzk- 1 dSIlwy 19.22 4663(अ) 25-10-23 izfr 100 batSD'ku 200 fexzk-@ 1577(अ) 271 92.33 31-03-23 100 fefy- fefy- वाईल 272 dSIlwy 100 मिलीग्राि 1 कैप्सूल 21.40 2124(अ) 04-05-23 273 फ्लड्रोकोर्टचसोन गोली 0.1 मिलीग्राि 1 गोली 13.20 2541(अ) 08-06-23 274 फ्लुनाररजजन गोली 5 मिलीग्राि 1 गोली 2.48 4663(अ) 25-10-23 275 फ्लुनाररजजन गोली 10 मिलीग्राि 1 गोली 4.82 1574(अ) 31-03-23 276 फ्लसु सोटाइन कैप्सूल 20 मिलीग्राि 1 कैप्सूल 3.99 1574(अ) 31-03-23 277 फ्लुससोटाइन कैप्सूल 60 मिलीग्राि 1 कैप्सूल 11.10 1574(अ) 31-03-23 278 फ्लुससोटाइन कैप्सूल 40 मिलीग्राि 1 कैप्सूल 6.49 1574(अ) 31-03-23 279 फ्लुससोटाइन कैप्सूल 10 मिलीग्राि 1 कैप्सूल 3.32 4663(अ) 25-10-23 280 फ्लुससोटाइन गोली 10 मिलीग्राि 1 गोली 2.78 2124(अ) 04-05-23 281 फ्लुससोटाइन गोली 40 मिलीग्राि 1 गोली 5.56 2124(अ) 04-05-23 282 फ्लुससोटाइन गोली 60 मिलीग्राि 1 गोली 8.25 2124(अ) 04-05-2312 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 283 फ्लुससोटाइन गोली 20 मिलीग्राि 1 गोली 4.15 2124(अ) 04-05-23 इजं ेक्शन 25 1574(अ) 284 फ्लूफेनजीन 1 मि.ली. 55.26 31-03-23 मिलीग्राि/मि.ली. 285 फोजलक एजसड गोली 5 मिलीग्राि 1 गोली 1.51 1574(अ) 31-03-23 286 फ्रैमाइसेरटन क्रीि 1 % 1 ग्राि 1.66 2541(अ) 08-06-23 287 फ़्यूरोसेमाइड गोली 40 मिलीग्राि 1 गोली 0.91 4663(अ) 25-10-23 इजं ेक्शन 10 1574(अ) 288 फ़्यूरोसेमाइड 1 मि.ली. 2.99 31-03-23 मिलीग्राि/मि.ली. vksjy fyD;bw ZM 10 289 1 fefy- 3.32 4663(अ) 25-10-23 fexkz-@fefy- 290 फ्यूजसजडक एजसड क्रीि 2 % 1 ग्राि 9.83 1574(अ) 31-03-23 291 जिदफरटजनब गोली 250 मिलीग्राि 1 गोली 237.14 4663(अ) 25-10-23 पाउडर फोर इजं ेक्शन 1000 1574(अ) 292 िेमजसटाबाइन 1 वाईल 5592.55 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 200 4663(अ) 293 िेमजसटाबाइन 1 वाईल 1299.80 25-10-23 मिलीग्राि इजं ेक्शन 40 मिलीग्राि / 2125(अ) 294 िेंटामाइजसन मि.ली. (1.5 मि.ली.) 1 मि.ली. 2.90 04-05-23 इजं ेक्शन 10 1574(अ) 295 िेंटामाइजसन 1 मि.ली. 2.41 31-03-23 मिलीग्राि/मि.ली. batSD'ku 40 fexkz- 1577(अ) 296 @fefy- ¼izfr iSd 10 1 fefy- 1.51 31-03-23 fefy-½ batSD'ku 40 fexkz- 4663(अ) 297 @fefy- ¼izfr iSd 20 1 fefy- 1.55 25-10-23 fefy-½ batSD'ku 40 fexkz- 1577(अ) 298 @fefy- ¼izfr iSd 30 1 fefy- 1.23 31-03-23 fefy-½ batSD'ku 40 fexkz- 299 @fefy- 2 1 मि.ली. 4.85 2124(अ) 04-05-23 300 जललमेपाइराइड गोली 2 मिलीग्राि 1 गोली 5.80 4663(अ) 25-10-23 301 जललमेपाइराइड गोली 1 मिलीग्राि 1 गोली 3.70 1574(अ) 31-03-23 302 ललूकोि इजं ेक्शन 25% 1 मि.ली. 0.20 1574(अ) 31-03-23 जललसेररन/ललीसेरॉल 1579(अ) 303 (आईपी में उल्लेख दकए टॉमपकल-लोशन 1 मि.ली. 1.23 31-03-23 गए अनुसार) जललसेररन/ललीसेरॉल 4663(अ) 304 (आईपी में उल्लेख दकए टॉमपकल - क्रीि 1 ग्राि 2.37 25-10-23 गए अनुसार) 305 जललसरील ररजनरेट इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 6.19 4663(अ) 25-10-23 lcfyaxq,y xksyh 0-5 306 1 xksyh 1.27 4663(अ) 25-10-23 fexkz- इजं ेक्शन 0.2 1574(अ) 307 ललाइकोपीरोलेट 1 मि.ली. 14.53 31-03-23 मिलीग्राि/मि.ली. 308 जग्रसोफुजल्वन गोली 250 मिलीग्राि 1 गोली 1.77 1574(अ) 31-03-23 309 हलै ोपेरीडोल गोली 5 मिलीग्राि 1 गोली 3.57 4663(अ) 25-10-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 13 310 हलै ोपेरीडोल गोली 10 मिलीग्राि 1 गोली 4.78 4663(अ) 25-10-23 ओरल मलमक्वड 2 1574(अ) 311 हलै ोपेरीडोल 1 मि.ली. 2.24 31-03-23 मिलीग्राि/5मि.ली. batSD'ku 5 fexkz- 312 1 fefy- 6.51 1577(अ) 31-03-23 @fefy- 313 xksyh 20 fexkz- 1 xksyh 5.36 4663(अ) 25-10-23 314 हलै ोपेरीडोल गोली 1.5 मिलीग्राि 1 गोली 1.58 1697(अ) 12-04-23 315 हालोथाने मलक़िंड फोर इनहले ेशन 1 मि.ली. 6.10 4663(अ) 25-10-23 इजं ेक्शन 1000 आईय/ू 1574(अ) 316 हपे ाररन 1 मि.ली. 21.21 31-03-23 मि.ली. इजं ेक्शन 5000 आईय ू / 1574(अ) 317 हपे ाररन 1 मि.ली. 59.96 31-03-23 मि.ली. 318 लाइसेंस के नसिं ार 1 वाईल 5498.70 4663(अ) 25-10-23 319 लाइसेंस के नसिं ार 1 fefy- 78.82 1577(अ) 31-03-23 320 होमेरोजपन ड्रोप 2% 1 मि.ली. 6.40 1574(अ) 31-03-23 bles a 52 fexkz- 321 1 vkbZ;wMh 4103.53 4663(अ) 25-10-23 ysoksuksxZLs Vsªy 'kkfey gS ह्यूमन कोररओजनक 1574(अ) 322 इजं ेक्शन 5000 आईय ू 1 वाइल 417.47 31-03-23 गोनाडोरोजपन जललसेररन/ललीसेरॉल 323 (आईपी में उल्लेख दकए इजं ेक्शन 10000 आईय ू 1 वाईल 928.30 4663(अ) 25-10-23 गए अनुसार) जललसेररन/ललीसेरॉल 324 (आईपी में उल्लेख दकए इजं ेक्शन 2000 आईय ू 1 वाईल 343.66 1579(अ) 31-03-23 गए अनुसार) 325 हाइड्रोसलोरोजथयाजिड गोली 25 मिलीग्राि 1 गोली 1.75 4663(अ) 25-10-23 326 हाइड्रोसलोरोजथयाजिड गोली 12.5 मिलीग्राि 1 गोली 1.04 1574(अ) 31-03-23 पाउडर फोर इजं ेक्शन 100 1574(अ) 327 हाइड्रोकार्टचसोन 1 वाईल 44.79 31-03-23 मिलीग्राि 328 हाइड्रोकार्टचसोन गोली 10 मिलीग्राि 1 गोली 6.70 1574(अ) 31-03-23 पाउडर फोर इजं ेक्शन 20 1574(अ) 329 हाइड्रोकार्टचसोन 1 वाइल 65.60 31-03-23 0मिलीग्राि 330 हाइड्रोकार्टचसोन गोली 5 मिलीग्राि 1 गोली 3.12 4663(अ) 25-10-23 331 हाइड्रोकार्टचसोन गोली 20 मिलीग्राि 1 गोली 14.89 4663(अ) 25-10-23 हायड्रोससीप्रोपायल 4663(अ) 332 इजं ेक्शन 2% 1 मि.ली. 29.21 25-10-23 जमथायलसेलुलॉि 333 हाइड्रोससीसलोरोिीन गोली 400 मिलीग्राि 1 गोली 13.80 1574(अ) 31-03-23 334 हाइड्रोससीसलोरोिीन गोली 200 मिलीग्राि 1 गोली 6.36 4663(अ) 25-10-23 335 हाइड्रोससीयूररया कैप्सूल 500 मिलीग्राि 1 कैप्सूल 12.12 1574(अ) 31-03-23 336 आइबुप्रोफेन गोली 200 मिलीग्राि 1 गोली 0.71 4663(अ) 25-10-23 337 आइबुप्रोफेन गोली 400 मिलीग्राि 1 गोली 1.20 4663(अ) 25-10-23 ओरल मलमक्वड 100 1574(अ) 338 आइबुप्रोफेन 1 मि.ली. 0.22 31-03-23 मिलीग्राि / 5 मि.ली.(पी) batSD'ku ds fy, ikmMj 339 2000 fexzk- 1 वाईल 643.16 4663(अ) 25-10-23 340 batSD'ku ds fy, ikmMj 1 वाईल 318.96 1577(अ) 31-03-2314 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 1000 fexzk- 341 इमैरटजनब गोली 100 मिलीग्राि 1 गोली 69.75 1574(अ) 31-03-23 342 इमैरटजनब गोली 400 मिलीग्राि 1 गोली 199.62 1574(अ) 31-03-23 343 dSIlwy 100 fexzk- 1 dSIlwy 73.48 1577(अ) 31-03-23 batSD'ku 40 344 1 fefy- 16.99 4663(अ) 25-10-23 vkbZ;w@fefy- इंजेटशन 100 4663(अ) 345 इंसुजलन ललार्िचन 1 fefy- 203.46 25-10-23 आईय ू/ मम.ली. इंसुजलन इंटरमीजडएट 4663(अ) 346 इजं ेक्शन 40 आई/मि.ली. 1 मि.ली. 16.99 25-10-23 एकसटंग (एनपीएर्) batSD'ku 300 fexkz- 347 1 fefy- 16.90 4663(अ) 25-10-23 vk;ksfMu@fefy- इंजेटशन 140 to 350 ममलीग्राम 348 आयोहसे सोल 1 मम.ली. 14.24 4663(अ) 25-10-23 आयोडडन.ली.मम/ (350ममलीग्राम) इंजेटशन हेत ु इररनोटेकन 349 िॉेयशू न 20 1 मम.ली. 964.89 1579(अ) 31-03-23 एर्सीएलररहाइड्रेट ममलीग्राम/मम.ली. इजं ेक्शन 20 4663(अ) 350 आयरन सुक्रोि 1 मि.ली. 57.41 25-10-23 मिलीग्राि/मि.ली. 351 आइसोफ्लुरेन मलक़िंड फोर इनहले ेशन 1 मि.ली. 9.65 1574(अ) 31-03-23 352 आइसोजनयाजजड गोली 300 मिलीग्राि 1 गोली 1.29 2540(अ) 08-06-23 353 आइसोजनयाजजड गोली 100 मिलीग्राि 1 गोली 0.65 2540(अ) 08-06-23 354 आइसोसॉरबाइड जडजनरेट गोली 5 मिलीग्राि 1 गोली 0.82 4663(अ) 25-10-23 355 आइसोसॉरबाइड जडजनरेट गोली 10मिलीग्राि 1 गोली 0.81 4663(अ) 25-10-23 356 इस्ट्पघुला ग्रेनलिं ेस/ हस्कपाउडर / 1 ग्राि 0.94 1574(अ) 31-03-23 ओरल मलमक्वड 10 357 इराकोनािोल मिलीग्राि / मि.ली. 1 मि.ली. 4.94 1574(अ) 31-03-23 र्कैप्िलू 100 358 इराकोनािोल 1 र्कैप्िलू 16.67 1579(अ) 31-03-23 ममलीग्राम र्कैप्िलू 200 359 इराकोनािोल 1 र्कैप्िलू 22.12 1579(अ) 31-03-23 ममलीग्राम 360 ykblasl ds :i es a 1 vkbZ;wMh 281.02 4663(अ) 25-10-23 361 आइवरमेजसटन गोली 6 ममलीग्राम 1 गोली 21.58 1578(अ) 31-03-23 362 आइवरमेजसटन गोली 12 ममलीग्राम 1 गोली 37.37 1578(अ) 31-03-23 लाइििें र्के अनिु ाि िापनीि इंसेफेलाइरटस 363 (4 एमिीजी िे 6 1 वाइल 677.17 2124(अ) 04-05-23 वैससीन एमिीजी) िापनीि इंसेफेलाइरटस लाइििें र्के अनिु ाि 364 1 वाइल 518.66 2124(अ) 04-05-23 वैससीन (3 एमिीजी तर्क)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 15 इजं ेक्शन 50 365 केटामाइन 1 मि.ली. 12.12 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 366 लेबेटालोल इजं ेक्शन 5 मिलीग्राि/मि.ली. 1 मि.ली. 49.98 1574(अ) 31-03-23 गोली 100 367 लेबेटालोल 1 गोली 15.16 4663(अ) 25-10-23 ममलीग्राम ओरल मलमक्वड 10 ग्राि 368 लैसटुलोि 1 मि.ली. 1.23 1574(अ) 31-03-23 /15मि.ली. 369 लैमीवुडीन गोली 100 मिलीग्राि 1 गोली 10.40 1574(अ) 31-03-23 370 लैमीवुडीन गोली 150 मिलीग्राि 1 गोली 10.86 1574(अ) 31-03-23 पाउडर फोर इजं ेक्शन 5000 371 एल- ऐस्ट्पैरिाइनेस 1 वाईल 1034.88 4663(अ) 25-10-23 केयू पाउडर फोर इजं ेक्शन 372 एल- ऐस्ट्पैरिाइनेस 1 वाईल 1707.74 4663(अ) 25-10-23 10000 केय ू 373 लैटानोप्रोस्ट्ट ड्रोप 0.005% 1 मि.ली. 232.58 2542(अ) 08-06-23 374 लेजनलेडोमाइड कैप्सूल 5 मिलीग्राि 1 कैप्सूल 67.25 1574(अ) 31-03-23 375 लेजनलेडोमाइड कैप्सूल 25 मिलीग्राि 1 कैप्सूल 292.28 4663(अ) 25-10-23 376 लेरोजोल गोली 2.5 मिलीग्राि 1 गोली 29.32 4663(अ) 25-10-23 पाउडर फोर इजं ेक्शन 22.5 377 ल्यूप्रोलाइड एसीटेट 1 वाईल 17081.50 4663(अ) 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 378 ल्यूप्रोलाइड एसीटेट 1 वाईल 9294.48 4663(अ) 25-10-23 11.25 मिलीग्राि पाउडर फोर इजं ेक्शन 3.75 379 ल्यूप्रोलाइड एसीटेट 1 वाईल 3112.67 1574(अ) 31-03-23 मिलीग्राि 380 लेवेरटरासेटम गोली 250 मिलीग्राि 1 गोली 6.30 1574(अ) 31-03-23 381 लेवेरटरासेटम गोली 500 मिलीग्राि 1 गोली 12.98 1574(अ) 31-03-23 िोडीफाइड ररलीज गोली 382 लेवेरटरासेटम 1 गोली 18.30 4663(अ) 25-10-23 750 मिलीग्राि 383 लेवेरटरासेटम गोली 750 मिलीग्राि 1 गोली 19.34 1574(अ) 31-03-23 ओरल मलमक्वड 100 384 लेवेरटरासेटम 1 मि.ली. 3.97 4663(अ) 25-10-23 मिलीग्राि/मि.ली. (पी) इजं ेक्शन 100 मिलीग्राि/ 385 लेवेरटरासेटम 1 मि.ली. 23.02 4663(अ) 25-10-23 मि.ली. िोडीफाईड ररलीज –गोली लेवोडोपा (ए) + 386 200 मिलीग्राि (ए) + 1 गोली 4.73 1574(अ) 31-03-23 कार्बचडोपा (बी) 50 मिलीग्राि (बी) गोली 100 ममलीग्राम लेवोडोपा (ए) + 387 (ए) + 25 ममलीग्राम 1 गोली 2.58 4663(अ) 25-10-23 कार्बचडोपा (बी) (बी) गोली 100 ममलीग्राम लेवोडोपा (ए) + 388 (ए) + 10 ममलीग्राम 1 गोली 1.76 1574(अ) 31-03-23 कार्बचडोपा (बी) (बी) लेवोडोपा (ए) + गोली 250 मिलीग्राि (ए) 389 1 गोली 4.42 4663(अ) 25-10-23 कार्बचडोपा (बी) +25 मिलीग्राि (बी) िोडीफाइड ररलीज –गोली लेवोडोपा (ए) + 390 100 मिलीग्राि (ए) + 25 1 गोली 2.79 1574(अ) 31-03-23 कार्बचडोपा (बी) मिलीग्राि (बी)16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 391 जलवोफ़्लॉससाजसन गोली 750 मिलीग्राि 1 गोली 12.45 4663(अ) 25-10-23 392 जलवोफ़्लॉससाजसन गोली 250 मिलीग्राि 1 गोली 4.82 1697(अ) 12-04-23 393 जलवोफ़्लॉससाजसन गोली 500 मिलीग्राि 1 गोली 8.99 1697(अ) 12-04-23 394 लेवोथायरोजससन गोली 50 एिसीजी 1 गोली 1.03 1574(अ) 31-03-23 395 लेवोथायरोजससन गोली 75 एिसीजी 1 गोली 1.44 4663(अ) 25-10-23 396 लेवोथायरोजससन गोली 88 एिसीजी 1 गोली 1.65 4663(अ) 25-10-23 397 लेवोथायरोजससन गोली 112 एिसीजी 1 गोली 1.66 4663(अ) 25-10-23 398 लेवोथायरोजससन गोली 25 एिसीजी 1 गोली 1.45 4663(अ) 25-10-23 399 लेवोथायरोजससन गोली 62.5 एिसीजी 1 गोली 1.61 1574(अ) 31-03-23 400 लेवोथायरोजससन गोली 12.5 एिसीजी 1 गोली 1.48 1574(अ) 31-03-23 401 लेवोथायरोजससन गोली 100 एिसीजी 1 गोली 1.32 1574(अ) 31-03-23 402 लेवोथायरोजससन गोली 125 एिसीजी 1 गोली 1.69 1574(अ) 31-03-23 403 लेवोथायरोजससन गोली 150 एिसीजी 1 गोली 1.70 1577(अ) 31-03-23 404 जलग्नोकेन टोमपकल फोि म2-5 % 1 ग्राि/मि.ली. 1.13 1574(अ) 31-03-23 405 जलग्नोकेन इजं ेक्शन 2% 1 मि.ली. 1.04 1574(अ) 31-03-23 406 batSD'ku 1% 1 fefy- 8.87 4663(अ) 25-10-23 batSD'ku 5% Xywdkst 407 1 fefy- 3.50 4663(अ) 25-10-23 7-5% ds lkFk batSD'ku 2% ¼,½ $ 408 1%200000 ¼5 1 fefy- 1.05 1577(अ) 31-03-23 ,elhth@fefy-½ ¼ch½ 409 जलनेजोजलड गोली 600 मिलीग्राि 1 गोली 35.67 4663(अ) 25-10-23 गोली 300 410 जलनेिोजलड 1 गोली 22.65 4663(अ) 25-10-23 ममलीग्राम 411 जलजथयम गोली 300 मिलीग्राि 1 गोली 1.63 4663(अ) 25-10-23 412 लोपेरामाइड गोली 2 मिलीग्राि 1 गोली 2.28 4663(अ) 25-10-23 413 dSIlwy 2 fexzk- 1 dSIlwy 3.79 4663(अ) 25-10-23 लोजपनवीर (ए) + गोली 200 मिलीग्राि (ए) 414 1 गोली 47.97 4663(अ) 25-10-23 ररटोनवीर (बी) + 50 मिलीग्राि (बी) 415 लोरािेपेम गोली 1 मिलीग्राि 1 गोली 2.31 4663(अ) 25-10-23 416 लोरािेपेम गोली 2 मिलीग्राि 1 गोली 2.81 1574(अ) 31-03-23 batSD'ku 2 fexzk- 417 1 fefy- 8.10 4663(अ) 25-10-23 @fefy- इजं ेक्शन 500 418 मैगनीजियम सल्फेट 1 मि.ली. 4.87 4663(अ) 25-10-23 मिलीग्राि/मि.ली. 419 मैजनटोल इजं ेक्शन 20 % 1 मि.ली. 0.35 4663(अ) 25-10-23 420 batSD'ku 10% 1 fefy- 0.19 1577(अ) 31-03-23 421 मेबेंडािोल गोली 100 मिलीग्राि 1 गोली 2.90 1574(अ) 31-03-23 ओरल मलमक्वड 100 422 मेबेंडािोल 1 मि.ली. 0.84 1574(अ) 31-03-23 मिलीग्राि/5 मि.ली. (पी) मेड्रोससीप्रोिेस्ट्टेरोन 423 गोली 10 मिलीग्राि 1 गोली 6.25 4663(अ) 25-10-23 एसीटेट[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 17 मेड्रोससीप्रोिेस्ट्टेरोन इजं ेक्शन 150 मिलीग्राि 424 1 मि.ली. 289.77 4663(अ) 25-10-23 एसीटेट /मि.ली. ओरल मलमक्वड 100 425 मेफानाजमक एजसड 1 मि.ली. 0.56 1574(अ) 31-03-23 मिलीग्राि / 5 मि.ली. (पी) 426 xksyh 250 fexzk- 1 xksyh 2.11 4663(अ) 25-10-23 427 मेफ्लोिाइन गोली 250 मिलीग्राि 1 गोली 52.16 4663(अ) 25-10-23 428 मेललुमाइन डायरीजोएट इजं ेक्शन 60% डब्ल्यू वी / 1 मि.ली. 9.47 1574(अ) 31-03-23 429 मेललुमाइन डायरीजोएट इजं ेक्शन 76% डब्ल्यू वी / 1 मि.ली. 10.20 1574(अ) 31-03-23 इंजेटशन हेत ु पाउडि 500 430 मेरोपेनम ममलीग्राम 1 वाईल 723.02 1579(अ) 31-03-23 (ट्राइहाइड्रटे र्के रूप में) इंजेटशन र्के मलये पाउडि 1000 431 मेरोपेनम ममलीग्राम 1 वाईल 952.74 4663(अ) 25-10-23 (ट्राइहाइड्रटे र्के रूप में) इजं ेक्शन 100 432 मेस्ना 1 मि.ली. 15.51 4663(अ) 25-10-23 मिलीग्राि/मि.ली. 433 मेटफोर्मचन गोली 1000 मिलीग्राि 1 गोली 3.49 4663(अ) 25-10-23 434 मेटफोर्मचन गोली 500 मिलीग्राि 1 गोली 2.02 4663(अ) 25-10-23 िोडीफाइड ररलीज गोली 435 मेटफोर्मचन 1 गोली 4.05 4663(अ) 25-10-23 1000 मिलीग्राि 436 मेथोरेससेट गोली 10 मिलीग्राि 1 गोली 13.29 4663(अ) 25-10-23 437 मेथोरेससेट गोली 2.5 मिलीग्राि 1 गोली 5.31 1574(अ) 31-03-23 438 xksyh 5 fexzk- 1 xksyh 9.43 4663(अ) 25-10-23 439 जमथाइलिोमेररन गोली 0.125 मिलीग्राि 1 गोली 8.94 4663(अ) 25-10-23 इजं ेक्शन 0.2 440 जमथाइलिोमेररन 1 मि.ली. 14.95 4663(अ) 25-10-23 मिलीग्राि/मि.ली. batSD'ku 40 fexkz-@ 441 1 fefy- 45.67 4663(अ) 25-10-23 fefy- 442 मेटोसलोप्रमाइड गोली 10 मिलीग्राि 1 गोली 1.35 4663(अ) 25-10-23 इजं ेक्शन 5 मिलीग्राि/मि.ली. 443 मेटोसलोप्रमाइड 1 मि.ली. 2.67 4663(अ) 25-10-23 (लेस देन 10 मि.ली. पकै ) batSD'ku 5 fexzk- @fefy- ¼10 fefy- 444 1 fefy- 1.63 4663(अ) 25-10-23 औि अधिर्क iSd½ ओरल मलमक्वड 5 445 मेटोसलोप्रमाइड 1 मि.ली. 0.50 1577(अ) 31-03-23 मिलीग्राि/5मि.ली. (पी) 446 मेटोप्रोलोल गोली 25 मिलीग्राि 1 गोली 4.20 1574(अ) 31-03-23 447 मेटोप्रोलोल गोली 50 मिलीग्राि 1 गोली 5.84 1574(अ) 31-03-23 िोडीफाईड ररलीज गोली 448 मेटोप्रोलोल 1 गोली 14.99 1574(अ) 31-03-23 100 मिलीग्राि 449 मेटोप्रोलोल गोली 100 मिलीग्राि 1 गोली 11.13 1574(अ) 31-03-2318 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 450 dSIlwy 25 fexzk- 1 dSIlwy 4.14 4663(अ) 25-10-23 451 dSIlwy 50 fexzk- 1 dSIlwy 5.82 4663(अ) 25-10-23 इंजेटशन 1 452 मेटोप्रोलोल 1 मम.ली. 3.40 4663(अ) 25-10-23 ममलीग्राम .ली.मम / 453 मेरोजनडािोल गोली 200 मिलीग्राि 1 गोली 0.82 4663(अ) 25-10-23 454 मेरोजनडािोल गोली 400 मिलीग्राि 1 गोली 1.52 1574(अ) 31-03-23 इजं ेक्शन 500 455 मेरोजनडािोल 1 मि.ली. 0.21 1574(अ) 31-03-23 मिलीग्राि/100मि.ली. ओरल मलमक्वड 200 456 मेरोजनडािोल 1 मि.ली. 0.52 4663(अ) 25-10-23 मिलीग्राि/5मि.ली. (पी) नैजल स्रै 1.25 मिलीग्राि 457 जमडाजोलम 1 मि.ली. 216.82 4663(अ) 25-10-23 / क़िंएसन नैजल स्रै 0.5 मिलीग्राि / 458 जमडाजोलम 1 मि.ली. 79.93 1574(अ) 31-03-23 क़िंएसन इजं ेक्शन 1 मिलीग्राि/ 459 जमडाजोलम 1 मि.ली. 5.92 1574(अ) 31-03-23 मि.ली. इजं ेक्शन 5 मिलीग्राि/ 460 जमडाजोलम 1 मि.ली. 10.88 4663(अ) 25-10-23 मि.ली. 461 जमफेजप्रस्ट्टोन गोली 200 मिलीग्राि 1 गोली 350.92 4663(अ) 25-10-23 462 जमसोप्रोस्ट्टोल गोली 200 एिसीजी 1 गोली 18.97 1574(अ) 31-03-23 463 जमसोप्रोस्ट्टोल गोली 100 एिसीजी 1 गोली 9.92 1574(अ) 31-03-23 464 मोंटेलुकास्ट्ट गोली 4 मिलीग्राि 1 गोली 10.03 1574(अ) 31-03-23 465 मोंटेलुकास्ट्ट गोली 10 मिलीग्राि 1 गोली 16.44 4663(अ) 25-10-23 इजं ेक्शन 466 मॉर्फचन 1 मि.ली. 19.60 4663(अ) 25-10-23 10मिलीग्राि/मि.ली. इजं ेक्शन 15 467 मॉर्फचन 1 मि.ली. 14.93 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 468 मोससीफ्लोससाजसन गोली 400 मिलीग्राि 1 गोली 25.82 1574(अ) 31-03-23 469 मुजपरोजसन ओइंटमेंट 2% 1 ग्राम 20.29 1579(अ) 31-03-23 470 मायकोफेनोलेट मोफेरटल गोली 250 मिलीग्राि 1 गोली 49.60 1574(अ) 31-03-23 इजं ेक्शन 200 471 एन-एजसटाइलजसस्ट्टीन 1 मि.ली. 23.64 4663(अ) 25-10-23 मिलीग्राि/मि.ली. इजं ेक्शन 0.4 472 नालोससोन 1 मि.ली. 92.73 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 473 नैटामाइजसन ड्रोप 5% 1 मि.ली. 23.38 4663(अ) 25-10-23 इजं ेक्शन 0.5 474 जनओजस्ट्टलमाइन 1 मि.ली. 5.01 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 475 जनओजस्ट्टलमाइन गोली 15 मिलीग्राि 1 गोली 4.59 4663(अ) 25-10-23 476 नेजवरेपीन गोली 200 मिलीग्राि 1 गोली 15.80 4663(अ) 25-10-23 जनकोटीन (जनकोटीन 477 लॉजेंग 2 ममलीग्राम 1 लॉजेंग 7.92 4663(अ) 25-10-23 ररप्लेसमेंट थेरेपी के जलए) जनकोटीन (जनकोटीन 478 गम 2 ममलीग्राम 1 गम 8.59 4663(अ) 25-10-23 ररप्लेसमेंट थेरेपी के जलए) जनकोटीन (जनकोटीन 479 गम 4 ममलीग्राम 1 गम 10.64 1579(अ) 31-03-23 ररप्लेसमेंट थेरेपी के जलए)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 19 जनकोटीन (जनकोटीन 480 लॉजेंग 4 ममलीग्राम 1 लॉजेंग 9.75 1579(अ) 31-03-23 ररप्लेसमेंट थेरेपी के जलए) 481 जनफेजडजपन गोली 10 मिलीग्राि 1 गोली 1.54 4663(अ) 25-10-23 482 dSIlwy 10 fexzk- 1 dSIlwy 0.95 1577(अ) 31-03-23 483 नाइट्रोफ्यिू न्टाइन गोली 100 मिलीग्राि 1 गोली 8.11 4663(अ) 25-10-23 484 नन टोइन dSIlwy 100 fexzk- 1 dSIlwy 8.64 1577(अ) 31-03-23 vksjy fyD;bw ZM 25 485 टोइन fexkz-@5 fefy- 1 fefy- 0.89 4663(अ) 25-10-23 इजं ेक्शन 2 मिलीग्राि/ 486 नॉिएड्रने ालाईन 1 मि.ली. 20.17 1574(अ) 31-03-23 मि.ली. 487 नोिेधिस्टिोन गोली 5 मिलीग्राि 1 गोली 5.39 1574(अ) 31-03-23 488 ओमेप्राज़ोल कैप्सूल 20 मिलीग्राि 1 कैप्सूल 2.87 1574(अ) 31-03-23 489 xksyh 20 fexkz- 1 xksyh 4.34 4663(अ) 25-10-23 490 dSIlwy 10 fexzk- 1 dSIlwy 2.41 1577(अ) 31-03-23 vksjy fyD;bw ZM ds fy, 491 1 xkze 1.51 1577(अ) 31-03-23 ikmMj 20 fexzk- 492 dSIlwy 40 fexzk- 1 dSIlwy 8.45 1577(अ) 31-03-23 493 ओंडान्िेट्रॉन गोली 4 मिलीग्राि 1 गोली 5.14 4663(अ) 25-10-23 ओरल मलमक्वड 2 494 ओंडान्िेट्रॉन 1 मि.ली. 1.26 4663(अ) 25-10-23 मिलीग्राि/5 मि.ली. (पी) 495 ओंडान्िेट्रॉन इजं ेक्शन 2 मिलीग्राि/मि.ली. 1 मि.ली. 5.96 1574(अ) 31-03-23 496 ओंडान्िेट्रॉन गोली 8 मिलीग्राि 1 गोली 9.06 4663(अ) 25-10-23 497 ykblasl ds :i es a 1 fefy- 0.15 4663(अ) 25-10-23 ऑरमेलोजससफेन 498 गोली 30 जमलीग्राम 1 गोली 8.44 1579(अ) 31-03-23 (सेंटक्रोमन) इजं ेक्शन 5 499 ऑक्टिक्प्लक्प्टन मिलीग्राि/मि.ली. in 10 1 वाईल 2233.95 4663(अ) 25-10-23 मि.ली. वाईल 500 ऑटिीटोमिन इजं ेक्शन 5 आईय/ूमि.ली. 1 मि.ली. 17.84 4663(अ) 25-10-23 batSD'ku 10 501 1 fefy- 39.87 1577(अ) 31-03-23 vkbZ;w@fefy- batSD'ku 30 fexkz-@5 502 fefy-batSD'ku 100 1 fefy- 215.44 1577(अ) 31-03-23 fexkz-@16-7 fefy- 503 पटैं ोप्राज़ोल इजं ेक्शन 40 मिलीग्राि 1 वाईल 50.45 1574(अ) 31-03-23 504 पेिामिटामोल गोली 650 मिलीग्राि 1 गोली 2.01 4663(अ) 25-10-23 ओरल मलमक्वड 125 505 पेिामिटामोल 1 मि.ली. 0.37 1574(अ) 31-03-23 मिलीग्राि/5 मि.ली. (पी) ओरल मलमक्वड 250 506 पेिामिटामोल 1 मि.ली. 0.67 1574(अ) 31-03-23 मिलीग्राि/5 मि.ली. (पी) ओरल मलमक्वड 120 507 पेिामिटामोल 1 मि.ली. 0.61 4663(अ) 25-10-23 मिलीग्राि/5 मि.ली. (पी)20 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 508 पेिामिटामोल गोली 500 मिलीग्राि 1 गोली 0.90 4663(अ) 25-10-23 509 पेिामिटामोल सपोमसटरी 80 मिलीग्राि 1 सपोमसटरी 6.66 1574(अ) 31-03-23 510 पेिामिटामोल सपोमसटरी 170 मिलीग्राि 1 सपोमसटरी 7.95 4663(अ) 25-10-23 इंजेटशन 150 511 पिै ािीटामोल ममलीग्राम / मम.ली. 1 मि.ली. 3.97 2124(अ) 04-05-23 (2 मम.ली.) इंजेटशन 150 512 पेिामिटामोल मिलीग्राि / मि.ली. (100 1 मि.ली. 1.60 2125(अ) 04-05-23 मि.ली.) 513 Øhe 5% 1 xkze 1.85 1577(अ) 31-03-23 514 yks'ku 1% 1 fefy- 1.00 4663(अ) 25-10-23 515 Øhe 1% 1 xkze 1.50 1577(अ) 31-03-23 1 fefy- 516 yks'ku 5% 1.00 4663(अ) 25-10-23 @xzke 517 पमेधिन जेल 5% 1 ग्राि 1.31 2540(अ) 08-06-23 batSD'ku 22-75 fexzk- 518 1 fefy- 2.76 4663(अ) 25-10-23 @fefy-¼2 fefy-½ batSD'ku 22-75 fexzk- 519 1 fefy- 2.06 1577(अ) 31-03-23 @fefy-¼10 fefy-½ 520 फेनोबार्बटि ोन गोली 30 मिलीग्राि 1 गोली 1.31 1574(अ) 31-03-23 521 फेनोबार्बटि ोन गोली 60 मिलीग्राि 1 गोली 1.89 1574(अ) 31-03-23 इजं ेक्शन 200 522 फेनोबार्बटि ोन 1 मि.ली. 22.14 1574(अ) 31-03-23 मिलीग्राि/मि.ली. ओरल मलमक्वड 20 523 फेनोबार्बटि ोन 1 मि.ली. 0.49 1574(अ) 31-03-23 मिलीग्राि / 5 मि.ली. (पी) 524 फेनीटोइन गोली 300 मिलीग्राि 1 गोली 5.48 1574(अ) 31-03-23 इजं ेक्शन 50 525 फ़िनाइटोइन 1 मि.ली. 5.95 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 526 मोडीफाइड रिलीज 1 xksyh 6.57 1577(अ) 31-03-23 xksyh 300 fexzk- 527 xksyh 100 fexzk- 1 xksyh 1.76 1577(अ) 31-03-23 528 xksyh 50 fexkz- 1 xksyh 0.84 1577(अ) 31-03-23 vksjy fyD;bw ZM 30 529 1 fefy- 0.35 4663(अ) 25-10-23 fexkz-@5 fefy- (पी) vksjy fyD;bw ZM 125 530 1 fefy- 1.10 4663(अ) 25-10-23 fexkz-@5 fefy- (पी) 531 dSIlwy 300 fexzk- 1 dSIlwy 4.65 1577(अ) 31-03-23 532 dSIlwy 100 fexzk- 1 dSIlwy 1.83 4663(अ) 25-10-23 फाइटोमेनाडडयोन इजं ेक्शन 10 533 1 मि.ली. 53.09 4663(अ) 25-10-23 मिलीग्राि/मि.ली. (ववटाममन[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 21 534 xksyh 10 fexkz- 1 xksyh 14.54 1577(अ) 31-03-23 535 वपलोर्कावपनि ड्रोप 2 % 1 मि.ली. 10.83 1574(अ) 31-03-23 पाउडर फोर इजं ेक्शन 1000 वपपेिामिमलन (ए) + 536 मिलीग्राि (ए)+125 1 वाईल 99.66 1574(अ) 31-03-23 टाज़ोबटै टम (बी) मिलीग्राि (बी) पाउडर फोर इजं ेक्शन 2000 वपपेिामिमलन (ए) + 537 मिलीग्राि (ए) +250 1 वाईल 191.55 4663(अ) 25-10-23 टाज़ोबटै टम (बी) मिलीग्राि (बी) पाउडर फोर इजं ेक्शन 4000 वपपेिामिमलन (ए) + 538 मिलीग्राि (ए) +500 1 वाईल 399.41 4663(अ) 25-10-23 टाज़ोबटै टम (बी) मिलीग्राि (बी) ओरल मलमक्वड 500 539 पोटेमशयम टलोिाइड 1 मि.ली. 0.30 1574(अ) 31-03-23 मिलीग्राि/5 मि.ली. इजं ेक्शन 150 540 पोटेमशयम टलोिाइड 1 मि.ली. 2.40 4663(अ) 25-10-23 मिलीग्राि/मि.ली. 541 पोवीडोन आयोडीन सोलूशन 5% 1 मि.ली. 0.44 4663(अ) 25-10-23 542 पोवीडोन आयोडीन सोलूशन 7.5% 1 मि.ली. 0.82 4663(अ) 25-10-23 543 पोवीडोन आयोडीन सोलूशन 10% 1 मि.ली. 0.96 1574(अ) 31-03-23 544 पोवीडोन आयोडीन िोेयशू न 4% 1 मि.ली. 1.74 2168(अ) 11-05-23 प्रमै लडॉक्टिम इजं ेक्शन 25 545 1 मि.ली. 4.56 1574(अ) 31-03-23 मिलीग्राि/मि.ली. टलोिाइड ( पीएएम) 546 प्रेडननिोलोन गोली 40मिलीग्राि 1 गोली 3.41 4663(अ) 25-10-23 ओरल मलमक्वड 5 547 प्रेडननिोलोन 1 मि.ली. 0.49 1574(अ) 31-03-23 मिलीग्राि/5 मि.ली. (पी) ओरल मलमक्वड 15 548 प्रेडननिोलोन मिलीग्राि/5मि.ली.(पी) 1 मि.ली. 0.86 1574(अ) 31-03-23 549 प्रेडननिोलोन गोली 10 मिलीग्राि 1 गोली 1.20 4663(अ) 25-10-23 550 प्रेडननिोलोन गोली 5 मिलीग्राि 1 गोली 0.68 1574(अ) 31-03-23 551 प्रेडननिोलोन गोली 20 मिलीग्राि 1 गोली 2.40 4663(अ) 25-10-23 552 प्रेडननिोलोन ड्रोप 1% 1 मि.ली. 5.76 1574(अ) 31-03-23 batSD'ku 40 553 1 fefy- 16.99 4663(अ) 25-10-23 vkbZ;w@fefy- 554 प्राइमाटवीन गोली 7.5 मिलीग्राि 1 गोली 2.38 4663(अ) 25-10-23 555 प्राइमाटवीन गोली 15 मिलीग्राि 1 गोली 5.14 4663(अ) 25-10-23 556 xksyh 2-5 fexkz- 1 xksyh 1.75 4663(अ) 25-10-23 557 प्रोपिर्काइन आई ड्रॉप 0.5% 1 मि.ली. 10.25 4663(अ) 25-10-23 इजं ेक्शन 10 558 प्रोपोफोल 1 मि.ली. 6.50 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 559 प्रोप्रानोलोल गोली 40 मिलीग्राि 1 गोली 3.22 4663(अ) 25-10-23 560 प्रोप्रानोलोल गोली 10 मिलीग्राि 1 गोली 1.31 1574(अ) 31-03-23 561 प्रोप्रानोलोल गोली 20 मिलीग्राि 1 गोली 3.20 4663(अ) 25-10-2322 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 562 dSIlwy 40 fexzk- 1 dSIlwy 4.25 4663(अ) 25-10-23 र्कैप्िलू 20 563 प्रोप्रानोलोल 1 र्कैप्िलू 2.35 1578(अ) 31-03-23 ममलीग्राम र्कैप्िलू 10 564 प्रोप्रानोलोल 1 र्कैप्िलू 2.00 4663(अ) 25-10-23 ममलीग्राम इजं ेक्शन 10 565 प्रोटामाइन िेफेट 1 मि.ली. 9.78 4663(अ) 25-10-23 मिलीग्राि/मि.ली. 566 पायिाज़ीनामाईड गोली 1000 मिलीग्राि 1 गोली 10.53 4663(अ) 25-10-23 567 पायिाज़ीनामाईड गोली 500 मिलीग्राि 1 गोली 4.89 4663(अ) 25-10-23 568 पायिाज़ीनामाईड गोली 750 मिलीग्राि 1 गोली 7.21 4663(अ) 25-10-23 569 पायिाज़ीनामाईड गोली 1500 मिलीग्राि 1 गोली 11.81 4663(अ) 25-10-23 570 पाइरिडोक्टिन गोली 100 मिलीग्राि 1 गोली 5.98 4663(अ) 25-10-23 571 xksyh 10 fexkz- 1 xksyh 0.11 1577(अ) 31-03-23 572 क्टवननन गोली 300 मिलीग्राि 1 गोली 5.65 1574(अ) 31-03-23 batSD'ku 300 fexzk-@ 573 र्कुनेन fefy- 1 fefy- 9.50 4663(अ) 25-10-23 574 िेबीज वटै िीन एज लाइसेंस 1 वाइल 378.71 1574(अ) 31-03-23 575 िाेटेग्रेववि गोली 400 मिलीग्राि 1 गोली 147.80 4663(अ) 25-10-23 576 िाममवप्रल गोली 2.5 मिलीग्राि 1 गोली 5.21 1574(अ) 31-03-23 577 िाममवप्रल गोली 5 मिलीग्राि 1 गोली 8.18 1574(अ) 31-03-23 578 dSIlwy 2-5 fexkz- 1 dSIlwy 4.66 1577(अ) 31-03-23 579 dSIlwy 5 fexzk- 1 dSIlwy 7.19 4663(अ) 25-10-23 580 रिबावायरिन कैप्सूल 200 मिलीग्राि 1 कैप्सूल 26.49 1574(अ) 31-03-23 581 रिफैक्पपमिन कैप्सूल 600 मिलीग्राि 1 कैप्सूल 11.36 4663(अ) 25-10-23 582 रिफैक्पपमिन कैप्सूल 450 मिलीग्राि 1 कैप्सूल 5.67 1574(अ) 31-03-23 583 रिफैक्पपमिन कैप्सूल 150 मिलीग्राि 1 कैप्सूल 2.29 4663(अ) 25-10-23 584 रिफैक्पपमिन कैप्सूल 300 मिलीग्राि 1 कैप्सूल 4.61 4663(अ) 25-10-23 ओरल मलमक्वड 100 585 रिफैक्पपमिन 1 मि.ली. 0.47 1574(अ) 31-03-23 मिलीग्राि/5मि.ली.(पी) 586 रििपेिीडोन गोली 1 मिलीग्राि 1 गोली 3.03 4663(अ) 25-10-23 587 रििपेिीडोन गोली 2 मिलीग्राि 1 गोली 4.48 1574(अ) 31-03-23 588 रििपेिीडोन गोली 4 मिलीग्राि 1 गोली 7.36 4663(अ) 25-10-23 ओरल मलमक्वड 1 589 रििपेिीडोन 1 मि.ली. 2.21 4663(अ) 25-10-23 मिलीग्राि/मि.ली. इजं ेक्शन (लोंगएमक्टंग) 25 590 रििपेिीडोन 1 मि.ली. 1930.30 2125(अ) 04-05-23 मिलीग्राि इजं ेक्शन (लोंगएमक्टंग) 591 रििपेिीडोन 1 मि.ली. 2649.41 2125(अ) 04-05-23 37.5 मिलीग्राि 592 रिटोनवीि गोली 100 मिलीग्राि 1 गोली 29.21 4663(अ) 25-10-23 इजं ेक्शन 10 593 रिट्कक्टिमबै 1 मि.ली. 761.81 4663(अ) 25-10-23 मिलीग्राि/मि.ली.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 23 594 िोटा वाईिि वक्ै टिन लाईििें र्के अनिु ाि 1 वाईल 854.58 4663(अ) 25-10-23 595 िेै बटु ामोल गोली 4 मिलीग्राि 1 गोली 0.21 1574(अ) 31-03-23 596 िेै बटु ामोल गोली 2 मिलीग्राि 1 गोली 0.18 4663(अ) 25-10-23 ओरल मलमक्वड 2 597 िेै बटु ामोल 1 मि.ली. 0.18 4663(अ) 25-10-23 मिलीग्राि/5मि.ली. इनहले ेशन 598 िेै बटु ामोल (एिडीआई(*डीपीआई/ 1 एिडीआई 0.49 1574(अ) 31-03-23 100 एिसीजी / डोज रेमस्परेटर सॉ्यूशन (सॉ्यशू न 599 िेै बटु ामोल फोर नेब्लयिंलाइज़र 5 मिलीग्राि / 1 मि.ली. 0.68 1574(अ) 31-03-23 मि.ली.) 600 िमै लमिमलर्क एमिड ओइटं िटें 3-6% (6%) 1 ग्राि 2.02 4663(अ) 25-10-23 ओइंटमेंट 3-6% 601 िेमलिाईर्कामिड 1 ग्राम 2.06 1579(अ) 31-03-23 (3%) bugys s'ku र्के मलये 602 1 fefy- 31.17 4663(अ) 25-10-23 मलक़ुड िोडडयम इजं ेक्शन (एज पर आईपी) - 603 1 मि.ली. 1.35 4663(अ) 25-10-23 8.4% बाइर्काबोनेट batSD'ku (आईपी र्के 604 1 fefy- 1.01 4663(अ) 25-10-23 अनिु ाि) 7-5% 605 िोडडयम वेै प्रोएट गोली 300 मिलीग्राि 1 गोली 4.46 1574(अ) 31-03-23 ओरल मलमक्वड 200 606 िोडडयम वेै प्रोएट 1 मि.ली. 0.65 1574(अ) 31-03-23 मिलीग्राि/5 मि.ली. (पी) 607 िोडडयम वेै प्रोएट गोली 200 मिलीग्राि 1 गोली 3.59 4663(अ) 25-10-23 िोडीफाइड ररलीज – गोली 608 िोडडयम वेै प्रोएट 1 गोली 9.28 1574(अ) 31-03-23 500 मिलीग्राि 609 िोडडयम वेै प्रोएट गोली 500 मिलीग्राि 1 गोली 8.12 4663(अ) 25-10-23 िोडीफाइड ररलीज – गोली 610 िोडडयम वेै प्रोएट 1 गोली 6.10 4663(अ) 25-10-23 300 मिलीग्राि इजं ेक्शन 611 िोडडयम वेै प्रोएट 1 मि.ली. 6.75 4663(अ) 25-10-23 100मिलीग्राि/मि.ली. 612 िोफोिबवु ीि गोली 400 मिलीग्राि 1 गोली 525.12 4663(अ) 25-10-23 batSD'ku ds fy, ikmMj 613 3 fexkz- 1 वाईल- 1359.00 4663(अ) 25-10-23 614 स्पिै ोनोलाटटोंन गोली 50 मिलीग्राि 1 गोली 4.37 1574(अ) 31-03-23 615 स्पिै ोनोलाटटोंन गोली 25 मिलीग्राि 1 गोली 2.19 4663(अ) 25-10-23 इजं ेक्शन 15,00,000 616 स्ट्रेप्टोफर्कनेज 1 वाईल 1877.33 1574(अ) 31-03-23 आईय ू पाउडर फोर इजं ेक्शन 750 617 स्ट्रेप्टोमाइमिन 1 वाईल 10.10 1574(अ) 31-03-23 मिलीग्राि पाउडर फोर इजं ेक्शन 1000 618 स्ट्रेप्टोमाइमिन 1 वाईल 10.86 1574(अ) 31-03-23 मिलीग्राि इजं ेक्शन 50 मिलीग्राि 619 िक्टिनीर्कोमलन 1 मि.ली. 5.21 2540(अ) 08-06-23 /मि.ली. 620 िेफािालाक्ज़न गोली 500 मिलीग्राि 1 गोली 4.72 1574(अ) 31-03-2324 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 621 िमु ाट्रट्रप्टान गोली 25 मिलीग्राि 1 गोली 32.50 2540(अ) 08-06-23 622 िमु ाट्रट्रप्टान गोली 50 मिलीग्राि 1 गोली 55.68 2540(अ) 08-06-23 623 टैक्रोमलमि कैप्सूल 0.5 मिलीग्राि 1 कैप्सूल 20.66 1574(अ) 31-03-23 624 टैक्रोमलमि कैप्सूल 1 मिलीग्राि 1 कैप्सूल 40.62 1574(अ) 31-03-23 625 टैक्रोमलमि कैप्सूल 2 मिलीग्राि 1 कैप्सूल 84.34 4663(अ) 25-10-23 626 टैक्रोमलमि गोली 1 मिलीग्राि 1 गोली 39.98 4886(अ) 10-11-23 627 टैक्रोमलमि गोली 2 मिलीग्राि 1 गोली 77.69 4886(अ) 10-11-23 628 टैक्रोमलमि गोली 0.5 मिलीग्राि 1 गोली 20.97 4886(अ) 10-11-23 629 टामोटिीफेन गोली 20 मिलीग्राि 1 गोली 2.95 4663(अ) 25-10-23 630 टामोटिीफेन गोली 10 मिलीग्राि 1 गोली 2.21 4663(अ) 25-10-23 631 टेक्ेमिटिन गोली 20 मिलीग्राि 1 गोली 3.88 4663(अ) 25-10-23 632 टेक्ेमिटिन गोली 40 मिलीग्राि 1 गोली 6.76 1574(अ) 31-03-23 633 टेक्ेमिटिन गोली 80 मिलीग्राि 1 गोली 10.40 1574(अ) 31-03-23 634 टेमोज़ोलोमाइड कैप्सूल 20 मिलीग्राि 1 कैप्सूल 441.33 1574(अ) 31-03-23 635 टेमोज़ोलोमाइड कैप्सूल 250 मिलीग्राि 1 कैप्सूल 4304.01 1574(अ) 31-03-23 636 टेमोज़ोलोमाइड कैप्सूल 100 मिलीग्राि 1 कैप्सूल 1508.70 1574(अ) 31-03-23 637 टेमोज़ोलोमाइड गोली 20 मिलीग्राि 1 गोली 336.65 4886(अ) 10-11-23 638 टेमोज़ोलोमाइड गोली 250 मिलीग्राि 1 गोली 3758.15 4886(अ) 10-11-23 इजं ेक्शन 40 मिलीग्राि / 639 टेनेटटेप्लेि 1 वाईल 50389.69 4663(अ) 25-10-23 वाईल इजं ेक्शन 30 मिलीग्राि / 640 टेनेटटेप्लेि 1 वाईल 36910.02 4663(अ) 25-10-23 वाईल 641 टेनेमलक्ललक्प्टन गोली 20 ममलीग्राम 1 गोली 11.09 4663(अ) 25-10-23 टेनोफोववि 642 अलाफेनामाइड गोली 25 मिलीग्राि 1 गोली 48.87 1574(अ) 31-03-23 फ्यमू िेट (टीएएफ) टेनोफोववि डडिोप्रोटिील गोली 300 मिलीग्राि (ए) 643 1 गोली 45.58 4663(अ) 25-10-23 + 300 मिलीग्राि (बी) फ्यमू िेट (ए) + लमै मवडु ाइन (बी) टेनोफोववि डडिोप्रॉक्टिल गोली 300 मिलीग्राि (ए) 644 फ्यमू िेट) + + 300 मिलीग्राि (बी) + 1 गोली 102.85 4663(अ) 25-10-23 600 मिलीग्राि (सी) लमै मवडु ाइन (बी) + ए़िावविेंज़ (िी) टेनोफोववि डडिप्रॉक्टिल 645 गोली 300 मिलीग्राि 1 गोली 45.84 4663(अ) 25-10-23 फ्यमू िेट (टी डी एफ)*[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 25 646 टर्बनि ाफाईन क्रीम 1% 1 ग्राम 5.26 4663(अ) 25-10-23 647 ( जमली) 1 वाईल- 25.53 1577(अ) 31-03-23 1 वाईल - 648 12.47 4663(अ) 25-10-23 (0.5 जमली.) ¼0-5 fefy-½ 649 िैमलडोमाइड कैप्सूल 50 मिलीग्राि 1 कैप्सूल 31.16 4663(अ) 25-10-23 650 िैमलडोमाइड कैप्सूल 100 मिलीग्राि 1 कैप्सूल 62.01 1574(अ) 31-03-23 651 धियाममन गोली 100 मिलीग्राि 1 गोली 4.46 1574(अ) 31-03-23 इजं ेक्शन 100 652 धियाममन 1 मि.ली. 22.59 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 653 धियोपेंटोन पाउडर फोर इजं ेक्शन 1 ग्राि 1 वाईल 55.32 2540(अ) 08-06-23 पाउडर फोर इजं ेक्शन 0.5 654 धियोपेंटोन 1 वाईल 45.69 2540(अ) 08-06-23 ग्राि 655 ट्रटमोलोल ड्रॉप 0.5 % 1 मि.ली. 13.40 4663(अ) 25-10-23 इनहले ेशन (एिडीआई( 9 656 ट्रटयोट्रोवपयम 1 एिडीआई 2.78 1574(अ) 31-03-23 एिसीजी डोज / इनहले ेशन (डीपीआई( 18 657 ट्रटयोट्रोवपयम 1 डीपीआई 10.71 4663(अ) 25-10-23 एिसीजी डोज / इजं ेक्शन 50 658 ट्रामाडोल मिलीग्राि/मि.ली. 1 मि.ली. 11.78 1574(अ) 31-03-23 ( प टू 2 मि.ली. पकै ) 659 dSIlwy 50 fexzk- 1 dSIlwy 4.82 1577(अ) 31-03-23 660 dSIlwy 100 fexzk- 1 dSIlwy 9.04 4663(अ) 25-10-23 661 ट्रामाडोल गोली 50 मिलीग्राि 1 गोली 9.70 4886(अ) 10-11-23 662 ट्रामाडोल गोली 100 मिलीग्राि 1 गोली 24.48 4886(अ) 10-11-23 इजं ेक्शन 100 663 ट्रेनेटज़ाममर्क एमिड 1 मि.ली. 13.71 1574(अ) 31-03-23 मिलीग्राि/मि.ली. 664 ट्रेनेटज़ाममर्क एमिड गोली 500 मिलीग्राि 1 गोली 18.54 1574(अ) 31-03-23 इजं ेक्शन 440 665 ट्रस्टुज़ुमाब 1 वाईल 54725.21 4663(अ) 25-10-23 मिलीग्राि/50 मि.ली. 666 ट्राइहेक्टिफेननडाइल गोली 2 मिलीग्राि 1 गोली 1.37 4663(अ) 25-10-23 667 ट्रॉवपर्कैमाइड आई ड्रॉप 1 % 1 मि.ली. 9.43 4663(अ) 25-10-23 668 वेलगन्ै िीटलोववि गोली 450 मिलीग्राि 1 गोली 400.73 1574(अ) 31-03-23 पाउडर फोर इजं ेक्शन 500 669 वनै र्कॉमायमिन 1 वाईल 317.64 4663(अ) 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 1000 670 वनै र्कॉमायमिन 1 वाईल 470.27 4663(अ) 25-10-23 मिलीग्राि पाउडर फोर इजं ेक्शन 250 671 वनै र्कॉमायमिन 1 वाईल 251.25 1574(अ) 31-03-23 मिलीग्राि र्कैप्िलू 250 672 वनै र्कॉमायमिन 1 र्कैप्िलू 152.39 1578(अ) 31-03-23 ममलीग्राम पाउडर फोर इजं ेक्शन 10 673 वेर्कुिोननयम मिलीग्राि रत्येक वाईल 117.37 4663(अ) 25-10-2326 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] पाउडर फोर इजं ेक्शन 4 674 वेर्कुिोननयम मिलीग्राि रत्येक वाईल 74.40 1574(अ) 31-03-23 675 वेिापाममल गोली 80 मिलीग्राि 1 गोली 1.59 1574(अ) 31-03-23 676 वेिापाममल गोली 40 मिलीग्राि 1 गोली 0.86 1574(अ) 31-03-23 677 ववक्न्क्रस्टाईन इजं ेक्शन 1 मिलीग्राि/मि.ली. 1 मि.ली. 57.52 4663(अ) 25-10-23 xksyh 50000 vkbZ;w 678 (च्यएू बल गोली 1 xksyh 0.73 4663(अ) 25-10-23 िट्रहत) batSD'ku 50000 679 1 fefy- 2.26 1577(अ) 31-03-23 vkbZ;w@fefy- 680 वािफरिन गोली 5 मिलीग्राि 1 गोली 2.40 2540(अ) 08-06-23 681 वािफरिन गोली 3 मिलीग्राि 1 गोली 3.18 2540(अ) 08-06-23 682 वारफररन गोली 2 मिलीग्राि 1 गोली 2.72 2540(अ) 08-06-23 683 वारफररन गोली 1 मिलीग्राि 1 गोली 2.46 2540(अ) 08-06-23 684 िाइलोमेटाजोजलन नेजल ड्रोप 0.05 % 1 मि.ली. 4.19 1574(अ) 31-03-23 685 िाइलोमेटाजोजलन नेजल ड्रोप 0.1% 1 मि.ली. 5.12 1574(अ) 31-03-23 जजडोवुडाइन (ए) + गोली 300 मिलीग्राि (ए) 686 लेजमवुडाइन (बी) + + 150 मिलीग्राि (बी) + 1 गोली 21.13 1574(अ) 31-03-23 नेजवरापीन (सी) 200 मिलीग्राि (सी) जिडोवुडाइन (ए) + गोली 300 मिलीग्राि (ए) 687 1 गोली 21.09 1574(अ) 31-03-23 लेजमवुडाइन (बी) +150 मिलीग्राि (बी) मडस्पमसमबल गोली 20 688 किंक सल्फेट 1 गोली 3.41 4886(अ) 10-11-23 मिलीग्राि पाउडर फोर इजं ेक्शन 4 689 जोलेड्रोजनक एजसड 1 वाईल 2392.05 4663(अ) 25-10-23 मिलीग्राि 690 जोल्पीडमे गोली 5 मिलीग्राि 1 गोली 6.21 1574(अ) 31-03-23 691 जोल्पीडमे गोली 10 मिलीग्राि 1 गोली 8.51 1574(अ) 31-03-23 िारुनवीर (ए) + गोली 600 मिलीग्राि + (ए) 692 1 गोली 146.46 939(अ) 28-02-24 100 मिलीग्राि (बी) ररटोनवीर (बी) ननर्कोटीन (ननर्कोटीन ओरल डोसेज 2 693 रिप्लिे मेंट िेिेपी र्के मिलीग्राि पैमस्टल 1 पक्ै स्टल 7.12 939(अ) 28-02-24 मलए) ननर्कोटीन (ननर्कोटीन ओरल डोसेज 4 694 रिप्लेिमेंट िेिेपी र्के मिलीग्राि पैमस्टल 1 पक्ै स्टल 7.83 939(अ) 28-02-24 मलए) 695 लेवोनोगेस्ट्रेल गोली 1.5 मिलीग्राि 1 गोली 75.35 939(अ) 28-02-24 सोमलड ओरल डोसेज 696 र्कॉलेर्कैक्ेिफेिॉलमलै फॉिम 1000 आईय ूसैशे / 1 ग्राम 23.14 939(अ) 28-02-24 पाउडर / ग्रेूय्ू स टेनोफोववि गोली 300 मिलीग्राि + 697 डडिप्रॉक्टिल 300 मिलीग्राि +50 1 गोली 114.99 939(अ) 28-02-24 मिलीग्राि फ्यमू िेट +[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 27 लमै मवडु डन + डोेयटू ेग्रेववि 698 xkys h 300 fexzk- 1 xksyh 13.59 938(अ) 28-02-24 batSD'ku ds fy, 699 ikmMj 12 yk[k 1 वाईल 19.81 938(अ) 28-02-24 ;wfuV batSD'ku ds fy, 700 ikmMj 6 yk[k 1 वाईल 11.69 938(अ) 28-02-24 ;wfuV batSD'ku 50 701 1 fefy- 20.96 938(अ) 28-02-24 ,elhth@fefy- 702 dSIlwy 5 fexzk- 1 dSIlwy 5.04 938(अ) 28-02-24 batSD'ku 20 fexzk- 703 1 fefy- 11.24 938(अ) 28-02-24 @fefy- 704 dSIlwy 40 fexzk- 1 dSIlwy 5.67 938(अ) 28-02-24 batSD'ku ds fy, 705 1 वाईल 188.65 938(अ) 28-02-24 ikmMj 500 fexzk- ykbvksfQykftM 1 वाईल ikWyhoys saV 706 ऐज ओफ 10 665.26 938(अ) 28-02-24 लाइििें मम.ली. lkys qcy@fyD;wbM 1 वाईल 707 ikWyhoys saV ऐज ओफ 10 428.67 938(अ) 28-02-24 लाइििें मम.ली. xksyh 2 fexzk- 1 xksyh 708 31.16 938(अ) 28-02-24 xksyh 5 fexzk- 1 xksyh 709 77.21 938(अ) 28-02-24 710 xksyh 2 fexzk- 1 xksyh 91.34 938(अ) 28-02-24 711 xksyh 5 fexzk- 1 xksyh 86.04 938(अ) 28-02-24 batSD'ku 1 fexzk- 1 fefy- 712 30.54 938(अ) 28-02-24 @fefy- batSD'ku 250 fexzk-@5 1 fefy- 713 2.04 938(अ) 28-02-24 fefy- 1 xksyh कंनवेंसनल / एफिवेिटें / डडस्पमिबि ल / 714 एंटरिर्क लेवपत 0.67 938(अ) 28-02-24 गोमलयााँ 325 ममलीग्राम bugys s”ku ¼,eMhvkbZ½ 1 ehVj Mkst 715 1.41 938(अ) 28-02-24 100 ,elhth@Mkst bugys s”ku ¼,eMhvkbZ½ 1 ehVj Mkst 716 2.03 938(अ) 28-02-24 200 ,elhth@Mkst bugys s”ku ¼MhihvkbZ½ 1 Mkst 717 3.33 938(अ) 28-02-24 200 ,elhth@Mkst uts y Lizs 100 1 Mkst 718 0.81 938(अ) 28-02-24 ,elhth@Mkst bugys s”ku ¼,eMhvkbZ½ 1 ehVj Mkst 719 100 ,elhth ¼,½ $ 6 2.12 938(अ) 28-02-24 ,elhth ¼ch½28 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] bugys s”ku ¼MhihvkbZ½ 1 Mkst 720 100 ,elhth ¼,½ $ 6 4.32 938(अ) 28-02-24 ,elhth ¼ch½ bugys s”ku ¼MhihvkbZ½ 1 Mkst 721 200 ,elhth ¼,½ $ 6 5.72 938(अ) 28-02-24 ,elhth ¼ch½ bugys s”ku ¼MhihvkbZ½ 1 Mkst 722 400 ,elhth ¼,½ $ 6 6.62 938(अ) 28-02-24 ,elhth ¼ch½ ऑटिीजन - मेडडर्कल उद्देश्य टयर्ू बर्क 723 मलक्टवड मडे डर्कल 17.02 1580(अ) 31-03-23 र्के मलये लाइििें मीटि ऑटिीजन ऑटिीजन (मिमलडं ि मेडडर्कल उद्देश्य टयर्ू बर्क 724 28.83 1580(अ) 31-03-23 में) र्के मलये लाइििें मीटि मेडडर्कल उद्देश्य टयर्ू बर्क 725 नाईट्रि ऑटिाईड 285.98 4663(अ) 25-10-23 र्के मलये लाइििें मीटि डडस्पोजेबल पेन में इंजेटशन 100 726 1 मम.ली. 244.14 1581 (अ) 31-03-23 इंिमु लन ललाधगनि आईय ू .ली.मम / - ( 0.00551% ) 11(3) (5) a b िे 0.00551 (5) यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-।। के रूप म ें इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िान े को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 29 माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लने े की जतजथ स े उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मल्ू य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V (4) (ञ) (1) u II I II III II IV ड [dk-a l-a@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक MINISTRY OF CHEMICALS AND FERTILIZERS (Department of Pharmaceuticals) (NATIONAL PHARMACEUTICAL PRICING AUTHORITY) ORDER New Delhi, the 26th March, 2024 S.O. 1547(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:30 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Ceiling price Existing S.O., No. & Date (wef 1.4.2024 Sl. Dosage form and Medicines Unit with WPI @ No. strength 0.00551%) (in Rs.) (1) (2) (3) (4) (5) (6a) (6b) 1 6-Mercaptopurine Tablet 50mg 1 Tablet 5.26 4663(E) 25-10-23 2 Abacavir Tablet 300 mg 1 Tablet 48.59 1574(E) 31-03-23 Abacavir (A) + Lamivudine Tablet 600mg (A) 4663(E) 25-10-23 3 1 Tablet 72.32 (B) +300mg (B) 4 Acetazolamide Tablet 250mg 1 Tablet 4.06 4663(E) 25-10-23 5 Acetazolamide Capsule 250mg 1 Capsule 5.05 4663(E) 25-10-23 Enteric coated 4663(E) 25-10-23 6 Acetylsalicylic acid 1 Tablet 0.35 Tablet 75 mg Conventional/Effer 4663(E) 25-10-23 vescent/Dispersible/ 7 Acetylsalicylic acid 1 Tablet 0.71 Enteric coated Tablets 150 mg Powder for 4663(E) 25-10-23 8 Actinomycin D 1 Vial 331.03 Injection 0.5mg 9 Acyclovir Tablet 400mg 1 Tablet 13.66 4663(E) 25-10-23 10 Acyclovir Tablet 200mg 1 Tablet 7.61 1574(E) 31-03-23 Powder for 4663(E) 25-10-23 11 Acyclovir 1 Vial 426.40 Injection 250 mg Powder for 4663(E) 25-10-23 12 Acyclovir 1 Vial 528.45 Injection 500 mg 13 Acyclovir Tablet 800mg 1 Tablet 37.66 1574(E) 31-03-23 14 Acyclovir Ointment 3% 1 GM 11.67 1574(E) 31-03-23 Oral liquid 4663(E) 25-10-23 15 Acyclovir 1 ML 1.36 400mg/5mL (p) 16 Adenosine Injection 3mg/mL 1 ML 92.86 4663(E) 25-10-23 17 Adrenaline Injection1mg/mL 1 ML 12.23 1574(E) 31-03-23 Oral liquid 1577(E) 31-03-23 18 Albendazole 1 ML 1.79 200mg/5mL(p) 19 Albendazole Tablet 400mg 1 Tablet 7.04 1577(E) 31-03-23 Chewable Tablet 4663(E) 25-10-23 20 Albendazole 1 Tablet 8.13 400mg 21 Allopurinol Tablet 300mg 1 Tablet 5.63 4663(E) 25-10-23 22 Allopurinol Tablet 100mg 1 Tablet 1.89 1574(E) 31-03-23 23 Alprostadil Injection 0.5mg/mL 1 ML 6106.75 1574(E) 31-03-23 Injection 4663(E) 25-10-23 24 Amikacin 1 ML 54.17 250mg/mL 25 Amiodarone Tablet 200mg 1 Tablet 11.51 1574(E) 31-03-23 26 Amiodarone Tablet 100mg 1 Tablet 6.14 1574(E) 31-03-23 27 Amiodarone Injection 50mg/mL 1 ML 21.13 1574(E) 31-03-23 28 Amitriptyline Tablet 50mg 1 Tablet 5.99 4663(E) 25-10-23 29 Amitriptyline Tablet 75mg 1 Tablet 5.45 4663(E) 25-10-23 30 Amitriptyline Tablet 25mg 1 Tablet 2.49 4663(E) 25-10-23 31 Amitriptyline Tablet 10mg 1 Tablet 2.39 4663(E) 25-10-23 32 Amlodipine Tablet 2.5mg 1 Tablet 1.79 1574(E) 31-03-23 33 Amlodipine Tablet 5mg 1 Tablet 2.50 1574(E) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 31 34 Amlodipine Tablet 10mg 1 Tablet 5.45 4663(E) 25-10-23 35 Amoxicillin Capsule 250mg 1 Capsule 2.44 1574(E) 31-03-23 36 Amoxicillin Capsule 500mg 1 Capsule 7.36 4663(E) 25-10-23 Oral liquid 250 4663(E) 25-10-23 37 Amoxicillin 1 ML 1.56 mg/5 mL (p) Powder for 1578(E) 31-03-23 38 Amoxicillin 1 Vial 24.79 Injection 250 mg Powder for 4663(E) 25-10-23 39 Amoxicillin 1 Vial 54.65 Injection 500 mg Oral liquid 125 1579(E) 31-03-23 40 Amoxicillin 1 ML 1.02 mg/5 mL (p) Powder for 4663(E) 25-10-23 Amoxicillin (A) + Clavulanic 41 Injection 1 g (A) 1 Vial 140.66 acid (B) +200mg (B) Powder for 4663(E) 25-10-23 Amoxicillin (A) + Clavulanic 42 Injection 500mg 1 Vial 101.35 acid (B) (A) + 100mg (B) Dry Syrup 125mg 1574(E) 31-03-23 Amoxicillin (A) + Clavulanic 43 (A) + 31.25 1 ML 2.05 acid (B) (B)/5mL(p) Amoxicillin (A) +Clavulanic Tablet 500 mg (A) 4663(E) 25-10-23 44 1 Tablet 18.30 acid (B) + 125 mg (B) Oral liquid 200 mg 4663(E) 25-10-23 Amoxicillin (A) +Clavulanic 45 (A) + 28.5mg(B)/5 1 ML 2.02 acid (B) mL(p) Amphotericin 1577(E) 31-03-23 46 Amphotericin B B(conventional) - 1 Vial 227.40 Injection 50mg/vial Powder for 1574(E) 31-03-23 47 Ampicillin 1 Vial 14.25 Injection 500 mg Artemether (A) + Tablet 40 mg (A) + 1574(E) 31-03-23 48 1 Tablet 18.04 Lumefantrine (B) 240 mg (B) Tablet 4663(E) 25-10-23 Artemether (A) 49 80mg(A)+480mg(B 1 Tablet 25.51 +Lumefantrine(B) ) Artemether (A) +Lumefantrine Tablet 20 mg (A) + 4663(E) 25-10-23 50 1 Tablet 12.65 (B) 120 mg (B) Powder for 4663(E) 25-10-23 51 Artesunate 1 Vial 244.73 Injection 60 mg Powder for 4663(E) 25-10-23 52 Artesunate 1 Vial 454.44 Injection 120mg Combi pack (A+B) 4663(E) 25-10-23 Artesunate (A) + Sulphadoxine 1 Tablet 50mg (A) 1 Combi 53 22.55 -Pyrimethamine (B) + 1Tablet (500mg + Pack 25mg) (B) 54 Ascorbic acid (Vitamin C) Tablet 100mg 1 Tablet 0.24 4663(E) 25-10-23 55 Ascorbic acid (Vitamin C) Tablet 500mg 1 Tablet 1.48 1577(E) 31-03-23 Tablet 300mg(A) + 1574(E) 31-03-23 56 Atazanavir (A) +Ritonavir(B) 1 Tablet 99.83 Tablet 100mg(B) 57 Atorvastatin Tablet 40mg 1 Tablet 19.30 4663(E) 25-10-23 58 Atorvastatin Tablet 20mg 1 Tablet 12.56 4663(E) 25-10-23 59 Atorvastatin Tablet 10mg 1 Tablet 4.94 1574(E) 31-03-23 60 Atorvastatin Tablet 80mg 1 Tablet 40.58 4663(E) 25-10-23 61 Atracurium Injection 10 mg/ml 1 ML 16.98 4663(E) 25-10-23 62 Atropine Drops 1% 1 ML 3.94 4663(E) 25-10-23 63 Atropine Ointment 1% 1 GM 4.71 4663(E) 25-10-2332 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 64 Atropine Injection 0.6mg/mL 1 ML 4.57 1574(E) 31-03-23 65 Azathioprine Tablet 50mg 1 Tablet 11.26 4663(E) 25-10-23 66 Azathioprine Tablet 25mg(p) 1 Tablet 7.24 1578(E) 31-03-23 Powder for 1574(E) 31-03-23 67 Azithromycin 1 Vial 204.72 Injection 500mg 68 Azithromycin Tablet 250mg 1 Tablet 11.65 4663(E) 25-10-23 69 Azithromycin Tablet 500mg 1 Tablet 23.57 4663(E) 25-10-23 Oral liquid 200 4663(E) 25-10-23 70 Azithromycin 1 ML 3.41 mg/5 mL (p) 71 Azithromycin Capsule250mg 1 Capsule 10.62 4663(E) 25-10-23 72 Azithromycin Tablet 1000mg 1 Tablet 57.78 4663(E) 25-10-23 73 Azithromycin Capsule 500mg 1 Capsule 19.03 2124(E) 04-05-23 74 Baclofen Tablet 20mg 1 Tablet 16.28 1574(E) 31-03-23 75 Baclofen Tablet 10mg 1 Tablet 11.90 4663(E) 25-10-23 76 Baclofen Tablet 5mg 1 Tablet 6.37 4663(E) 25-10-23 Injection 100 1574(E) 31-03-23 77 Bendamustine hydrochloride 1 Vial 4946.80 mg/vial 78 Benzoyl peroxide Gel 2.5 1 GM 3.62 1574(E) 31-03-23 79 Benzoyl peroxide Gel 5 % 1 GM 7.97 1574(E) 31-03-23 80 Benzoyl peroxide Gel 3.5% 1 GM 10.11 1578(E) 31-03-23 81 Betamethasone Injection 4mg/mL 1 ML 4.74 1577(E) 31-03-23 82 Betamethasone valerate Cream 0.05% 1 GM 0.67 1574(E) 31-03-23 83 Betamethasone valerate Cream 0.1% 1 GM 1.04 1574(E) 31-03-23 84 Bicalutamide Tablet 50mg 1 Tablet 43.30 1574(E) 31-03-23 85 Bisacodyl Tablet 5mg 1 Tablet 1.17 4663(E) 25-10-23 1 4663(E) 25-10-23 86 Bisacodyl Suppository 5mg 9.98 Suppository Powder for 1574(E) 31-03-23 87 Bleomycin 1 Vial 677.41 Injection 15units Powder for 4663(E) 25-10-23 88 Bortezomib 1 Vial 5260.50 Injection 2mg Respirator solution 4663(E) 25-10-23 89 Budesonide for use in nebulizer 1 ML 11.90 0.5mg/mL Respirator solution 1577(E) 31-03-23 90 Budesonide for use in nebulizer 1 ML 13.14 1mg/mL Injection 0.5 % 4663(E) 25-10-23 91 Bupivacaine 1 ML 7.39 with 7.5 % glucose 92 Bupivacaine Injection 0.5 % 1 ML 4.42 4663(E) 25-10-23 93 Bupivacaine Injection 0.25% 1 ML 2.83 4663(E) 25-10-23 Tablet (Sub- 4663(E) 25-10-23 94 Buprenorphine 1 Tablet 9.43 lingual)0.4mg Tablet (Sub- 4663(E) 25-10-23 Buprenorphine (A) +Naloxone 95 lingual) 1 Tablet 36.98 (B) 2mg(A)+0.5mg(B) Tablet (Sub- 4663(E) 25-10-23 Buprenorphine (A) +Naloxone lingual) 96 1 Tablet 11.82 (B) 0.4mg(A)+0.1mg (B) Oral liquid 20 1574(E) 31-03-23 97 Caffeine 1 ML 245.68 mg/mL 98 Caffeine Injection 20mg/mL Per ML 250.50 1577(E) 31-03-23 99 Calamine Lotion (As per IP) 1 ML 0.95 1577(E) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 33 100 Calcium folinate Tablet 15mg 1 Tablet 47.54 4663(E) 25-10-23 101 Capecitabine Tablet 500mg 1 Tablet 112.73 4663(E) 25-10-23 Modified Release – 4663(E) 25-10-23 102 Carbamazepine 1 Tablet 2.40 Tablet 200mg Modified Release – 1574(E) 31-03-23 103 Carbamazepine 1 Tablet 4.66 Tablet 400mg 104 Carbamazepine Tablet 400mg 1 Tablet 3.55 1574(E) 31-03-23 105 Carbamazepine Tablet 200mg 1 Tablet 1.57 4663(E) 25-10-23 Oral liquid 1574(E) 31-03-23 106 Carbamazepine 1 ML 0.31 100mg/5mL(p) 107 Carbamazepine Tablet 100mg 1 Tablet 1.07 4663(E) 25-10-23 108 Carbimazole Tablet 10mg 1 Tablet 4.26 1574(E) 31-03-23 109 Carbimazole Tablet 5mg 1 Tablet 2.19 4663(E) 25-10-23 110 Carbimazole Tablet 20mg 1 Tablet 13.87 4663(E) 25-10-23 111 Carboplatin Injection 10mg/mL 1 ML 59.07 4663(E) 25-10-23 112 Carboxymethyl cellulose Drops 0.5% 1 ML 12.30 4663(E) 25-10-23 113 Carboxymethyl cellulose Drops 1% 1 ML 16.58 1574(E) 31-03-23 114 Cefadroxil Tablet 500mg 1 Tablet 4.47 1574(E) 31-03-23 Oral liquid 1574(E) 31-03-23 115 Cefadroxil 1 ML 0.68 125mg/5mL(p) 116 Cefixime Tablet 400mg 1 Tablet 22.10 4663(E) 25-10-23 117 Cefixime Tablet 200mg 1 Tablet 9.78 4663(E) 25-10-23 Oral liquid 50 mg/5 4663(E) 25-10-23 118 Cefixime 1 ML 1.63 mL (p) Oral liquid 4663(E) 25-10-23 119 Cefixime 1 ML 2.39 100mg/5mL(p) 120 Cefixime Capsule 200mg 1 Capsule 14.68 4663(E) 25-10-23 Powder for 4663(E) 25-10-23 121 Cefotaxime 1 Vial 17.72 Injection 250 mg Powder for 4663(E) 25-10-23 122 Cefotaxime 1 Vial 24.38 Injection 500 mg Powder for 1574(E) 31-03-23 123 Cefotaxime 1 Vial 39.96 Injection 1000mg Powder for 1574(E) 31-03-23 124 Ceftazidime 1 Vial 227.02 Injection 1000mg Powder for 4663(E) 25-10-23 125 Ceftazidime 1 Vial 79.07 Injection 250 mg Powder for 4663(E) 25-10-23 126 Ceftriaxone 1 Vial 50.28 Injection 500 mg Powder for 1574(E) 31-03-23 127 Ceftriaxone 1 Vial 28.34 Injection 250 mg Powder for 1574(E) 31-03-23 128 Ceftriaxone 1 Vial 62.38 Injection 1000mg Powder for 1574(E) 31-03-23 129 Ceftriaxone 1 Vial 138.12 Injection 2000mg 130 Cefuroxime Tablet 500mg 1 Tablet 51.43 1578(E) 31-03-23 131 Cefuroxime Injection 1500 mg 1 Vial 338.76 1579(E) 31-03-23 132 Cetirizine Tablet 10mg 1 Tablet 1.88 1574(E) 31-03-23 Oral liquid 1574(E) 31-03-23 133 Cetirizine 1 ML 0.66 5mg/5mL(p) 134 Chloroquine Tablet 150 mg 1 Tablet 1.17 4663(E) 25-10-23 Oral liquid 4663(E) 25-10-23 135 Chloroquine 1 ML 0.34 50mg/5mL34 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 136 Cholecalciferol Tablet 1000 IU 1 Tablet 4.31 4663(E) 25-10-23 Oral liquid 400 1574(E) 31-03-23 137 Cholecalciferol 1 ML 2.61 IU/mL Solid oral dosage 1574(E) 31-03-23 138 Cholecalciferol form 60000 IU 1 Tablet 22.50 Tablets 139 Cholecalciferol Capsule 60000 IU 1 Capsule 30.78 4663(E) 25-10-23 140 Cholecalciferol Capsule 1000 IU 1 Capsule 4.89 4663(E) 25-10-23 Sache t/ Granuels / 1578(E) 31-03-23 141 Cholecalciferol 1 GM 33.98 Powder 60000 IU 142 Ciprofloxacin Tablet 250mg 1 tablet 2.20 4663(E) 25-10-23 143 Ciprofloxacin Tablet 500mg 1 tablet 4.25 4663(E) 25-10-23 144 Ciprofloxacin Drops 0.3 % 1 ML 1.54 4663(E) 25-10-23 Injection 1574(E) 31-03-23 145 Ciprofloxacin 1 ML 0.20 200mg/100mL Oral liquid 1577(E) 31-03-23 146 Ciprofloxacin 1 ML 0.74 250mg/5mL(p) 147 Ciprofloxacin Ointment 0.3% 1 GM 1.29 4663(E) 25-10-23 148 Cisplatin Injection 1mg/mL 1 ML 7.09 4663(E) 25-10-23 149 Clarithromycin Tablet 250mg 1 Tablet 23.89 1574(E) 31-03-23 150 Clarithromycin Tablet 500mg 1 Tablet 39.84 4663(E) 25-10-23 Oral liquid 4663(E) 25-10-23 151 Clarithromycin 1 ML 4.61 125mg/5mL(p) 152 Clindamycin Capsule 150mg 1 Capsule 16.36 4663(E) 25-10-23 153 Clindamycin Capsule 300mg 1 Capsule 28.37 4663(E) 25-10-23 154 Clindamycin Tablet 300mg 1 Tablet 18.97 1574(E) 31-03-23 155 Clindamycin Injection150mg/mL 1 ML 60.60 1579(E) 31-03-23 156 Clobazam Tablet 5mg 1 Tablet 5.73 4663(E) 25-10-23 157 Clobazam Tablet 10mg 1 Tablet 9.84 1574(E) 31-03-23 158 Clofazimine Capsule100mg 1 Capsule 3.98 2540(E) 08-06-23 159 Clofazimine Capsule 50mg 1 Capsule 2.11 2540(E) 08-06-23 160 Clomiphene citrate Capsule 50mg 1 Capsule 27.37 2124(E) 04-05-23 161 Clomiphene citrate Capsule 100 mg 1 Capsule 51.14 2124(E) 04-05-23 162 Clomiphene citrate Tablet 100 mg 1 Tablet 13.95 4663(E) 25-10-23 163 Clomiphene citrate Tablet 50mg 1 Tablet 8.84 4663(E) 25-10-23 164 Clomipramine Tablet 10 mg 1 Tablet 2.85 4663(E) 25-10-23 165 Clomipramine Tablet 25 mg 1 Tablet 6.22 1577(E) 31-03-23 166 Clomipramine Tablet 75 mg 1 Tablet 16.46 4663(E) 25-10-23 167 Clonazepam Tablet 0.25mg 1 Tablet 2.02 4663(E) 25-10-23 168 Clonazepam Tablet 0.5mg 1 Tablet 3.45 1574(E) 31-03-23 169 Clonazepam Tablet 1mg 1 Tablet 4.77 4663(E) 25-10-23 170 Clopidogrel Tablet 75mg 1 Tablet 6.66 1574(E) 31-03-23 171 Clopidogrel Tablet 150 mg 1 Tablet 20.48 1574(E) 31-03-23 172 Clotrimazole Lotion 1% 1 ML 3.89 1577(E) 31-03-23 173 Clotrimazole Pessary 100mg 1 Pessary 10.01 1577(E) 31-03-23 174 Clotrimazole Drops 1% 1 ML 3.37 1577(E) 31-03-23 175 Clotrimazole Cream1% 1 GM 3.00 1577(E) 31-03-23 176 Clozapine Tablet 25mg 1 Tablet 2.78 1574(E) 31-03-23 177 Clozapine Tablet 50mg 1 Tablet 5.19 1574(E) 31-03-23 178 Clozapine Tablet 100 mg 1 Tablet 8.45 1574(E) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 35 179 Colchicine Tablet 0.5mg 1 Tablet 3.26 1574(E) 31-03-23 Co-trimoxazole 4663(E) 25-10-23 Tablet 400 mg (A) 180 [Sulphamethoxazole (A) 1 Tablet 0.90 + 80 mg (B) +Trimethoprim(B)]* Co-trimoxazole 4886(E) 10-11-23 Tablet 800mg (A) + 181 [Sulphamethoxazole 1 Tablet 2.30 160 mg (B) (A)+Trimethoprim (B)] Co-trimoxazole Oral liquid 200 mg 4663(E) 25-10-23 182 [Sulphamethoxazole(A) (A) + 40 1 ML 0.35 +Trimethoprim(B)]* mg(B)/5mL(p) Powder for 1574(E) 31-03-23 183 Cyclophosphamide 1 Vial 73.48 Injection 500mg 184 Cyclophosphamide Tablet 50mg 1 Tablet 3.73 1577(E) 31-03-23 185 Cycloserine Capsule250mg 1 Capsule 59.19 4663(E) 25-10-23 186 Cycloserine Tablet 250mg 1 Tablet 46.01 1577(E) 31-03-23 187 Cyclosporine Capsule 25 mg 1 Capsule 28.04 1574(E) 31-03-23 Oral liquid 1574(E) 31-03-23 188 Cyclosporine 1 ML 80.58 100mg/mL(p) 189 Cyclosporine Capsule 50 mg 1 Capsule 55.11 4663(E) 25-10-23 190 Cyclosporine Capsule 100mg 1 Capsule 103.12 4663(E) 25-10-23 Injection 4663(E) 25-10-23 191 Cytosine arabinoside 1 Vial 1130.33 1000mg/vial Injection 1574(E) 31-03-23 192 Cytosine arabinoside 1 Vial 139.59 100mg/vial Injection 1574(E) 31-03-23 193 Cytosine arabinoside 1 Vial 536.33 500mg/vial 194 Dabigatran Capsule 110mg 1 Capsule 31.81 2822(E) 28-06-23 195 Dabigatran Capsule 150mg 1 Capsule 35.59 2822(E) 28-06-23 Powder for 4663(E) 25-10-23 196 Dacarbazine 1 Vial 381.75 Injection 200mg Powder for 4663(E) 25-10-23 197 Dacarbazine 1 Vial 518.83 Injection 500mg 198 Daclatasvir Tablet 60mg 1 Tablet 199.97 4663(E) 25-10-23 199 Dapsone Tablet 100 mg 1 Tablet 0.41 2540(E) 08-06-23 200 Darunavir Tablet 600mg 1 Tablet 154.44 4663(E) 25-10-23 201 Dexamethasone Tablet 0.5mg 1 Tablet 0.22 1574(E) 31-03-23 202 Dexamethasone Tablet 4 mg 1 Tablet 4.62 4663(E) 25-10-23 Injection 4mg/mL 2124(E) 04-05-23 203 Dexamethasone 1 ML 5.09 (2 ML) Injection 4mg/mL 2125(E) 04-05-23 204 Dexamethasone 1 ML 2.57 (5 ML) Injection 4mg/mL 4663(E) 25-10-23 205 Dexamethasone 1 ML 1.57 (Pack of 10ML) Injection 4mg/mL 4663(E) 25-10-23 206 Dexamethasone 1 ML 1.35 (Pack of 20 ML) Injection 4mg/mL 4663(E) 25-10-23 207 Dexamethasone 1 ML 0.90 (Pack of 30ML) 208 Diazepam Tablet 5 mg 1 Tablet 1.63 4663(E) 25-10-23 209 Diazepam Injection 5mg/mL 1 ML 5.54 4663(E) 25-10-23 210 Diazepam Tablet 2 mg 1 Tablet 1.44 4663(E) 25-10-23 1 4663(E) 25-10-23 211 Diazepam Suppository 5mg 6.19 Suppository 212 Diclofenac Tablet 50mg 1 Tablet 2.05 1574(E) 31-03-23 213 Diclofenac Injection 25mg/mL 1 ML 1.69 1574(E) 31-03-2336 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Injection 10mg/mL 4663(E) 25-10-23 214 Dicyclomine (Less than 10ML 1 ML 3.32 Pack) Injection 10mg/mL 4663(E) 25-10-23 215 Dicyclomine (10 ML & more 1 ML 2.10 pack)) 216 Diethylcarbamazine (DEC) Tablet 100mg 1 Tablet 1.67 1574(E) 31-03-23 217 Diethylcarbamazine (DEC) Tablet 50mg 1 Tablet 0.56 1574(E) 31-03-23 Oral liquid 1574(E) 31-03-23 218 Diethylcarbamazine (DEC) 1 ML 0.48 120mg/5mL(p) 219 Digoxin Tablet 0.25mg 1 Tablet 1.33 1574(E) 31-03-23 Oral 4663(E) 25-10-23 220 Digoxin 1 ML 1.47 liquid0.05mg/mL Injection 4663(E) 25-10-23 221 Digoxin 1 ML 3.87 0.25mg/mL 222 Diltiazem Tablet 60mg 1 Tablet 5.46 1574(E) 31-03-23 223 Diltiazem Tablet 30mg 1 Tablet 2.68 4663(E) 25-10-23 224 Diltiazem Injection 5mg/mL 1 ML 3.50 4663(E) 25-10-23 225 Dinoprostone Gel 0.5mg 1 GM 84.72 4663(E) 25-10-23 226 Dobutamine Injection 50 mg/ml 1 ML 9.03 4663(E) 25-10-23 Powder for 1574(E) 31-03-23 227 Docetaxel 1 Vial 2868.39 Injection 20mg Powder for 1574(E) 31-03-23 228 Docetaxel 1 Vial 10333.69 Injection 80mg 229 Dolutegravir Tablet 50mg 1 Tablet 112.79 1574(E) 31-03-23 230 Domperidone Tablet 10mg 1 Tablet 2.31 4663(E) 25-10-23 Oral Liquid 1574(E) 31-03-23 231 Domperidone 1 ML 1.24 1mg/mL 232 Donepezil Tablet 10mg 1 Tablet 17.46 4663(E) 25-10-23 233 Donepezil Tablet 5mg 1 Tablet 12.11 4663(E) 25-10-23 234 Dopamine Injection 40mg/mL 1 ML 4.77 4663(E) 25-10-23 235 Doxorubicin Injection2mg/mL 1 ML 31.75 1577(E) 31-03-23 236 Doxycycline Capsule 100mg 1 Capsule 3.08 1574(E) 31-03-23 237 Doxycycline Tablet100mg 1 Tablet 1.22 1577(E) 31-03-23 Powder for 4663(E) 25-10-23 238 Doxycycline 1 Vial 502.64 Injection 100 mg 239 D-Penicillamine Capsule 250 mg 1 Capsule 15.65 1574(E) 31-03-23 240 DPT+ Hib+ Hep B Vaccine As licensed Per 0.1 ML 75.65 4663(E) 25-10-23 241 Efavirenz Tablet 600mg 1 Tablet 70.59 1574(E) 31-03-23 242 Efavirenz Tablet 200 mg (p) 1 Tablet 22.54 4663(E) 25-10-23 243 Efavirenz Capsule 200 mg 1 Capsule 21.98 2124(E) 04-05-23 244 Enalapril Tablet 5mg 1 Tablet 3.70 1574(E) 31-03-23 245 Enalapril Tablet 2.5mg 1 Tablet 2.19 4663(E) 25-10-23 Injection40mg/0.4 4663(E) 25-10-23 246 Enoxaparin mL , injection 0.10 ML 111.99 60mg/0.6 ml 247 Entecavir Tablet 1mg 1 Tablet 130.24 4663(E) 25-10-23 248 Entecavir Tablet 0.5mg 1 Tablet 84.44 4663(E) 25-10-23 Injection 1574(E) 31-03-23 249 Erythropoietin 1 ML 549.58 2000IU/mL Injection 10000 1574(E) 31-03-23 250 Erythropoietin 1 ML 1969.11 IU/mL 251 Escitalopram Tablet 5mg 1 Tablet 5.02 1574(E) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 37 252 Escitalopram Tablet 10mg 1 Tablet 9.00 1574(E) 31-03-23 253 Escitalopram Tablet 20mg 1 Tablet 14.36 1574(E) 31-03-23 254 Esmolol Injection10 mg/mL 1 ML 26.38 1577(E) 31-03-23 255 Ethambutol Tablet 600mg 1 Tablet 4.08 1574(E) 31-03-23 256 Ethambutol Tablet 800mg 1 Tablet 4.96 4663(E) 25-10-23 257 Ethambutol Tablet 400mg 1 Tablet 2.61 1574(E) 31-03-23 258 Ethambutol Tablet 200mg 1 Tablet 1.14 1577(E) 31-03-23 Ethinylestradiol (A)+ Tablet 0.03mg(A) + 1574(E) 31-03-23 259 1 Tablet 3.17 Levonorgestrel (B) Tablet 0.15mg(B) 260 Ethionamide Tablet 250mg 1 Tablet 14.81 1574(E) 31-03-23 261 Etoposide Capsule 50mg 1 Capsule 56.63 1574(E) 31-03-23 262 Etoposide Injection 20mg/mL 1 ML 34.51 1574(E) 31-03-23 263 Filgrastim Injection 300mcg 1 Vial 1159.97 1574(E) 31-03-23 264 Fluconazole Tablet 400mg 1 Tablet 29.75 4663(E) 25-10-23 265 Fluconazole Tablet 200mg 1 Tablet 17.46 4663(E) 25-10-23 266 Fluconazole Tablet 100mg 1 Tablet 7.62 1574(E) 31-03-23 267 Fluconazole Tablet 150mg 1 Tablet 12.06 1574(E) 31-03-23 268 Fluconazole Tablet 50mg 1 Tablet 9.68 4663(E) 25-10-23 269 Fluconazole Capsule 200mg 1 Capsule 40.11 4663(E) 25-10-23 270 Fluconazole Capsule 150mg 1 Capsule 19.22 4663(E) 25-10-23 Injection Per 100 ML 1577(E) 31-03-23 271 Fluconazole 92.33 200mg/100mL Vial 272 Fluconazole Capsule 100mg 1 Capsule 21.40 2124(E) 04-05-23 273 Fludrocortisone Tablet 0.1mg 1 Tablet 13.20 2541(E) 08-06-23 274 Flunarizine Tablet 5mg 1 Tablet 2.48 4663(E) 25-10-23 275 Flunarizine Tablet 10mg 1 Tablet 4.82 1574(E) 31-03-23 276 Fluoxetine Capsule 20 mg 1 Capsule 3.99 1574(E) 31-03-23 277 Fluoxetine Capsule 60 mg 1 Capsule 11.10 1574(E) 31-03-23 278 Fluoxetine Capsule 40 mg 1 Capsule 6.49 1574(E) 31-03-23 279 Fluoxetine Capsule 10 mg 1 Capsule 3.32 4663(E) 25-10-23 280 Fluoxetine Tablet 10 mg 1 Tablet 2.78 2124(E) 04-05-23 281 Fluoxetine Tablet 40 mg 1 Tablet 5.56 2124(E) 04-05-23 282 Fluoxetine Tablet 60 mg 1 Tablet 8.25 2124(E) 04-05-23 283 Fluoxetine Tablet 20 mg 1 Tablet 4.15 2124(E) 04-05-23 284 Fluphenazine Injection 25mg/mL 1 ML 55.26 1574(E) 31-03-23 285 Folic Acid Tablet 5 mg 1 Tablet 1.51 1574(E) 31-03-23 286 Framycetin Cream 1 % 1 GM 1.66 2541(E) 08-06-23 287 Furosemide Tablet 40mg 1 Tablet 0.91 4663(E) 25-10-23 288 Furosemide Injection 10mg/mL 1 ML 2.99 1574(E) 31-03-23 Oral liquid 4663(E) 25-10-23 289 Furosemide 1 ML 3.32 10mg/mL 290 Fusidic acid Cream 2 % 1 GM 9.83 1574(E) 31-03-23 291 Gefitinib Tablet 250mg 1 Tablet 237.14 4663(E) 25-10-23 Powder for 1574(E) 31-03-23 292 Gemcitabine 1 Vial 5592.55 Injection 1000mg Powder for 4663(E) 25-10-23 293 Gemcitabine 1 Vial 1299.80 Injection 200 mg Injection 40mg/mL 2125(E) 04-05-23 294 Gentamicin 1 ML 2.90 (1.5 ml) 295 Gentamicin Injection 10mg/mL 1 ML 2.41 1574(E) 31-03-2338 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Injection 40mg/mL 1577(E) 31-03-23 296 Gentamicin 1 ML 1.51 (Pack of 10ml) Injection 40mg/mL 4663(E) 25-10-23 297 Gentamicin 1 ML 1.55 (Pack of 20ml) Injection 40mg/mL 1577(E) 31-03-23 298 Gentamicin 1 ML 1.23 Pack of 30ml) Injection 40mg/mL 2124(E) 04-05-23 299 Gentamicin 1 ML 4.85 (2ml) 300 Glimepiride Tablet 2mg 1 Tablet 5.80 4663(E) 25-10-23 301 Glimepiride Tablet 1mg 1 Tablet 3.70 1574(E) 31-03-23 302 Glucose Injection 25% 1 ML 0.20 1574(E) 31-03-23 Glycerin/glycerol (as 1579(E) 31-03-23 303 Topical - Lotion 1 ML 1.23 mentioned in IP) Glycerin/glycerol (as 4663(E) 25-10-23 304 Topical - Cream 1 GM 2.37 mentioned in IP) 305 Glyceryl trinitrate Injection 5mg/mL 1 ML 6.19 4663(E) 25-10-23 Sublingual Tablet 4663(E) 25-10-23 306 Glyceryl trinitrate 1 Tablet 1.27 0.5mg 307 Glycopyrrolate Injection 0.2mg/mL 1 ML 14.53 1574(E) 31-03-23 308 Griseofulvin Tablet 250mg 1 Tablet 1.77 1574(E) 31-03-23 309 Haloperidol Tablet 5mg 1 Tablet 3.57 4663(E) 25-10-23 310 Haloperidol Tablet 10mg 1 Tablet 4.78 4663(E) 25-10-23 Oral liquid 1574(E) 31-03-23 311 Haloperidol 1 ML 2.24 2mg/5mL 312 Haloperidol Injection 5mg/mL 1 ML 6.51 1577(E) 31-03-23 313 Haloperidol Tablet 20mg 1 Tablet 5.36 4663(E) 25-10-23 314 Haloperidol Tablet 1.5mg 1 Tablet 1.58 1697(E) 12-04-23 Liquid for 4663(E) 25-10-23 315 Halothane 1 ML 6.10 inhalation Injection 1574(E) 31-03-23 316 Heparin 1 ML 21.21 1000IU/mL Injection 1574(E) 31-03-23 317 Heparin 1 ML 59.96 5000IU/mL 318 Hepatitis B immunoglobulin As Licensed 1 Vial 5498.70 4663(E) 25-10-23 319 Hepatitis B vaccine As Licensed 1 ML 78.82 1577(E) 31-03-23 320 Homatropine Drops 2% 1 ML 6.40 1574(E) 31-03-23 Contains 52 mg of 4663(E) 25-10-23 321 Hormone Releasing IUD 1 IUD 4103.53 Levonorgestrel Human chorionic gonado 1574(E) 31-03-23 322 Injection 5000 IU 1 Vial 417.47 tropin Human chorionic gonado 4663(E) 25-10-23 323 Injection10000IU 1 Vial 928.30 tropin Human chorionic gonado 1579(E) 31-03-23 324 Injection2000 IU 1 Vial 343.66 tropin 325 Hydrochlorothiazide Tablet 25 mg 1 Tablet 1.75 4663(E) 25-10-23 326 Hydrochlorothiazide Tablet 12.5mg 1 Tablet 1.04 1574(E) 31-03-23 Powder for 1574(E) 31-03-23 327 Hydrocortisone 1 Vial 44.79 Injection 100mg 328 Hydrocortisone Tablet 10mg 1 Tablet 6.70 1574(E) 31-03-23 Powder for 1574(E) 31-03-23 329 Hydrocortisone 1 Vial 65.60 Injection 200mg 330 Hydrocortisone Tablet 5mg 1 Tablet 3.12 4663(E) 25-10-23 331 Hydrocortisone Tablet 20mg 1 Tablet 14.89 4663(E) 25-10-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 39 Hydroxy propylmethyl 4663(E) 25-10-23 332 Injection 2% 1 ML 29.21 cellulose 333 Hydroxychloroquine Tablet 400mg 1 Tablet 13.80 1574(E) 31-03-23 334 Hydroxychloroquine Tablet 200mg 1 Tablet 6.36 4663(E) 25-10-23 335 Hydroxyurea Capsule 500mg 1 Capsule 12.12 1574(E) 31-03-23 336 Ibuprofen Tablet 200mg 1 Tablet 0.71 4663(E) 25-10-23 337 Ibuprofen Tablet 400mg 1 Tablet 1.20 4663(E) 25-10-23 Oral liquid 1574(E) 31-03-23 338 Ibuprofen 1 ML 0.22 100mg/5mL(p) Powder for 4663(E) 25-10-23 339 Ifosfamide 1 Vial 643.16 Injection 2000mg Powder for 1577(E) 31-03-23 340 Ifosfamide 1 Vial 318.96 Injection 1000mg 341 Imatinib Tablet 100mg 1 Tablet 69.75 1574(E) 31-03-23 342 Imatinib Tablet 400mg 1 Tablet 199.62 1574(E) 31-03-23 343 Imatinib Capsule 100mg 1 Capsule 73.48 1577(E) 31-03-23 344 Insulin (Soluble) Injection 40 IU/ml 1 ml 16.99 4663(E) 25-10-23 345 Insulin Glargine Injection 100 IU/ml 1 ML 203.46 4663(E) 25-10-23 Insulin Intermediate Acting 4663(E) 25-10-23 346 Injection 40IU/mL 1 ML 16.99 (NPH) Injection 300mg 4663(E) 25-10-23 347 Iohexol 1 ML 16.90 iodine/mL Injection 350mg 4663(E) 25-10-23 348 Iohexol 1 ML 14.24 iodine/mL Solution for 1579(E) 31-03-23 349 Irinotecan HCltrihydrate 1 ML 964.89 injection 20mg/mL 350 Iron sucrose Injection 20mg/mL 1 ML 57.41 4663(E) 25-10-23 Liquid for 1574(E) 31-03-23 351 Isoflurane 1 ML 9.65 inhalation 352 Isoniazid Tablet 300mg 1 Tablet 1.29 2540(E) 08-06-23 353 Isoniazid Tablet 100mg 1 Tablet 0.65 2540(E) 08-06-23 354 Isosorbide dinitrate Tablet 5mg 1 Tablet 0.82 4663(E) 25-10-23 355 Isosorbide dinitrate Tablet 10mg 1 Tablet 0.81 4663(E) 25-10-23 Granules/Husk/Pow 1574(E) 31-03-23 356 Ispaghula 1 GM 0.94 der Oral liquid 1574(E) 31-03-23 357 Itraconazole 1 ML 4.94 10mg/mL 358 Itraconazole Capsule 100mg 1 Capsule 16.67 1579(E) 31-03-23 359 Itraconazole Capsule 200mg 1 Capsule 22.12 1579(E) 31-03-23 360 IUD containing Copper As licensed 1 IUD 281.02 4663(E) 25-10-23 361 Ivermectin Tablet 6 mg 1 Tablet 21.58 1578(E) 31-03-23 362 Ivermectin Tablet 12 mg 1 Tablet 37.37 1578(E) 31-03-23 As licensed (4mcg 2124(E) 04-05-23 363 Japanese encephalitis vaccine 1 Vial 677.17 to 6 mcg) As licensed (upto 3 2124(E) 04-05-23 364 Japanese encephalitis vaccine 1 Vial 518.66 mcg) 365 Ketamine Injection 50mg/mL 1 ML 12.12 1574(E) 31-03-23 366 Labetalol Injection 5mg/mL 1 ML 49.98 1574(E) 31-03-23 367 Labetalol Tablet 100 mg 1 Tablet 15.16 4663(E) 25-10-23 Oral liquid 10 1574(E) 31-03-23 368 Lactulose 1 ML 1.23 g/15mL 369 Lamivudine Tablet 100mg 1 Tablet 10.40 1574(E) 31-03-2340 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 370 Lamivudine Tablet 150mg 1 Tablet 10.86 1574(E) 31-03-23 Powder for 4663(E) 25-10-23 371 L-Asparaginase 1 Vial 1034.88 Injection 5000 KU Powder for 4663(E) 25-10-23 372 L-Asparaginase 1 Vial 1707.74 Injection 10000KU 373 Latanoprost Drops 0.005% 1 ML 232.58 2542(E) 08-06-23 374 Lenalidomide Capsule 5mg 1 Capsule 67.25 1574(E) 31-03-23 375 Lenalidomide Capsule 25 mg 1 Capsule 292.28 4663(E) 25-10-23 376 Letrozole Tablet 2.5mg 1 Tablet 29.32 4663(E) 25-10-23 Powder for 4663(E) 25-10-23 377 Leuprolide acetate 1 Vial 17081.50 injection 22.5 mg Powder for 4663(E) 25-10-23 378 Leuprolide acetate 1 Vial 9294.48 injection 11.25mg Powder for 1574(E) 31-03-23 379 Leuprolide acetate 1 Vial 3112.67 injection 3.75 mg 380 Levetiracetam Tablet 250mg 1 Tablet 6.30 1574(E) 31-03-23 381 Levetiracetam Tablet 500mg 1 Tablet 12.98 1574(E) 31-03-23 Modified Release 4663(E) 25-10-23 382 Levetiracetam 1 Tablet 18.30 Tablet 750mg 383 Levetiracetam Tablet 750mg 1 Tablet 19.34 1574(E) 31-03-23 Oral liquid 100 4663(E) 25-10-23 384 Levetiracetam 1 ML 3.97 mg/mL (p) Injection 4663(E) 25-10-23 385 Levetiracetam 1 ML 23.02 100mg/mL Modified Release– 1574(E) 31-03-23 386 Levodopa (A) + Carbidopa (B) Tablet 200mg (A) + 1 Tablet 4.73 50mg (B) Tablet 100 mg (A) 4663(E) 25-10-23 387 Levodopa (A) +Carbidopa(B) 1 Tablet 2.58 + 25 mg (B) Tablet 100 mg (A) 1574(E) 31-03-23 388 Levodopa (A) +Carbidopa(B) 1 Tablet 1.76 + 10 mg (B) Tablet 250mg(A) 4663(E) 25-10-23 389 Levodopa (A) +Carbidopa(B) 1 Tablet 4.42 +25mg(B) Modified Release– 1574(E) 31-03-23 390 Levodopa (A) +Carbidopa(B) Tablet 100 mg (A) 1 Tablet 2.79 + 25 mg (B) 391 Levofloxacin Tablet 750mg 1 Tablet 12.45 4663(E) 25-10-23 392 Levofloxacin Tablet 250mg 1 Tablet 4.82 1697(E) 12-04-23 393 Levofloxacin Tablet 500mg 1 Tablet 8.99 1697(E) 12-04-23 394 Levothyroxine Tablet 50mcg 1 Tablet 1.03 1574(E) 31-03-23 395 Levothyroxine Tablet 75mcg 1 Tablet 1.44 4663(E) 25-10-23 396 Levothyroxine Tablet 88 mcg 1 Tablet 1.65 4663(E) 25-10-23 397 Levothyroxine Tablet 112 mcg 1 Tablet 1.66 4663(E) 25-10-23 398 Levothyroxine Tablet 25 mcg 1 Tablet 1.45 4663(E) 25-10-23 399 Levothyroxine Tablet 62.5mcg 1 Tablet 1.61 1574(E) 31-03-23 400 Levothyroxine Tablet 12.5mcg 1 Tablet 1.48 1574(E) 31-03-23 401 Levothyroxine Tablet 100mcg 1 Tablet 1.32 1574(E) 31-03-23 402 Levothyroxine Tablet 125mcg 1 Tablet 1.69 1574(E) 31-03-23 403 Levothyroxine Tablet 150 mcg 1 Tablet 1.70 1577(E) 31-03-23 Topical forms 2-5 1574(E) 31-03-23 404 Lignocaine 1 GM/ML 1.13 % 405 Lignocaine Injection 2% 1 ML 1.04 1574(E) 31-03-23 406 Lignocaine Injection 1% 1 ML 8.87 4663(E) 25-10-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 41 Injection 5% with 4663(E) 25-10-23 407 Lignocaine 1 ML 3.50 7.5% glucose Injection2%(A)+1:2 1577(E) 31-03-23 Lignocaine (A) 408 00000(5 1 ML 1.05 +Adrenaline(B) mcg/mL)(B) 409 Linezolid Tablet 600mg 1 Tablet 35.67 4663(E) 25-10-23 410 Linezolid Tablet 300 mg 1 Tablet 22.65 4663(E) 25-10-23 411 Lithium Tablet 300mg 1 Tablet 1.63 4663(E) 25-10-23 412 Loperamide Tablet 2mg 1 Tablet 2.28 4663(E) 25-10-23 413 Loperamide Capsule 2mg 1 Capsule 3.79 4663(E) 25-10-23 Tablet 200 mg (A) 4663(E) 25-10-23 414 Lopinavir (A) + Ritonavir(B) 1 Tablet 47.97 + 50mg (B) 415 Lorazepam Tablet 1 mg 1 Tablet 2.31 4663(E) 25-10-23 416 Lorazepam Tablet 2 mg 1 Tablet 2.81 1574(E) 31-03-23 417 Lorazepam Injection 2mg/mL 1 ML 8.10 4663(E) 25-10-23 Injection 4663(E) 25-10-23 418 Magnesium sulphate 1 ML 4.87 500mg/mL 419 Mannitol Injection 20 % 1 ML 0.35 4663(E) 25-10-23 420 Mannitol Injection 10 % 1 ML 0.19 1577(E) 31-03-23 421 Mebendazole Tablet 100 mg 1 Tablet 2.90 1574(E) 31-03-23 Oral liquid 1574(E) 31-03-23 422 Mebendazole 1 ML 0.84 100mg/5mL(p) 423 Medroxyprogesterone acetate Tablet 10 mg 1 Tablet 6.25 4663(E) 25-10-23 Injection 4663(E) 25-10-23 424 Medroxyprogesterone acetate 1 ML 289.77 150mg/mL Oral liquid 1574(E) 31-03-23 425 Mefenamic acid 1 ML 0.56 100mg/5mL(p) 426 Mefenamic acid Tablet 250 mg 1 Tablet 2.11 4663(E) 25-10-23 427 Mefloquine Tablet 250 mg 1 Tablet 52.16 4663(E) 25-10-23 428 Meglumine diatrizoate Injection 60%w/v 1 ML 9.47 1574(E) 31-03-23 429 Meglumine diatrizoate Injection 76%w/v 1 ML 10.20 1574(E) 31-03-23 Powder for 1579(E) 31-03-23 430 Meropenem Injection 500 mg 1 Vial 723.02 (as trihydrate) Powder for 4663(E) 25-10-23 431 Meropenem Injection1000mg 1 Vial 952.74 (as trihydrate) Injection 4663(E) 25-10-23 432 Mesna 1 ML 15.51 100mg/mL 433 Metformin Tablet 1000mg 1 Tablet 3.49 4663(E) 25-10-23 434 Metformin Tablet 500mg 1 Tablet 2.02 4663(E) 25-10-23 Modified release 4663(E) 25-10-23 435 Metformin 1 Tablet 4.05 Tablet 1000mg 436 Methotrexate Tablet 10mg 1 tablet 13.29 4663(E) 25-10-23 437 Methotrexate Tablet 2.5mg 1 tablet 5.31 1574(E) 31-03-23 438 Methotrexate Tablet 5mg 1 Tablet 9.43 4663(E) 25-10-23 439 Methylergometrine Tablet 0.125mg 1 Tablet 8.94 4663(E) 25-10-23 440 Methylergometrine Injection 0.2mg/mL 1 ML 14.95 4663(E) 25-10-23 441 Methylprednisolone Injection 40mg/mL 1 ML 45.67 4663(E) 25-10-23 442 Metoclopramide Tablet 10mg 1 Tablet 1.35 4663(E) 25-10-23 Injection 5mg/mL 4663(E) 25-10-23 443 Metoclopramide (Less than 10ML 1 ML 2.67 Pack)42 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Injection 5mg/mL 4663(E) 25-10-23 444 Metoclopramide (10 ML & More 1 ML 1.63 Pack) Oral liquid 1577(E) 31-03-23 445 0.50 Metoclopramide 5mg/5mL(p) 1 ML 446 Metoprolol Tablet 25mg 1 Tablet 4.20 1574(E) 31-03-23 447 Metoprolol Tablet 50mg 1 Tablet 5.84 1574(E) 31-03-23 Modified Release 1574(E) 31-03-23 448 Metoprolol 1 Tablet 14.99 Tablet 100 mg 449 Metoprolol Tablet 100 mg 1 Tablet 11.13 1574(E) 31-03-23 450 Metoprolol Capsule 25mg 1 Capsule 4.14 4663(E) 25-10-23 451 Metoprolol Capsule 50mg 1 Capsule 5.82 4663(E) 25-10-23 452 Metoprolol Injection 1mg/ML 1 ML 3.40 4663(E) 25-10-23 453 Metronidazole Tablet 200mg 1 Tablet 0.82 4663(E) 25-10-23 454 Metronidazole Tablet 400mg 1 Tablet 1.52 1574(E) 31-03-23 Injection 1574(E) 31-03-23 455 Metronidazole 1 ML 0.21 500mg/100mL Oral liquid 4663(E) 25-10-23 456 Metronidazole 1 ML 0.52 200mg/5mL(p) Nasal Spray 4663(E) 25-10-23 457 Midazolam 1 ML 216.82 1.25mg/ actuation Nasal Spray 0.5 1574(E) 31-03-23 458 Midazolam 1 ML 79.93 mg/actuation 459 Midazolam Injection 1mg/mL 1 ML 5.92 1574(E) 31-03-23 460 Midazolam Injection 5mg/mL 1 ML 10.88 4663(E) 25-10-23 461 Mifepristone Tablet 200mg 1 Tablet 350.92 4663(E) 25-10-23 462 Misoprostol Tablet 200mcg 1 Tablet 18.97 1574(E) 31-03-23 463 Misoprostol Tablet 100mcg 1 Tablet 9.92 1574(E) 31-03-23 464 Montelukast Tablet 4 mg 1 Tablet 10.03 1574(E) 31-03-23 465 Montelukast Tablet 10 mg 1 Tablet 16.44 4663(E) 25-10-23 466 Morphine Injection 10mg/mL 1 ML 19.60 4663(E) 25-10-23 467 Morphine Injection 15mg/mL 1 ML 14.93 1574(E) 31-03-23 468 Moxifloxacin Tablet 400mg 1 Tablet 25.82 1574(E) 31-03-23 469 Mupirocin Ointment 2% 1 GM 20.29 1579(E) 31-03-23 470 Mycophenolate mofetil Tablet 250mg 1 Tablet 49.60 1574(E) 31-03-23 Injection 200 4663(E) 25-10-23 471 N-acetylcysteine 1 ML 23.64 mg/mL 472 Naloxone Injection 0.4mg/mL 1 ML 92.73 1574(E) 31-03-23 473 Natamycin Drops 5% 1 ML 23.38 4663(E) 25-10-23 474 Neostigmine Injection 0.5mg/mL 1 ML 5.01 1574(E) 31-03-23 475 Neostigmine Tablet 15mg 1 Tablet 4.59 4663(E) 25-10-23 476 Nevirapine Tablet 200 mg 1 Tablet 15.80 4663(E) 25-10-23 Nicotine (for nicotine 4663(E) 25-10-23 477 Lozenge 2mg 1 Lozenges 7.92 replacement therapy) Nicotine (for nicotine 4663(E) 25-10-23 478 Gum 2 mg 1 Gum 8.59 replacement therapy) Nicotine (for nicotine 1579(E) 31-03-23 479 Gum 4 mg 1 Gum 10.64 replacement therapy) Nicotine (for nicotine 1579(E) 31-03-23 480 Lozenge 4mg 1 Lozenges 9.75 replacement therapy) 481 Nifedipine Tablet 10mg 1 Tablet 1.54 4663(E) 25-10-23 482 Nifedipine Capsule10mg 1 Capsule 0.95 1577(E) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 43 483 Nitrofurantoin Tablet 100 mg 1 Tablet 8.11 4663(E) 25-10-23 484 Nitrofurantoin Capsule 100 mg 1 Capsule 8.64 1577(E) 31-03-23 Oral liquid 4663(E) 25-10-23 485 Nitrofurantoin 1 ML 0.89 25mg/5mL(p) 486 Noradrenaline Injection 2mg/mL 1 ML 20.17 1574(E) 31-03-23 487 Norethisterone Tablet 5mg 1 Tablet 5.39 1574(E) 31-03-23 488 Omeprazole Capsule 20 mg 1 Capsule 2.87 1574(E) 31-03-23 489 Omeprazole Tablet 20 mg 1 Tablet 4.34 4663(E) 25-10-23 490 Omeprazole Capsule 10 mg 1 Capsule 2.41 1577(E) 31-03-23 Powder for oral 1577(E) 31-03-23 491 Omeprazole 1 GM 1.51 liquid 20mg 492 Omeprazole Tablet 40 mg 1 Tablet 8.45 1577(E) 31-03-23 493 Ondansetron Tablet 4 mg 1 Tablet 5.14 4663(E) 25-10-23 Oral liquid 4663(E) 25-10-23 494 Ondansetron 1 ML 1.26 2mg/5mL(p) 495 Ondansetron Injection 2mg/mL 1 ML 5.96 1574(E) 31-03-23 496 Ondansetron Tablet 8 mg 1 Tablet 9.06 4663(E) 25-10-23 497 Oral rehydration salts As licensed 1 ML 0.15 4663(E) 25-10-23 498 Ormeloxifene (Centchroman) Tablet 30mg 1 Tablet 8.44 1579(E) 31-03-23 Injection 5 mg/mL 4663(E) 25-10-23 499 Oxaliplatin 1 Vial 2233.95 in 10 mL vial 500 Oxytocin Injection 5 IU/mL 1 ML 17.84 4663(E) 25-10-23 501 Oxytocin Injection 10IU/mL 1 ML 39.87 1577(E) 31-03-23 Injection 30 mg/5 1577(E) 31-03-23 502 Paclitaxel mL, injection 100 1 ML 215.44 mg/16.7 ml 503 Pantoprazole Injection 40mg 1 Vial 50.45 1574(E) 31-03-23 504 Paracetamol Tablet 650mg 1 Tablet 2.01 4663(E) 25-10-23 Oral Liquid 125 1574(E) 31-03-23 505 Paracetamol 1 ML 0.37 mg/5 mL (p) Oral Liquid 250 1574(E) 31-03-23 506 Paracetamol 1 ML 0.67 mg/5 mL (p) Oral liquid 120 4663(E) 25-10-23 507 Paracetamol 1 ML 0.61 mg/5 mL (p) 508 Paracetamol Tablet 500mg 1 Tablet 0.90 4663(E) 25-10-23 1 1574(E) 31-03-23 509 Paracetamol Suppository 80mg 6.66 Suppository 1 4663(E) 25-10-23 510 Paracetamol Suppository 170mg 7.95 Suppository Injection 2124(E) 04-05-23 511 Paracetamol 1 ML 3.97 150mg/mL (2ML) Injection150mg/mL 2125(E) 04-05-23 512 Paracetamol 1 ML 1.60 (100 ML) 513 Permethrin Cream 5% 1 GM 1.85 1577(E) 31-03-23 514 Permethrin Lotion 1% 1 ML 1.00 4663(E) 25-10-23 515 Permethrin Cream 1% 1 GM 1.50 1577(E) 31-03-23 516 Permethrin Lotion 5% 1 ML/GM 1.00 4663(E) 25-10-23 517 Permethrin Gel 5% 1 GM 1.31 2540(E) 08-06-23 Injection 4663(E) 25-10-23 518 Pheniramine 1 ML 2.76 22.75mg/mL (2ml) Injection 1577(E) 31-03-23 519 Pheniramine 22.75mg/mL 1 ML 2.06 (10ml)44 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 520 Phenobarbitone Tablet 30mg 1 Tablet 1.31 1574(E) 31-03-23 521 Phenobarbitone Tablet 60mg 1 Tablet 1.89 1574(E) 31-03-23 Injection 1574(E) 31-03-23 522 Phenobarbitone 1 ML 22.14 200mg/mL Oral liquid 1574(E) 31-03-23 523 Phenobarbitone 1 ML 0.49 20mg/5mL (p) 524 Phenytoin Tablet 300mg 1 Tablet 5.48 1574(E) 31-03-23 525 Phenytoin Injection 50mg/mL 1 ML 5.95 1574(E) 31-03-23 Modified Release 1577(E) 31-03-23 526 Phenytoin 1 Tablet 6.57 Tablet 300mg 527 Phenytoin Tablet 100mg 1 Tablet 1.76 1577(E) 31-03-23 528 Phenytoin Tablet 50mg 1 Tablet 0.84 1577(E) 31-03-23 Oral liquid 30mg/5 4663(E) 25-10-23 529 Phenytoin 1 ML 0.35 mL(p) Oral liquid 4663(E) 25-10-23 530 Phenytoin 1 ML 1.10 125mg/5mL(p) 531 Phenytoin Capsule 300mg 1 Capsule 4.65 1577(E) 31-03-23 532 Phenytoin Capsule 100mg 1 Capsule 1.83 4663(E) 25-10-23 533 Phytomenadione (Vitamin K1) Injection 10mg/mL 1 ML 53.09 4663(E) 25-10-23 534 Phytomenadione (Vitamin K1) Tablet 10mg 1 Tablet 14.54 1577(E) 31-03-23 535 Pilocarpine Drops 2 % 1 ML 10.83 1574(E) 31-03-23 Powder for 1574(E) 31-03-23 Piperacillin (A) Injection 536 1 Vial 99.66 +Tazobactam(B) 1000mg(A)+125mg (B) Powder for 4663(E) 25-10-23 Piperacillin (A) Injection 537 1 Vial 191.55 +Tazobactam(B) 2000mg(A)+250mg (B) Powder for 4663(E) 25-10-23 Piperacillin (A) Injection 538 1 Vial 399.41 +Tazobactam(B) 4000mg(A)+500mg (B) Oral liquid 1574(E) 31-03-23 539 Potassium chloride 1 ML 0.30 500mg/5mL Injection 4663(E) 25-10-23 540 Potassium chloride 1 ML 2.40 150mg/mL 541 Povidone iodine Solution 5% 1 ML 0.44 4663(E) 25-10-23 542 Povidone iodine Solution 7.5% 1 ML 0.82 4663(E) 25-10-23 543 Povidone iodine Solution 10% 1 ML 0.96 1574(E) 31-03-23 544 Povidone iodine Solution 4% 1 ML 1.74 2168(E) 11-05-23 545 Pralidoxime chloride (2-PAM) Injection 25mg/mL 1 ML 4.56 1574(E) 31-03-23 546 Prednisolone Tablet 40mg 1 Tablet 3.41 4663(E) 25-10-23 Oral liquid 1574(E) 31-03-23 547 Prednisolone 1 ML 0.49 5mg/5mL(p) Oral liquid 1574(E) 31-03-23 548 Prednisolone 1 ML 0.86 15mg/5mL(p) 549 Prednisolone Tablet 10mg 1 Tablet 1.20 4663(E) 25-10-23 550 Prednisolone Tablet 5mg 1 Tablet 0.68 1574(E) 31-03-23 551 Prednisolone Tablet 20mg 1 Tablet 2.40 4663(E) 25-10-23 552 Prednisolone Drops 1% 1 ML 5.76 1574(E) 31-03-23 Premix Insulin 30:70 Injection Injection 40 IU /ml 1 ml 4663(E) 25-10-23 553 16.99 (Regular:NPH) 554 Primaquine Tablet 7.5mg 1 Tablet 2.38 4663(E) 25-10-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 45 555 Primaquine Tablet 15mg 1 Tablet 5.14 4663(E) 25-10-23 556 Primaquine Tablet 2.5mg 1 Tablet 1.75 4663(E) 25-10-23 557 Proparacaine Eye Drops0.5% 1 ML 10.25 4663(E) 25-10-23 558 Propofol Injection 10mg/mL 1 ML 6.50 1574(E) 31-03-23 559 Propranolol Tablet 40mg 1 Tablet 3.22 4663(E) 25-10-23 560 Propranolol Tablet 10mg 1 Tablet 1.31 1574(E) 31-03-23 561 Propranolol Tablet 20mg 1 Tablet 3.20 4663(E) 25-10-23 562 Propranolol Capsule 40mg 1 Capsule 4.25 4663(E) 25-10-23 563 Propranolol Capsule 20 mg 1 Capsule 2.35 1578(E) 31-03-23 564 Propranolol Capsule 10 mg 1 Capsule 2.00 4663(E) 25-10-23 565 Protamine Sulphate Injection 10mg/mL 1 ML 9.78 4663(E) 25-10-23 566 Pyrazinamide Tablet 1000mg 1 Tablet 10.53 4663(E) 25-10-23 567 Pyrazinamide Tablet 500mg 1 Tablet 4.89 4663(E) 25-10-23 568 Pyrazinamide Tablet 750mg 1 Tablet 7.21 4663(E) 25-10-23 569 Pyrazinamide Tablet 1500mg 1 Tablet 11.81 4663(E) 25-10-23 570 Pyridoxine Tablet 100 mg 1 Tablet 5.98 4663(E) 25-10-23 571 Pyridoxine Tablet 10mg 1 Tablet 0.11 1577(E) 31-03-23 572 Quinine Tablet 300 mg 1 Tablet 5.65 1574(E) 31-03-23 Injection 300 4663(E) 25-10-23 573 Quinine 1 ML 9.50 mg/mL 574 Rabies vaccine As licensed 1 Vial 378.71 1574(E) 31-03-23 575 Raltegravir Tablet 400mg 1 Tablet 147.80 4663(E) 25-10-23 576 Ramipril Tablet 2.5 mg 1 Tablet 5.21 1574(E) 31-03-23 577 Ramipril Tablet 5mg 1 Tablet 8.18 1574(E) 31-03-23 578 Ramipril Capsule 2.5mg 1 Capsule 4.66 1577(E) 31-03-23 579 Ramipril Capsule 5mg 1 Capsule 7.19 4663(E) 25-10-23 580 Ribavirin Capsule 200 mg 1 Capsule 26.49 1574(E) 31-03-23 581 Rifampicin Capsule 600mg 1 Capsule 11.36 4663(E) 25-10-23 582 Rifampicin Capsule 450mg 1 Capsule 5.67 1574(E) 31-03-23 583 Rifampicin Capsule 150mg 1 Capsule 2.29 4663(E) 25-10-23 584 Rifampicin Capsule 300mg 1 Capsule 4.61 4663(E) 25-10-23 Oral liquid 1574(E) 31-03-23 585 Rifampicin 1 ML 0.47 100mg/5mL(p) 586 Risperidone Tablet 1 mg 1 Tablet 3.03 4663(E) 25-10-23 587 Risperidone Tablet 2 mg 1 Tablet 4.48 1574(E) 31-03-23 588 Risperidone Tablet 4 mg 1 Tablet 7.36 4663(E) 25-10-23 589 Risperidone Oral liquid 1mg/mL 1 ML 2.21 4663(E) 25-10-23 Injection 2125(E) 04-05-23 590 Risperidone 1 ML 1930.30 (Longacting) 25mg Injection 2125(E) 04-05-23 591 Risperidone (Longacting) 37.5 1 ML 2649.41 mg 592 Ritonavir Tablet 100mg 1 Tablet 29.21 4663(E) 25-10-23 593 Rituximab Injection 10mg/mL 1 ML 761.81 4663(E) 25-10-23 594 Rota virus vaccine As licensed 1 Vial 854.58 4663(E) 25-10-23 595 Salbutamol Tablet 4 mg 1 Tablet 0.21 1574(E) 31-03-23 596 Salbutamol Tablet 2 mg 1 Tablet 0.18 4663(E) 25-10-23 Oral liquid 4663(E) 25-10-23 597 Salbutamol 1 ML 0.18 2mg/5mL 598 Salbutamol Inhalation 1 Dose 0.49 1574(E) 31-03-2346 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (MDI/DPI) 100mcg/dose Respirator Solution 1574(E) 31-03-23 599 Salbutamol (Solution for 1 ML 0.68 Nebulizer 5mg/mL) Ointment 3-6% 4663(E) 25-10-23 600 Salicylic acid 1 GM 2.02 (6%) 601 Salicylicacid Ointment 3% 1 GM 2.06 1579(E) 31-03-23 Liquid for 4663(E) 25-10-23 602 Sevoflurane 1 ML 31.17 inhalation Injection (as per IP) 4663(E) 25-10-23 603 Sodium bicarbonate 1 ML 1.35 - 8.4% Injection (as per IP) 4663(E) 25-10-23 604 Sodium bicarbonate 1 ML 1.01 - 7.5% 605 Sodium Valproate Tablet 300mg 1 Tablet 4.46 1574(E) 31-03-23 Oral liquid 1574(E) 31-03-23 606 Sodium Valproate 1 ML 0.65 200mg/5mL(p) 607 Sodium Valproate Tablet 200mg 1 Tablet 3.59 4663(E) 25-10-23 Modified Release – 1574(E) 31-03-23 608 Sodium Valproate 1 Tablet 9.28 Tablet 500mg 609 Sodium Valproate Tablet 500mg 1 Tablet 8.12 4663(E) 25-10-23 Modified Release – 4663(E) 25-10-23 610 Sodium Valproate 1 Tablet 6.10 Tablet 300mg Injection 4663(E) 25-10-23 611 Sodium Valproate 1 ML 6.75 100mg/mL 612 Sofosbuvir Tablet 400mg 1 Tablet 525.12 4663(E) 25-10-23 Powder for 4663(E) 25-10-23 613 Somatostatin 1 Vial 1359.00 Injection 3mg 614 Spironolactone Tablet 50mg 1 Tablet 4.37 1574(E) 31-03-23 615 Spironolactone Tablet 25mg 1 Tablet 2.19 4663(E) 25-10-23 Injection 1574(E) 31-03-23 616 Streptokinase 1 Vial 1877.33 15,00,000IU Powder for 1574(E) 31-03-23 617 Streptomycin 1 Vial 10.10 Injection 750 mg Powder for 1574(E) 31-03-23 618 Streptomycin 1 Vial 10.86 Injection 1000mg 619 Succinylcholine Injection 50mg/mL 1 ML 5.21 2540(E) 08-06-23 620 Sulfasalazine Tablet 500 mg 1 Tablet 4.72 1574(E) 31-03-23 621 Sumatriptan Tablet 25mg 1 Tablet 32.50 2540(E) 08-06-23 622 Sumatriptan Tablet 50mg 1 Tablet 55.68 2540(E) 08-06-23 623 Tacrolimus Capsule 0.5mg 1 Capusle 20.66 1574(E) 31-03-23 624 Tacrolimus Capsule 1mg 1 Capusle 40.62 1574(E) 31-03-23 625 Tacrolimus Capsule 2mg 1 Capusle 84.34 4663(E) 25-10-23 626 Tacrolimus Tablet 1mg 1 Tablet 39.98 4886(E) 10-11-23 627 Tacrolimus Tablet 2mg 1 Tablet 77.69 4886(E) 10-11-23 628 Tacrolimus Tablet 0.5mg 1 Tablet 20.97 4886(E) 10-11-23 629 Tamoxifen Tablet 20mg 1 Tablet 2.95 4663(E) 25-10-23 630 Tamoxifen Tablet 10mg 1 Tablet 2.21 4663(E) 25-10-23 631 Telmisartan Tablet 20mg 1 Tablet 3.88 4663(E) 25-10-23 632 Telmisartan Tablet 40mg 1 Tablet 6.76 1574(E) 31-03-23 633 Telmisartan Tablet 80mg 1 Tablet 10.40 1574(E) 31-03-23 634 Temozolomide Capsule 20 mg 1 Capsule 441.33 1574(E) 31-03-23 635 Temozolomide Capsule 250mg 1 Capsule 4304.01 1574(E) 31-03-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 47 636 Temozolomide Capsule 100mg 1 Capsule 1508.70 1574(E) 31-03-23 637 Temozolomide Tablet 20 mg 1 Tablet 336.65 4886(E) 10-11-23 638 Temozolomide Tablet 250 mg 1 Tablet 3758.15 4886(E) 10-11-23 639 Tenecteplase Injection 40mg/vial 1 Vial 50389.69 4663(E) 25-10-23 640 Tenecteplase Injection 30mg/vial 1 Vial 36910.02 4663(E) 25-10-23 641 Teneligliptin Tablet 20mg 1 Tablet 11.09 4663(E) 25-10-23 Tenofovir Alafenamide 1574(E) 31-03-23 642 Tablet 25mg 1 Tablet 48.87 Fumarate (TAF) Tenofovir Disproxil Fumarate Tablet 300mg (A) + 4663(E) 25-10-23 643 1 Tablet 45.58 (A) + Lamivudine (B) 300mg(B) Tenofovir Disproxil Fumarate Tablet 300mg(A)+ 4663(E) 25-10-23 644 (A) +Lamivudine (B) + 300mg (B) + 1 Tablet 102.85 Efavirenz(C) 600mg(C) Tenofovir Disproxil Fumarate 4663(E) 25-10-23 645 Tablet 300mg 1 Tablet 45.84 (TDF)* 646 Terbinafine Cream 1% 1 GM 5.26 4663(E) 25-10-23 647 Tetanus toxoid As licensed (5ml) 1 Vial 25.53 1577(E) 31-03-23 1 Vial 4663(E) 25-10-23 648 Tetanus toxoid As licensed (0.5ml) 12.47 (0.5ML) 649 Thalidomide Capsule 50 mg 1 Capsule 31.16 4663(E) 25-10-23 650 Thalidomide Capsule 100mg 1 Capsule 62.01 1574(E) 31-03-23 651 Thiamine Tablet 100 mg 1 Tablet 4.46 1574(E) 31-03-23 Injection 100 1574(E) 31-03-23 652 Thiamine 1 ML 22.59 mg/mL Powder for 2540(E) 08-06-23 653 Thiopentone 1 Vial 55.32 injection 1g Powder for 2540(E) 08-06-23 654 Thiopentone 1 Vial 45.69 injection 0.5g 655 Timolol Drops 0.5 % 1 ML 13.40 4663(E) 25-10-23 Inhalation (MDI) 9 1574(E) 31-03-23 656 Tiotropium 1 MD 2.78 mcg/dose Inhalation (DPI) 4663(E) 25-10-23 657 Tiotropium 1 DP 10.71 18mcg/dose Injection 50mg/mL 1574(E) 31-03-23 658 Tramadol 1 ML 11.78 (upto 2ml pack) 659 Tramadol Capsule 50mg 1 Capsule 4.82 1577(E) 31-03-23 660 Tramadol Capsule 100mg 1 Capsule 9.04 4663(E) 25-10-23 661 Tramadol Tablet 50mg 1 Tablet 9.70 4886(E) 10-11-23 662 Tramadol Tablet 100mg 1 Tablet 24.48 4886(E) 10-11-23 Injection 100 1574(E) 31-03-23 663 Tranexamic acid 1 ML 13.71 mg/mL 664 Tranexamic acid Tablet 500 mg 1 Tablet 18.54 1574(E) 31-03-23 Injection 4663(E) 25-10-23 665 Trastuzumab 1 Vial 54725.21 440mg/50mL 666 Trihexyphenidyl Tablet 2mg 1 Tablet 1.37 4663(E) 25-10-23 667 Tropicamide Eye drop 1 % 1 ML 9.43 4663(E) 25-10-23 668 Valganciclovir Tablet 450 mg 1 Tablet 400.73 1574(E) 31-03-23 Powder for 4663(E) 25-10-23 669 Vancomycin 1 Vial 317.64 Injection 500 mg Powder for 4663(E) 25-10-23 670 Vancomycin 1 Vial 470.27 Injection 1000mg Powder for 1574(E) 31-03-23 671 Vancomycin 1 Vial 251.25 Injection 250 mg48 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 672 Vancomycin Capsule 250 mg 1 Capsule 152.39 1578(E) 31-03-23 Powder for 4663(E) 25-10-23 673 Vecuronium Each Vial 117.37 injection 10mg Powder for 1574(E) 31-03-23 674 Vecuronium Each Vial 74.40 injection 4 mg 675 Verapamil Tablet 80 mg 1 Tablet 1.59 1574(E) 31-03-23 676 Verapamil Tablet 40mg 1 Tablet 0.86 1574(E) 31-03-23 677 Vincristine Injection 1mg/mL 1 ML 57.52 4663(E) 25-10-23 Tablet 50000IU 4663(E) 25-10-23 678 Vitamin A (including 1 Tablet 0.73 Chewable Tablet) Injection 1577(E) 31-03-23 679 Vitamin A 1 ML 2.26 50000IU/mL 680 Warfarin Tablet 5 mg 1 Tablet 2.40 2540(E) 08-06-23 681 Warfarin Tablet 3 mg 1 Tablet 3.18 2540(E) 08-06-23 682 Warfarin Tablet 2 mg 1 Tablet 2.72 2540(E) 08-06-23 683 Warfarin Tablet 1 mg 1 Tablet 2.46 2540(E) 08-06-23 684 Xylometazoline Nasal drops 0.05 % 1 ML 4.19 1574(E) 31-03-23 685 Xylometazoline Nasal drops 0.1% 1 ML 5.12 1574(E) 31-03-23 Tablet 1574(E) 31-03-23 Zidovudine (A) +Lamivudine 686 300mg(A)+150mg( 1 Tablet 21.13 (B) +Nevirapine(C) B)+200mg (c) Tablet 1574(E) 31-03-23 Zidovudine (A) 687 300mg(A)+150mg( 1 Tablet 21.09 +Lamivudine(B) B) Dispersible Tablet 4886(E) 10-11-23 688 Zinc Sulphate 1 Tablet 3.41 20mg Powder for 4663(E) 25-10-23 689 Zoledronic acid 1 Vial 2392.05 Injection 4mg 690 Zolpidem Tablet 5mg 1 Tablet 6.21 1574(E) 31-03-23 691 Zolpidem Tablet 10mg 1 Tablet 8.51 1574(E) 31-03-23 Tablet 600mg (A) + 939(E) 28-02-24 692 Darunavir (A) +Ritonavir (B) 1 Tablet 146.46 100mg (B) Nicotine (for nicotine Oral Dosage forms 939(E) 28-02-24 693 1 Pastille 7.12 replacement therapy) 2mg Pastille Nicotine (for nicotine Oral Dosage forms 939(E) 28-02-24 694 1 Pastille 7.83 replacement therapy) 4mg Pastille 695 Levonorgestrel Tablet 1.5mg 1 Tablet 75.35 939(E) 28-02-24 Solid oral dosage 939(E) 28-02-24 form 1000 IU 696 Cholecalciferol 1 Gram 23.14 Sachet/ Granuels / Powder Tenofovir Disproxil Fumarate Tablet 300mg + 939(E) 28-02-24 697 1 Tablet 114.99 + Lamivudine + Dolutegravir 300mg + 50 mg 698 Zidovudine Tablet 300 mg 1 Tablet 13.59 938(E) 28-02-24 Powder for 938(E) 28-02-24 699 Benzathine benzylpenicillin Injection 12 lac 1 Vial 19.81 units Powder for 938(E) 28-02-24 700 Benzathine benzylpenicillin 1 Vial 11.69 Injection 6 lac units 701 Fentanyl Injection 50mcg/ml 1 ml 20.96 938(E) 28-02-24 702 Folic Acid Capsule 5 mg 1 Capsule 5.04 938(E) 28-02-24 703 Hyoscine butylbromide Injection 20 mg/ml 1 ml 11.24 938(E) 28-02-24 704 Omeprazole Capsule 40 mg 1 Capsule 5.67 938(E) 28-02-24[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 49 Powder for 938(E) 28-02-24 705 Desferrioxamine 1 Vial 188.65 Injection 500mg Lyophilized 938(E) 28-02-24 1 Vial of 10 706 Snake venom antiserum polyvalent - As 665.26 ml Licensed Soluble/ Liquid 938(E) 28-02-24 1 Vial of 10 707 Snake Venom Antiserum Polyvalent - As 428.67 ml Licensed 708 Chlorambucil Tablet 2 mg 1 Tablet 31.16 938(E) 28-02-24 709 Chlorambucil Tablet 5 mg 1 Tablet 77.21 938(E) 28-02-24 710 Melphalan Tablet 2 mg 1 Tablet 91.34 938(E) 28-02-24 711 Melphalan Tablet 5 mg 1 Tablet 86.04 938(E) 28-02-24 712 Arsenic Trioxide Injection 1mg/ml 1 ml 30.54 938(E) 28-02-24 Injection 250 mg/5 938(E) 28-02-24 713 5-Fluorouracil 1 ml 2.04 ml Conventional / 938(E) 28-02-24 Effervescent / 714 Acetylsalicylic acid Dispersible / 1 Tablet 0.67 Enteric coated Tablets 325 mg Inhalation (MDI) 1 Metered 938(E) 28-02-24 715 Budesonide 1.41 100 mcg/dose Dose Inhalation (MDI) 1 Metered 938(E) 28-02-24 716 Budesonide 2.03 200 mcg/dose Dose Inhalation (DPI) 938(E) 28-02-24 717 Budesonide 1 Dose 3.33 200 mcg/dose Nasal Spray 100 938(E) 28-02-24 718 Budesonide 1 Dose 0.81 mcg/dose Inhalation (MDI) 938(E) 28-02-24 Budesonide (A)+ Formoterol 1 Metered 719 100 mcg (A) + 6 2.12 (B) Dose mcg (B) Inhalation (DPI) 938(E) 28-02-24 Budesonide (A)+ Formoterol 720 100 mcg (A) + 6 1 Dose 4.32 (B) mcg (B) Inhalation (DPI) 938(E) 28-02-24 Budesonide (A)+ Formoterol 721 200 mcg (A) + 6 1 Dose 5.72 (B) mcg (B) Inhalation (DPI) 938(E) 28-02-24 Budesonide (A)+ Formoterol 722 400 mcg (A) + 6 1 Dose 6.62 (B) mcg (B) Oxygen – Liquid Medical As licensed for 1580(E) 31-03-23 723 Cubic Meter 17.02 Oxygen medical purpose As licensed for 1580(E) 31-03-23 724 Oxygen (in cylinder) Cubic Meter 28.83 medical purpose As licensed for 4663(E) 25-10-23 725 Nitrous oxide Cubic Meter 285.98 medical purpose Disposable Pen containing 1581(E) 31-03-23 726 Injection 100 IU/ml 1 ML 244.14 Insulin Glargine Notes: - (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured, the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations. The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength.50 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above, the manufacturer shall approach NPPA for specific price approval for its formulations. (d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. (e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. & date as specified in column 6 (a) & 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director नई दिल्ली, 26 मार्,च 2024 का. आ. 1548(अ).— vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 4, 6, 10, 11, 14, 16, 17 18 a b[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 51 @ (0.00551%) 0.00551% (1) (2) (3) (4) (5) 6(a) 6(b) 1 5&,feukslsyhflfyd lqIiksftVªh 500 fexzk- fjVsu'ku 1 lqIiksftVªh 21.05 4663 (अ) 25.10.2023 ,flM ,fuek 2 5&,feukslsyhflfyd xksyh 400 fexzk- 1 xksyh 9.31 4663 (अ) 25.10.2023 ,flM 3 ,cdkohj ¼,½ $ xksyh 60 fexzk- ¼,½ $ 30 fexzk- 1 xksyh 25.00 1573 (अ) 31.03.2023 ysfeoqMhu ¼ch½ ¼ch½ 4 ,lhVkbylSyhflfyd bQsjoslsVa @fMLijflcy@,afVªd 1 xksyh 0.22 1573 (अ) 31.03.2023 ,flM dksfVM xksyh 100 fexzk- 5 ,lhVkbylSyhflfyd xksyh 100 fexzk- 1 xksyh 0.21 1573 (अ) 31.03.2023 ,flM 6 ,lhVkbylSyhflfyd xksyh 150 fexzk- 1 xksyh 0.50 1573 (अ) 31.03.2023 ,flM 7 ,lhVkbylSyhflfyd xksyh 350 fexzk- 1 xksyh 0.38 1573 (अ) 31.03.2023 ,flM 8 ,lhVkbylSyhflfyd xksyh 75 fexzk- 1 xksyh 0.38 1573 (अ) 31.03.2023 ,flM 9 vkWy&Vªkal jsVhukWbd dSIlwy 10 fexzk- 1 dSIlwy 101.85 1573 (अ) 31.03.2023 ,flM 10 ,EQksVsfjflu ch ¼fyfiM½ batSD'ku ds fy, ikmMj 50 izfr iSd 3990.62 1573 (अ) 31.03.2023 fexzk- 11 ,EQksVsfjflu ch batSD'ku ds fy, ikmMj 50 izfr iSd 9295.41 4663 (अ) 25.10.2023 ¼fyikslksey½ fexzk- 12 ,Eihflfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 26.56 1573 (अ) 31.03.2023 13 ,aVh&Mh bEequksXykscfqyu batSD'ku 300 ,elhth izfr iSd 2657.47 1573 (अ) 31.03.2023 14 ,aVh&Mh bEequksXykscfqyu batSD'ku 150 ,elhth izfr ok;y 2071.40 1573 (अ) 31.03.2023 15 ,aVh&jscht batSD'ku 150 vkbZ;w@fefy- 1 fefy- 3454.06 4663 (अ) 25.10.2023 bEequksXykscqfyu 16 ,aVh&jscht batSD'ku 300 vkbZ;w@fefy- 1 fefy- 121.77 1573 (अ) 31.03.2023 bEequksXykscqfyu 17 ,aVh&VsVul 250 vkbZ;w izfr iSd 1383.57 1573 (अ) 31.03.2023 bEequksXykscqfyu 18 vVslZ quVs ¼,½ $ xksyh 100 fexzk- ¼,½ $ 1 xksyh dksEch iSd 36.72 4663 (अ) 25.10.2023 lYQkMkWDlhu & ¼750 fexzk- $ 37-5 fexzk-½ ¼ch½ fifjeFs kkekbu ¼ch½ 19 vVslZ quVs ¼,½ $ xksyh 150 fexzk- ¼,½ $ 2 xksyh dksEch iSd 49.85 4663 (अ) 25.10.2023 lYQkMkWDlhu & ¼500 fexzk- $ 25 fexzk-½ ¼ch½ fifjeFs kkekbu ¼ch½ 20 vVslZ quVs ¼,½ $ xksyh 200 fexzk- ¼,½ $ 2 xksyh dksEch iSd 45.45 1573 (अ) 31.03.2023 lYQkMkWDlhu & ¼750 fexzk- $ 37-5 fexzk-½ ¼ch½ fifjeFs kkekbu ¼ch½ 21 vVslZ quVs ¼,½ $ xksyh 25 fexzk- ¼,½ $ 1 xksyh dksEch iSd 24.48 4663 (अ) 25.10.2023 lYQkMkWDlhu & ¼250 fexzk- $ 12-5 fexzk-½ ¼ch½ fifjeFs kkekbu ¼ch½ 22 chlhth oSDlhu izfr Mkst 11.12 1573 (अ) 31.03.2023 23 csutks,y isjkDlkbM Øhe 2-5% 1 xzke 2.90 1573 (अ) 31.03.2023 24 csutkby isfuflfyu batSD'ku ds fy, ikmMj 10 izfr iSd 9.71 4663 (अ) 25.10.2023 yk[k ;wfuV 25 chVkesFklksu tSy 0-05% 1 xzke 0.66 1573 (अ) 31.03.202352 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 26 chVkesFklksu yks'ku 0-1% 1 fefy- 1.02 1573 (अ) 31.03.2023 27 chVkesFklksu yks'ku 0-5% 1 fefy- 0.66 1573 (अ) 31.03.2023 28 cqMslksukbM usty Lizs 50 ,elhth@Mkst 1 Mkst 1.27 4663 (अ) 25.10.2023 29 cqMslksukbM bugsys'ku ¼MhihvkbZ½ 100 2.49 4663 (अ) 25.10.2023 ,elhth@Mkst 30 cqMslksukbM ¼,½ $ bugsys'ku ¼,eMhvkbZ½ 200 3.33 1573 (अ) 31.03.2023 QkseksVZ sjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ 31 cqMslksukbM ¼,½ $ bugsys'kku ¼,eMhvkbZ½ 400 3.80 1573 (अ) 31.03.2023 QkseksVZ sjksy ¼ch½ ,elhth ¼,½ $ 6 ,elhth ¼ch½ 32 dSfY'k;e dkWcksZusV Xksyh 500 fexzk- 1 xksyh 2.15 1573 (अ) 31.03.2023 33 dSfY'k;e XyqdksuVs batSD'ku 100 fexzk-@fefy- 1 fefy- 0.68 1573 (अ) 31.03.2023 34 lsQkMªksDlhy dSIlwy 500 fexzk- 1 dSIlwy 8.90 1573 (अ) 31.03.2023 35 lsQktksfyu batSD'ku ds fy, ikmMj 1 xzke izfr iSd 30.56 1573 (अ) 31.03.2023 36 lsQktksfyu batSD'ku ds fy, ikmMj 500 izfr iSd 19.37 1573 (अ) 31.03.2023 fexzk- 37 lsfQDlhe dSIlwy 400 fexzk- 1 dSIlwy 36.41 4663 (अ) 25.10.2023 38 lsfVªftu dSIlwy 10 fexzk- 1 dSIlwy 2.96 1573 (अ) 31.03.2023 39 DyksjgsDlkMhu lksy'q ku 5% ¼da'kuVªsV QkWj 1 fefy- 0.19 1573 (अ) 31.03.2023 fMyq'ku½ 40 DyksDlkflfyu dSIlwy 250 fexzk- 1 dSIlwy 1.41 1573 (अ) 31.03.2023 41 DyksDlkflfyu dSIlwy 500 fexzk- 1 dSIlwy 2.38 4663 (अ) 25.10.2023 42 DyksDlkflfyu xksyh 250 fexzk- 1 xksyh 2.15 1573 (अ) 31.03.2023 43 DyksDlkflfyu batSD'ku ds fy, ikmMj 250 izfr iSd 5.53 4663 (अ) 25.10.2023 fexzk- 44 dksxqys'ku QSDVj IX batSD'ku ds fy, ikmMj 600 izfr iSd 15339.76 1573 (अ) 31.03.2023 vkbZ;w 45 dksxs qys'ku QSDVj VIII batSD'ku ds fy, ikmMj 250 izfr iSd 4650.15 1573 (अ) 31.03.2023 vkbZ;w 46 dksxqys'ku QSDVj VIII batSD'ku ds fy, ikmMj 500 izfr iSd 11411.13 1573 (अ) 31.03.2023 vkbZ;w 47 lkbDyksLiksfju batSD'ku 50 fexzk-@fefy- 1 fefy- 335.80 1573 (अ) 31.03.2023 48 MkSuk:fclhu I.V. batSD'ku ds fy, ikmMj izfr iSd 302.76 1573 (अ) 31.03.2023 20 fexzk- ¼5 fexzk-@fefy-½ 49 MsDlkVªku&40 batSD'ku 10% 1 fefy- 1.05 1573 (अ) 31.03.2023 50 Mk;tsike vksjy fyD;wbZM 2 fexzk-@5 1 fefy- 3.40 4663 (अ) 25.10.2023 fefy- 51 fMDyksQus d dSIlwy 50 fexzk- 1 dSIlwy 0.76 1573 (अ) 31.03.2023 52 fMlkbDyksekbu vksjy lksyq'ku 10 fexzk-@5 1 fefy- 0.20 1573 (अ) 31.03.2023 fefy- 53 fMlkbDyksekbu xksyh 10 fexzk- 1 xksyh 0.13 1573 (अ) 31.03.2023 54 MkbuksizksLVksu xksyh 0-5 fexzk- 1 xksyh 62.31 4663 (अ) 25.10.2023 55 MkbQFksfj;k ,VhaVksDlhu 10000 vkbZ;w izfr iSd 1631.70 4663 (अ) 25.10.2023 56 MhihVh oSDlhu izfr 0-5 17.64 4663 (अ) 25.10.2023 fefy- 57 bQkohjsta dSIlwy 600 fexzk- 1 dSIlwy 78.09 1573 (अ) 31.03.2023 58 bFkkbZy ,Ydksgy lksY;q'ku 70 izfr'kr 1 fefy- 0.53 4663 (अ) 25.10.2023 ¼MhuspjM½ 59 Xkksyh 100 fexzk- byhesuVy Qsjl lkYV ¼,½ $ vk;ju ¼,½ $ 500 ,elhth 1 xksyh 0.28 1573 (अ) 31.03.2023 Qksfyd ,flM ¼ch½ ¼ch½ 60 ¶ywdksuktksy vksjy fyD;wbZM 50 fexzk-@5 1 fefy- 3.25 1573 (अ) 31.03.2023 fefy- 61 xkMkscsusV batSD'ku 529 fexzk-@fefy- 1 fefy- 135.69 4663 (अ) 25.10.2023 62 Xywdkst batSD'ku 50% 1 fefy- 0.61 4663 (अ) 25.10.2023 63 Xywdkst batSD'ku 5% 1000 fefy- 79.95 1573 (अ) 31.03.2023 Xykl[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 53 64 Xywdkst batSD'ku 5% 1000 fefy- 64.55 4663 (अ) 25.10.2023 ukWu Xykl 65 Xywdkst batSD'ku 5% 100 fefy- 22.45 4663 (अ) 25.10.2023 Xykl 66 Xywdkst batSD'ku 5% 100 fefy- 20.32 4663 (अ) 25.10.2023 ukWu Xykl 67 Xywdkst batSD'ku 5% 250 fefy- 31.01 1573 (अ) 31.03.2023 Xykl 68 Xywdkst batSD'ku 5% 250 fefy- 28.02 4663 (अ) 25.10.2023 ukWu Xykl 69 Xywdkst batSD'ku 5% 500 fefy- 44.02 4663 (अ) 25.10.2023 Xykl 70 Xywdkst batSD'ku 5% 500 fefy- 37.98 4663 (अ) 25.10.2023 ukWu Xykl 71 Xywdkst batSD'ku 10% izfr iSd 32.16 4663 (अ) 25.10.2023 ¼1000 fefy-½ 72 Xywdkst batSD'ku 10% izfr iSd 34.97 1573 (अ) 31.03.2023 ¼500 fefy-½ 73 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 1000 fefy- 80.48 1573 (अ) 31.03.2023 DyksjkbM ¼ch½ Xykl 74 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 1000 fefy- 65.03 1573 (अ) 31.03.2023 DyksjkbM ¼ch½ ukWu Xykl 75 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 100 fefy- 22.50 1573 (अ) 31.03.2023 DyksjkbM ¼ch½ Xykl 76 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 100 fefy- 20.34 4663 (अ) 25.10.2023 DyksjkbM ¼ch½ ukWu Xykl 77 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 250 fefy- 31.14 4663 (अ) 25.10.2023 DyksjkbM ¼ch½ Xykl 78 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9%¼ch½ 250 fefy- 28.12 1573 (अ) 31.03.2023 DyksjkbM ¼ch½ ukWu Xykl 79 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 500 fefy- 44.23 1573 (अ) 31.03.2023 DyksjkbM ¼ch½ Xykl 80 Xywdkst ¼,½ $ lksfM;e batSD'ku 5% ¼,½ $ 0-9% ¼ch½ 500 fefy- 38.21 1573 (अ) 31.03.2023 DyksjkbM ¼ch½ ukWu Xykl 81 XywVkjkyMsgkbM lksy'q ku 2% 1 fefy- 0.08 4663 (अ) 25.10.2023 82 xzhlksQqyfou xksyh 125 fexzk- 1 xksyh 1.02 1573 (अ) 31.03.2023 83 xzhlksQqyfou xksyh 375 fexzk- 1 xksyh 5.35 4663 (अ) 25.10.2023 84 gseksMk;ylhl ¶ywM ykblsal ds vuqlkj 1 fefy- 0.04 1573 (अ) 31.03.2023 85 g~;qeu ukWeZy lksyq'ku QkWj buQ~;wtu 5 1 fefy- 192.07 1573 (अ) 31.03.2023 bEequksXykscqfyu izfr'kr 86 g~;qeu ukWeZy lksyq'ku QkWj buQ~;wtu 10 1 fefy- 260.04 1573 (अ) 31.03.2023 bEequksXykscqfyu izfr'kr 87 g~;qeu ukWeZy lksyq'ku QkWj buQ~;wtu 1 fefy- 494.52 1573 (अ) 31.03.2023 bEequksXykscqfyu 16.5 izfr'kr 88 gkbMªksDyksjksFkkbtkbM xksyh 50 fexzk- 1 xksyh 0.10 1573 (अ) 31.03.2023 89 gkbMªkstu isjksDlkbM lksy'q ku 6% 1 fefy- 0.04 1573 (अ) 31.03.2023 90 इंिेसिन 1 12.31 1573 (अ) 31.03.2023 हाइड्रोससोकोबालाजमन 1 जम.ली. जमलीग्रामएमएल/ 91 vkbZcqizksQuq dSIlwy 400 fexzk- 1 dSIlwy 1.31 1573 (अ) 31.03.2023 92 1 lkWQ~V 3.33 1573 (अ) 31.03.2023 vkbZcqizksQuq dSIlwy 200 fexzk- tsyVs kbu dSIlwy 93 befsVuhc dSIlwy 400 fexzk- 1 dSIlwy 318.01 4663 (अ) 25.10.2023 94 vkbZizkVªksfi;e bugsy's ku ¼,eMhvkbZ@MhihvkbZ½ 1 Mkst 0.76 1573 (अ) 31.03.2023 20 ,elhth@Mkst 95 jslfijsVkWjh lksyq'ku QkWj ;wt 3.15 1573 (अ) 31.03.2023 vkbZizkVªksfi;e bu ucs qykbtj 250 1 fefy- ,elhth@fefy- 96 dSVkekbu batSD'ku 10 fexzk-@fefy- 1 fefy- 13.19 4663 (अ) 25.10.2023 97 ysoksuksxsLZ Vªsy xksyh 0-75 fexzk- 1 xksyh 28.65 4663 (अ) 25.10.202354 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 98 ysoksFkkbjksDlhu xksyh 37.50 ,elhth 1 xksyh 1.47 4663 (अ) 25.10.2023 99 fyXuksdus ¼,½ $ batSD'ku 1%¼,½ $ 0.56 1573 (अ) 31.03.2023 1%200000¼5 ,elhth@fefy-½ 1 fefy- ,Mªsukykbu ¼ch½ ¼ch½ 100 yksfiukohj ¼,½ xksyh 100 fexzk- ¼,½ $ 25 1 xksyh 29.28 4663 (अ) 25.10.2023 $fjVksukohj ¼ch½ fexzk- ¼ch½ 101 fetyl :csyk oSDlhu izfr iSd ¼0-5 110.07 4663 (अ) 25.10.2023 fefy-½ 102 fetyl oSDlhu oSDlhu izfr iSd ¼0-5 63.47 1573 (अ) 31.03.2023 fefy-½ 103 eFs kksVªsDlsV batSD'ku 50 fexzk-@fefy- 1 fefy- 49.86 1573 (अ) 31.03.2023 104 ममिाईलिोिाननमल ननयम टलोिईड पन्ैं ट 1% 1 fefy- 0.10 1573 (अ) 31.03.2023 (जेंमिया वाइलेट) 105 ममिाइलधिओनननन इंजेटशन 10 यम टलोिाइड 1 मम.ली. 27.13 1573 (अ) 31.03.2023 ममलीग्राम/मम.ली. (मेधिलीन ब्लू ) 106 feMktksye xksyh 7-5 fexzk- 1 xksyh 27.94 1573 (अ) 31.03.2023 107 eksQhZu ,lvkj xksyh 30 fexzk- 1 xksyh 6.78 1573 (अ) 31.03.2023 108 eksQhZu xksyh 10 fexzk- 1 xksyh 6.63 4663 (अ) 25.10.2023 109 ,u&,flVkbyflLVsu lpsV 200 fexzk- 1 xzke 11.20 1573 (अ) 31.03.2023 110 usohjkikbu vksjy fyD;wbZM 50 fexzk-@5 1 fefy- 1.04 1573 (अ) 31.03.2023 fefy- 111 vksesikztksy xksyh 10 fexzk- 1 xksyh 5.52 4663 (अ) 25.10.2023 112 ओिल पोमलओमाईमलट्रटि 1 fefy- 127.67 1573 (अ) 31.03.2023 वेटिीन 113 vksjy fjgkbMªs'ku ykblsal ds :i esa 1 xzke 1.11 1573 (अ) 31.03.2023 lkYVl 114 vksDlkyhIykVhu batSD'ku 100 fexzk-¼ykblsal ds izfr iSd 5563.91 4663 (अ) 25.10.2023 :i esa½ 115 ikjk&,feukslkfyflfyd xzsU;wyl ¼ykblsla ds :i es½a 1 xzke 3.54 1573 (अ) 31.03.2023 ,flM 116 isjkflVkeksy batSD'ku 150 fexzk-@fefy- izfr iSd ¼0-5 3.82 1573 (अ) 31.03.2023 fefy-½ 117 isjkflVkeksy batSD'ku 150 fexzk-@fefy- izfr iSd 5.22 1573 (अ) 31.03.2023 ¼1 fefy-½ 118 isjkflVkeksy batSD'ku 150 fexzk-@fefy- izfr iSd 10.84 1573 (अ) 31.03.2023 ¼3 fefy-½ 119 isjkflVkeksy batSD'ku 150 fexzk-@fefy- izfr iSd 13.65 4663 (अ) 25.10.2023 ¼4 fefy-½ 120 isjkflVkeksy batSD'ku 150 fexzk-@fefy- izfr iSd 16.46 4663 (अ) 25.10.2023 ¼5 fefy-½ 121 isjkflVkeksy batSD'ku 150 fexzk-@fefy- izfr iSd 22.07 4663 (अ) 25.10.2023 ¼7 fefy-½ 122 isfuflykekbu dSIlwy 250 fexzk- 1 dSIlwy 18.50 1573 (अ) 31.03.2023 123 QsuhysQjhu MªksIl 10% 1 fefy- 10.06 4663 (अ) 25.10.2023 124 QsuhysQjhu MªksIl 5% 1 fefy- 4.64 1573 (अ) 31.03.2023 125 QsuhVksbu bZvkj dSIlwy 300 fexzk- 1 dSIlwy 4.74 1573 (अ) 31.03.2023 126 QsuhVksbu batSD'ku 25 fexzk-@fefy- 1 fefy- 3.13 4663 (अ) 25.10.2023 127 fiyksdkjfiu MªksIl 4% 1 fefy- 14.54 1573 (अ) 31.03.2023 128 iksVsf'k;e ijeasxusV fØLVy QkWj VkWfidy lksyq'ku 1 xzke 0.55 4663 (अ) 25.10.2023 129 ikWfoMu vk;ksMhu स्क्रब 7-5% 1 fefy- 2.00 4663 (अ) 25.10.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 55 130 ikWfoMu vk;ksMhu vksbuVesaV 10% 1 xzke 6.48 1573 (अ) 31.03.2023 131 izkftD;wuVsy xksyh 600 fexzk 1 xksyh 43.25 4663 (अ) 25.10.2023 132 izsMfulksyksu batSD'ku 20 fexzk-@2 fefy- 1 fefy- 4.46 1573 (अ) 31.03.2023 133 ikbjkftukekbM vksjy fyD;wbZM 250 fexzk-@5 1 fefy- 0.76 1573 (अ) 31.03.2023 fefy- 134 fjQefiflu xksyh 150 fexzk- 1 xksyh 2.01 4663 (अ) 25.10.2023 135 fjQefiflu xksyh 300 fexzk- 1 xksyh 3.66 4663 (अ) 25.10.2023 136 fjaxj ySDVsV batSD'ku 1000 fefy- izfr iSd 99.32 4663 (अ) 25.10.2023 137 fjaxj ySDVsV batSD'ku 100 fefy- izfr iSd 26.00 1573 (अ) 31.03.2023 138 fjaxj ySDVsV batSD'ku 250 fefy- izfr iSd 44.33 1573 (अ) 31.03.2023 139 fjaxj ySDVsV batSD'ku 500 fefy- izfr iSd 56.50 4663 (अ) 25.10.2023 140 fjVksukohj dSIlwy 100 fexzk- 1 dSIlwy 35.14 4663 (अ) 25.10.2023 141 lsycqVkeksy dSIlwy 4 fexzk- 1 dSIlwy 0.74 1573 (अ) 31.03.2023 142 flYoj lYQkMkbftu Øhe 1% 1 xzke 0.63 4663 (अ) 25.10.2023 143 lksfM;e DyksjkbM batSD'ku 0-9% 1000 fefy- 73.88 4663 (अ) 25.10.2023 Xykl 144 lksfM;e DyksjkbM batSD'ku 0-9% 1 u0 k0 Wu0 Xf yef ky l - 58.27 4663 (अ) 25.10.2023 145 lksfM;e DyksjkbM batSD'ku 0-9% 10 X0 y f ke lfy - 21.84 1573 (अ) 31.03.2023 146 lksfM;e DyksjkbM batSD'ku 0-9% 100 fefy- 19.68 4663 (अ) 25.10.2023 ukWu Xykl 147 lksfM;e DyksjkbM batSD'ku 0-9% 250 fefy- 29.47 4663 (अ) 25.10.2023 Xykl 148 lksfM;e DyksjkbM batSD'ku 0-9% 250 fefy- 26.45 4663 (अ) 25.10.2023 ukWu Xykl 149 lksfM;e DyksjkbM batSD'ku 0-9% 500 fefy- 40.97 4663 (अ) 25.10.2023 Xykl 150 lksfM;e DyksjkbM batSD'ku 0-9% 500 fefy- 34.87 4663 (अ) 25.10.2023 ukWu Xykl 151 lksfM;e ukbZVªsV batSD'ku 30 fexzk-@fefy- 1 fefy- 32.35 4663 (अ) 25.10.2023 152 lksfM;e ukbVªksi:lkbM batSD'ku 10 fexzk-@fefy- 1 fefy- 32.15 4663 (अ) 25.10.2023 153 LVªsIVksfdukl batSD'ku 7]50]000 vkbZ;w izfr iSd 1567.42 4663 (अ) 25.10.2023 154 izfr iSd eas lLis'a ku QkWj buVªkVªkpsy izfr fefy- ljQsDVkaV buLVkbys'ku ¼ykblsla ds :i 83.27 1573 (अ) 31.03.2023 QksLQksfyfiM~ es½a l 155 प्रत्येर्क 0.5 ममली. डोिेि मे: डडप्िेरिया टोटिाइड प्रत्येर्क ≤ 5 एलएफ (≥ टी डी वैक्टिन 0.5 ममली. 23.33 1573 (अ) 31.03.2023 2आईयू) टेट्कनि पैर्क टोटिाइड ≥ 5 एलएफ (≥ 40 आईय)ू 156 प्रत्येर्क 0.5 ममली. डोिेि मे: डडप्िेरिया टोटिाइड ≤ 5 एलएफ (≥ 2 प्रत्येर्क 5 टी डी वैक्टिन 219.25 1573 (अ) 31.03.2023 आईयू) टेट्कनि टोटिाइड ममली. पैर्क ≥ 5 एलएफ (≥ 40 आईयू) 157 प्रत्येर्क 0.5 ममली. डोिेि प्रत्येर्क टी डी वैक्टिन 20.00 1573 (अ) 31.03.2023 मे: डडप्िेरिया टोटिाइड 0.5 ममली.56 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ≤ 25 एलएफ (≥ 30 पैर्क आईयू) टेट्कनि टोटिाइड ≥ 5 एलएफ (≥ 40 आईयू) 158 VsekstksyksekbM xksyh 100 fexzk- 1 xksyh 1925.59 4663 (अ) 25.10.2023 159 fVeksyksy MªksIl 0-25% 1 fefy- 6.44 4663 (अ) 25.10.2023 160 VªkekMksy batSD'ku 50 fexzk-@fefy- ¼20 1 fefy- 1.55 4663 (अ) 25.10.2023 fefy- iSd½ 161 osjkikfey batSD'ku 2-5 fexzk-@fefy- 1 fefy- 1.46 4663 (अ) 25.10.2023 162 fouOykLVhu batSD'ku 1 fexzk-@fefy- 1 fefy- 25.54 1573 (अ) 31.03.2023 163 foVkfeu , dSIlwy 50000 vkbZ;w 1 dSIlwy 0.68 1573 (अ) 31.03.2023 164 okVj QkWj batSD'ku batSD'ku izfr iSd ¼10 2.89 1573 (अ) 31.03.2023 fefy-½ 165 okVj QkWj batSD'ku batSD'ku izfr iSd 2.79 1573 (अ) 31.03.2023 ¼5 fefy-½ 166 okVj QkWj batSD'ku batSD'ku izfr iSd 57.40 4663 (अ) 25.10.2023 ¼500 fefy-½ 167 okVj QkWj batSD'ku batSD'ku izfr iSd 100.74 1573 (अ) 31.03.2023 ¼1000 fefy-½ 168 ftMksoqMkbu dSIlwy 300 fexzk- 1 dSIlwy 2.57 4663 (अ) 25.10.2023 169 tksyfiMse dSIlwy 5 fexzk- 1 dSIlwy 9.15 4663 (अ) 25.10.2023 - ( 0.00551% ) 11(3) (5) a b िे 0.00551 (5)[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 57 यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-II के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मल्ू य म ेंसंिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करन े के जलए उत्तरिायी होगा। V (4) (ञ) (1) u II I II III II IV ड [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक ORDER New Delhi, the 26th March, 2024 S.O. 1548(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical58 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date No. Strength 1.4.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) 1 5-aminosalicylic Acid Suppository 500 mg 1 Suppository 4663(E) 25.10.2023 21.05 Retention Enema 2 5-aminosalicylic Acid Tablet 400 mg 1 Tablet 9.31 4663(E) 25.10.2023 3 Abacavir (A) + Tablet 60 mg(A) + 1 Tablet 1573(E) 31.03.2023 25.00 Lamivudine (B) 30 mg(B) 4 Acetylsalicylic acid Effervescent/ Dispersible/ Enteric 1 Tablet 0.22 1573(E) 31.03.2023 coated Tablet 100 mg 5 Acetylsalicylic acid Tablet 100 mg 1 Tablet 0.21 1573(E) 31.03.2023 6 Acetylsalicylic acid Tablet 150 mg 1 Tablet 0.50 1573(E) 31.03.2023 7 Acetylsalicylic acid Tablet 350mg 1 Tablet 0.38 1573(E) 31.03.2023 8 Acetylsalicylic acid Tablet 75 mg 1 Tablet 0.38 1573(E) 31.03.2023 9 All-trans Retinoic Acid Capsule 10 mg 1 Capsule 1573(E) 31.03.2023 101.85 10 Amphotericin B (Lipid) Powder for Each Pack 1573(E) 31.03.2023 3990.62 Injection 50 mg 11 Amphotericin B Powder for Each Pack 4663(E) 25.10.2023 9295.41 (Liposomal) Injection 50 mg 12 Ampicillin Powder for Each Pack 1573(E) 31.03.2023 26.56 Injection 1 gm 13 Anti-D immunoglobulin Injection 300mcg Each Pack 2657.47 1573(E) 31.03.2023 14 Anti-D Immunoglobulin Injection 150mcg Each Vial 2071.40 1573(E) 31.03.2023 15 Anti-rabies Injection 150 IU/ml 1 ml 4663(E) 25.10.2023 3454.06 immunoglobulin 16 Anti-rabies Injection 300 IU/ml 1 ml 121.77 1573(E) 31.03.2023 immunoglobulin 17 Anti-tetanus 250IU Each Pack 1383.57 1573(E) 31.03.2023 immunoglobulin 18 Artesunate (A) + Tablet 100 mg(A) + Combi pack 4663(E) 25.10.2023 Sulphadoxine - 1 Tablet (750 mg+ 36.72 Pyrimethamine (B) 37.5 mg) (B) 19 Artesunate (A) + Tablet 150 mg(A) + Combi pack 4663(E) 25.10.2023 Sulphadoxine - 2 Tablet (500 mg+ 49.85 Pyrimethamine (B) 25 mg) (B) 20 Artesunate (A) + Tablet 200 mg(A) + Combi pack 1573(E) 31.03.2023 Sulphadoxine - 2 Tablet (750 mg+ 45.45 Pyrimethamine (B) 37.5 mg) (B) 21 Artesunate (A) + Tablet 25 mg(A) + Combi pack 4663(E) 25.10.2023 Sulphadoxine - 1 Tablet (250 mg+ 24.48 Pyrimethamine (B) 12.5 mg) (B) 22 BCG vaccine Each Dose 11.12 1573(E) 31.03.2023 23 Benzoyl Peroxide Cream 2.5% 1 gm 2.90 1573(E) 31.03.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 59 Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date No. Strength 1.4.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) 24 Benzyl penicillin Powder for Injection 10 Lac Each Pack 9.71 4663(E) 25.10.2023 Units 25 Betamethasone Gel 0.05% 1 gm 0.66 1573(E) 31.03.2023 26 Betamethasone Lotion 0.1% 1 ml 1.02 1573(E) 31.03.2023 27 Betamethasone Lotion 0.5% 1 ml 0.66 1573(E) 31.03.2023 28 Budesonide Nasal Spray 50 1 Dose 4663(E) 25.10.2023 1.27 mcg/dose 29 Budesonide Inhalation (DPI) Per Dose 4663(E) 25.10.2023 2.49 100 mcg/dose 30 Budesonide (A)+ Inhalation (MDI) Per Metered Formoterol (B) 200 mcg (A) + 6 3.33 1573(E) 31.03.2023 Dose mcg (B) 31 Budesonide (A)+ Inhalation (MDI) Per Metered Formoterol (B) 400 mcg (A) + 6 3.80 1573(E) 31.03.2023 Dose mcg (B) 32 Calcium Carbonate Tablet 500mg 1 Tablet 2.15 1573(E) 31.03.2023 33 Calcium gluconate Injection 100 mg/ml 1 ml 0.68 1573(E) 31.03.2023 34 Cefadroxil Capsule 500 mg 1 Capsule 8.90 1573(E) 31.03.2023 35 Cefazolin Powder for Each Pack 1573(E) 31.03.2023 30.56 Injection 1 gm 36 Cefazolin Powder for Each Pack 1573(E) 31.03.2023 19.37 Injection 500 mg 37 Cefixime Capsule 400 mg 1 Capsule 36.41 4663(E) 25.10.2023 38 Cetirizine Capsule 10 mg 1 Capsule 2.96 1573(E) 31.03.2023 39 Chlorhexidine Solution 5% 1 ml 1573(E) 31.03.2023 (Concentrate for 0.19 dilution) 40 Cloxacillin Capsule 250mg 1 Capsule 1.41 1573(E) 31.03.2023 41 Cloxacillin Capsule 500mg 1 Capsule 2.38 4663(E) 25.10.2023 42 Cloxacillin Tablet 250mg 1 Tablet 2.15 1573(E) 31.03.2023 43 Cloxacillin Powder for Each Pack 4663(E) 25.10.2023 5.53 Injection250mg 44 Coagulation factor IX Powder for Each Pack 1573(E) 31.03.2023 15339.76 Injection 600 IU 45 Coagulation factor VIII Powder for Each pack 1573(E) 31.03.2023 4650.15 Injection 250 IU 46 Coagulation factor VIII Powder for Each Pack 1573(E) 31.03.2023 11411.13 Injection 500 IU 47 Cyclosporine Injection 50 mg/ml 1 ml 335.80 1573(E) 31.03.2023 48 Daunarubicin Powder for I.V. Each pack 1573(E) 31.03.2023 Injection 20 mg (5 302.76 mg/ml) 49 Dextran-40 Injection 10% 1 ml 1.05 1573(E) 31.03.2023 50 Diazepam Oral Liquid 2 1 ml 4663(E) 25.10.2023 3.40 mg/5ml 51 Diclofenac Capsule 50 mg 1 Capsule 0.76 1573(E) 31.03.2023 52 Dicyclomine Oral Solution 1 ml 1573(E) 31.03.2023 0.20 10mg/5ml 53 Dicyclomine Tablet 10mg 1 Tablet 0.13 1573(E) 31.03.202360 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date No. Strength 1.4.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) 54 Dinoprostone Tablet 0.5mg 1 Tablet 62.31 4663(E) 25.10.2023 55 Diphtheria antitoxin 10000 IU Each Pack 1631.70 4663(E) 25.10.2023 56 DPT vaccine Per 0.5 ml 17.64 4663(E) 25.10.2023 57 Efavirenz Capsule 600 mg 1 Capsule 78.09 1573(E) 31.03.2023 58 Ethyl Alcohol (Denatured) Solution 70% 1 ml 0.53 4663(E) 25.10.2023 59 Ferrous Salt (A) + Folic Tablet 100mg Acid (B) elemental iron (A) + 1 Tablet 0.28 1573(E) 31.03.2023 500mcg (B) 60 Fluconazole Oral Liquid 1 ml 3.25 1573(E) 31.03.2023 50mg/5ml 61 Gadobenate Injection 529 mg/ml 1 ml 135.69 4663(E) 25.10.2023 62 Glucose Injection 50% 1 ml 0.61 4663(E) 25.10.2023 63 Glucose Injection 5% 1000ml Glass 79.95 1573(E) 31.03.2023 64 Glucose Injection 5% 1000ml Non- 4663(E) 25.10.2023 64.55 Glass 65 Glucose Injection 5% 100ml Glass 22.45 4663(E) 25.10.2023 66 Glucose Injection 5% 100ml Non- 4663(E) 25.10.2023 20.32 Glass 67 Glucose Injection 5% 250ml Glass 31.01 1573(E) 31.03.2023 68 Glucose Injection 5% 250ml Non- 4663(E) 25.10.2023 28.02 Glass 69 Glucose Injection 5% 500ml Glass 44.02 4663(E) 25.10.2023 70 Glucose Injection 5% 500ml Non- 4663(E) 25.10.2023 37.98 Glass 71 Glucose Injection 10% Each Pack 4663(E) 25.10.2023 32.16 (1000 ml) 72 Glucose Injection 10% Each Pack 1573(E) 31.03.2023 34.97 (500 ml) 73 Glucose (A) + Sodium Injection 5% (A) + 1000ml Glass 1573(E) 31.03.2023 80.48 Chloride (B) 0.9% (B) 74 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non- 1573(E) 31.03.2023 65.03 Chloride (B) 0.9% (B) Glass 75 Glucose (A) + Sodium Injection 5% (A) + 100ml Glass 1573(E) 31.03.2023 22.50 Chloride (B) 0.9% (B) 76 Glucose (A) + Sodium Injection 5% (A) + 100ml Non- 4663(E) 25.10.2023 20.34 Chloride (B) 0.9% (B) Glass 77 Glucose (A) + Sodium Injection 5% (A) + 250ml Glass 4663(E) 25.10.2023 31.14 Chloride (B) 0.9% (B) 78 Glucose (A) + Sodium Injection 5% (A) + 250ml Non- 1573(E) 31.03.2023 28.12 Chloride (B) 0.9% (B) Glass 79 Glucose (A) + Sodium Injection 5% (A) + 500ml Glass 1573(E) 31.03.2023 44.23 Chloride (B) 0.9% (B) 80 Glucose (A) + Sodium Injection 5% (A) + 500ml Non- 1573(E) 31.03.2023 38.21 Chloride (B) 0.9% (B) Glass 81 Glutaraldehyde Solution 2% 1 ml 0.08 4663(E) 25.10.2023 82 Griseofulvin Tablet 125mg 1 Tablet 1.02 1573(E) 31.03.2023 83 Griseofulvin Tablet 375 mg 1 Tablet 5.35 4663(E) 25.10.2023 84 Haemodialysis fluid As license 1 ml 0.04 1573(E) 31.03.2023 85 Human Normal Solution for 1 ml 192.07 1573(E) 31.03.2023[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 61 Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date No. Strength 1.4.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) Immunoglobulin infusion 5% 86 Human Normal Solution for 1 ml 260.04 1573(E) 31.03.2023 Immunoglobulin infusion 10% 87 Human Normal Solution for 1 ml 494.52 1573(E) 31.03.2023 Immunoglobulin infusion 16.5% 88 Hydrochlorothiazide Tablet 50 mg 1 Tablet 0.10 1573(E) 31.03.2023 89 Hydrogen peroxide Solution 6% 1 ml 0.04 1573(E) 31.03.2023 90 Hydroxocobalamin Injection 1 mg/ml 1 ML 12.31 1573(E) 31.03.2023 91 Ibuprofen Capsule 400 mg 1 Capsule 1.31 1573(E) 31.03.2023 92 Ibuprofen Capsule 200 mg 1 soft gelatin 1573(E) 31.03.2023 3.33 capsule 93 Imatinib Capsule 400 mg 1 Capsule 318.01 4663(E) 25.10.2023 94 Ipratropium Inhalation (MDI/DPI) 20 1 Dose 0.76 1573(E) 31.03.2023 mcg/dose 95 Ipratropium Respirator solution for use in Nebulizer 1 ml 3.15 1573(E) 31.03.2023 250 mcg/ml 96 Ketamine Injection 10 mg/ml 1 ml 13.19 4663(E) 25.10.2023 97 Levonorgestrel Tablet 0.75 mg 1 Tablet 28.65 4663(E) 25.10.2023 98 Levothyroxine Tablet 37.50 mcg 1 Tablet 1.47 4663(E) 25.10.2023 99 Lignocaine (A) + Injection 1% (A) + 1 ml 1573(E) 31.03.2023 Adrenaline (B) 1:200000 (5 0.56 mcg/ml) (B) 100 Lopinavir (A) + Ritonavir Tablet 100 mg(A) + 1 Tablet 4663(E) 25.10.2023 29.28 (B) 25 mg(B) 101 Measles Rubbela Vaccine Each Pack 4663(E) 25.10.2023 110.07 (0.5ml) 102 Measles vaccine Vaccine Each Pack 1573(E) 31.03.2023 63.47 (0.5ml) 103 Methotrexate Injection 50 mg/ml 1 ml 49.86 1573(E) 31.03.2023 104 Methylrosanilinium Paint 1% 1 ml 1573(E) 31.03.2023 0.10 chloride (Gentian Violet) 105 Methylthioninium Injection 10mg/ml 1 ML 1573(E) 31.03.2023 27.13 chloride (Methylene blue) 106 Midazolam Tablet 7.5mg 1 Tablet 27.94 1573(E) 31.03.2023 107 Morphine SR Tablet 30 mg 1 Tablet 6.78 1573(E) 31.03.2023 108 Morphine Tablet 10 mg 1 Tablet 6.63 4663(E) 25.10.2023 109 N-acetylcysteine Sachet 200mg 1 gm 11.20 1573(E) 31.03.2023 110 Nevirapine Oral Liquid 50 1 ml 1573(E) 31.03.2023 1.04 mg/5ml 111 Omeprazole Tablet 10 mg 1 Tablet 5.52 4663(E) 25.10.2023 112 Oral poliomyelitis vaccine 1 ml 127.67 1573(E) 31.03.2023 113 Oral Rehydration Salts As Licensed 1 gm 1.11 1573(E) 31.03.2023 114 Oxaliplatin Injection 100mg(as Each Pack 5563.91 4663(E) 25.10.2023 licensed) 115 Para-aminosalicylic acid Granules (As 1 gm 3.54 1573(E) 31.03.2023 licensed) 116 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023 3.82 ( 0.5 ml)62 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date No. Strength 1.4.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) 117 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023 5.22 (1 ml) 118 Paracetamol Injection 150 mg/ml Each Pack 1573(E) 31.03.2023 10.84 (3 ml) 119 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023 13.65 (4 ml) 120 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023 16.46 (5 ml) 121 Paracetamol Injection 150 mg/ml Each Pack 4663(E) 25.10.2023 22.07 (7 ml) 122 Penicillamine Capsule 250 mg 1 Capsule 18.50 1573(E) 31.03.2023 123 Phenylephrine Drop 10% 1 ml 10.06 4663(E) 25.10.2023 124 Phenylephrine Drops 5% 1 ml 4.64 1573(E) 31.03.2023 125 Phenytoin ERCapsule 300 mg 1 Capsule 4.74 1573(E) 31.03.2023 126 Phenytoin injection 25 mg/ml 1 ml 3.13 4663(E) 25.10.2023 127 Pilocarpine Drops 4% 1 ml 14.54 1573(E) 31.03.2023 128 Potassium permanganate Crystals for topical 1 gm 4663(E) 25.10.2023 0.55 solution 129 Povidone iodine Scrub 7.5% 1 ml 2.00 4663(E) 25.10.2023 130 Povidone iodine Ointment 10% 1 gm 6.48 1573(E) 31.03.2023 131 Praziquantel Tablet 600 mg 1 tablet 43.25 4663(E) 25.10.2023 132 Prednisolone Injection 20 mg/2ml 1 ml 4.46 1573(E) 31.03.2023 133 Pyrazinamide Oral Liquid 250 1 ml 1573(E) 31.03.2023 0.76 mg/5ml 134 Rifampicin Tablet 150 mg 1 Tablet 2.01 4663(E) 25.10.2023 135 Rifampicin Tablet 300 mg 1 Tablet 3.66 4663(E) 25.10.2023 136 Ringer Lactate Injection 1000ml Each Pack 99.32 4663(E) 25.10.2023 137 Ringer Lactate Injection 100ml Each Pack 26.00 1573(E) 31.03.2023 138 Ringer Lactate Injection 250ml Each Pack 44.33 1573(E) 31.03.2023 139 Ringer Lactate Injection 500ml Each Pack 56.50 4663(E) 25.10.2023 140 Ritonavir Capsule 100 mg 1 Capsule 35.14 4663(E) 25.10.2023 141 Salbutamol Capsule 4 mg 1 Capsule 0.74 1573(E) 31.03.2023 142 Silver Sulphadiazine Cream 1% 1 gm 0.63 4663(E) 25.10.2023 143 Sodium Chloride Injection 0.9% 1000ml Glass 73.88 4663(E) 25.10.2023 144 Sodium Chloride Injection 0.9% 1000ml Non- 4663(E) 25.10.2023 58.27 Glass 145 Sodium Chloride Injection 0.9% 100ml Glass 21.84 1573(E) 31.03.2023 146 Sodium Chloride Injection 0.9% 100ml Non- 4663(E) 25.10.2023 19.68 Glass 147 Sodium Chloride Injection 0.9% 250ml Glass 29.47 4663(E) 25.10.2023 148 Sodium Chloride Injection 0.9% 250ml Non- 4663(E) 25.10.2023 26.45 Glass 149 Sodium Chloride Injection 0.9% 500ml Glass 40.97 4663(E) 25.10.2023 150 Sodium Chloride Injection 0.9% 500ml Non- 4663(E) 25.10.2023 34.87 Glass 151 Sodium nitrite Injection 30 mg/ml 1 ml 32.35 4663(E) 25.10.2023 152 Sodium Nitroprusside Injection 10 mg/ml 1 ml 32.15 4663(E) 25.10.2023 153 Streptokinase Injection 7,50,000 Each Pack 4663(E) 25.10.2023 1567.42 IU[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 63 Sl. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date No. Strength 1.4.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) 154 Surfactant Suspension for Per mg of intratracheal Phospholipids 83.27 1573(E) 31.03.2023 instillation (As in the pack liensed) 155 TD Vaccine Each dose of 0.5ml contains: Diphtheria Toxoid ≤5Lf (≥ Each 0.5ml 23.33 1573(E) 31.03.2023 2IU) Tetanus Pack Toxoid ≥ 5Lf (≥ 40IU) 156 TD Vaccine Each dose of 0.5ml contains: Diphtheria Toxoid ≤5Lf (≥ Each 5ml Pack 219.25 1573(E) 31.03.2023 2IU) Tetanus Toxoid ≥ 5Lf (≥ 40IU) 157 TD Vaccine Each dose of 0.5ml contains: Diphtheria Toxoid ≤25Lf (≥ Each 0.5ml 20.00 1573(E) 31.03.2023 30IU) Tetanus Pack Toxoid ≥ 5Lf (≥ 40IU) 158 Temozolomide Tablet 100 mg 1 Tablet 1925.59 4663(E) 25.10.2023 159 Timolol Drops 0.25% 1 ml 6.44 4663(E) 25.10.2023 160 Tramadol Injection 50 mg/ml 1 ml 1.55 4663(E) 25.10.2023 (20 ml Pack) 161 Verapamil Injection 2.5 mg/ml 1 ml 1.46 4663(E) 25.10.2023 162 Vinblastine Injection 1mg/ml 1 ml 25.54 1573(E) 31.03.2023 163 Vitamin A Capsule 50000 IU 1 Capsule 0.68 1573(E) 31.03.2023 164 Water for Injection Injection Each Pack (10 2.89 1573(E) 31.03.2023 ml) 165 Water for Injection Injection Each Pack (5 2.79 1573(E) 31.03.2023 ml) 166 Water for Injection Injection Per 500 ml 57.40 4663(E) 25.10.2023 Pack 167 Water for Injection Injection Per 1000 ml 100.74 1573(E) 31.03.2023 Pack 168 Zidovudine Capsule 300 mg 1 Capsule 2.57 4663(E) 25.10.2023 169 Zolpidem Capsule 5 mg 1 Capsule 9.15 4663(E) 25.10.2023 Notes: - (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In respect of formulation where pack wise ceiling price is notified, for any other pack size manufactured the manufacturer shall approach NPPA under para 11(3) of DPCO, 2013 for specific price approval for its formulations. (c) In respect of any other scheduled formulation for which ceiling price is not mentioned above, themanufacturer shall approach NPPA for specific price approval for its formulations. (d) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any.64 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (e) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (f) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director नई दिल्ली, 26 मार्,च 2024 का. आ. 1549(अ).— नवम्बर 4, 6, 10, 11, 14, 17 ,16 ,4 18 a b[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 65 @ 0.00551% बढाकर 0.00551% 01.04.2024 से प्रभावी) ( ) (1) (2) (3) (4) (5) 6(a) 6(b) 1 ,lhVkby xksyh 300 fexzk 1568(अ) 1 xksyh 0.28 31-03-23 lkfyflfyd ,flM 2 dSfY'k;e dkcksuZ Vs xksyh 250 fexzk 1 xksyh 2.43 1568(अ) 31-03-23 3 daMksel 1 daMkse 11.37 4663(अ) 25-10-23 4 Msilksu xksyh 50 fexkz 1 xksyh 0.29 1568(अ) 31-03-23 5 esMªksDlh izkxs Ls Vsjksu xksyh 5 fexzk 1568(अ) 1 xksyh 3.72 31-03-23 ,flVVs 6 fjQefiflu xksyh 450 fexzk 1 xksyh 5.52 4663(अ) 25-10-23 - ( 0.00551% ) (5) 0.00551% (5) घ ङ यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-II के रूप म ें इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लने े की जतजथ स े उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मल्ू य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। च V (4)66 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ज 1 u II I झ II III II IV ञ (ट) [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक ORDER New Delhi, the 26th March, 2024 S.O. 1549(E).—In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Unit Ceiling price (wef Existing S.O. No. & Date Strength 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 6(a) 6(b) 1 Acetyl Salicylic Tablet 300mg 1 Tablet 0.28 1568 (E) 31-03-23 Acid 2 Calcium carbonate Tablet 250 mg 1 Tablet 2.43 1568 (E) 31-03-23 3 Condoms 1 Condom 11.37 4663(E) 25-10-23 4 Dapsone Tablet 50 mg 1 Tablet 0.29 1568 (E) 31-03-23 5 Medroxy Tablet 5mg 1 Tablet Progesterone 3.72 1568 (E) 31-03-23 Acetate 6 Rifampicin Tablet 450mg 1 Tablet 5.52 4663(E) 25-10-23[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 67 Notes: - a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Taxes as applicable, if any. c) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. & date as specified in column 6 (a)& 6 (b) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. i) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director68 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] नई दिल्ली, 26 मार्,च 2024 का. आ. 1550(अ).— , नवम्बर 4, 6, 10, 11, 14, 16, 17 18 a b एनएलईए म, आदेश र्के 0.00551% र्के अनिु ाि िंशोधित अतं गति अधिर्कतम र्कीमत (1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b) ओरल मलमक्वड 31015/21/202 सेफ्यरूोमक्स 125 3- 1. ि मिलीग्राि / 1 मि.ली. 5.28 5.31 5.31 1574(अ) 31-03-23 5 मि.ली. 08.02.2024 (पी) गोली 5 मिलीग्राि 31015/12/202 2. िोंटेलकिं ास्ट (चबाने 1 गोली 11. 72 12.01 12.01 3- 4663(अ) 25-10-23 योग्य समहत 19.02.2024 गोली) 31015/13/202 िायकोफेनो गोली 3. िोफल ेमेट ट ल मि5 ल0 ीग्र0 ाि 1 गोली 73. 88 74.59 74.59 3- 4663(अ) 25-10-23 22.02.2024 - (6) के .03. तक बनाए रखना जारी रखेंगे । सारणी के कॉलि (7) िे मनमदष्टम ( @0.00551% )[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 69 िे . . को या बराबर 0.00551 (6) /या (7) यदि संिोधन दकया िाता ह ैतो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-।। के रूप म ें इलसे रॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िान े को अजधकतम खुिरा मूल्य म ें संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लने े की जतजथ से उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मल्ू य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। (6) /या (7) V (4) (1) u II I II III II IV [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक70 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ORDER New Delhi, the 26th March, 2024 S.O. 1550(E).—In implementation of directions of review orders issued by the Department of Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order(s) specified in column (8) of the table below and in exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 9(a) & 9(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (6) and further revised the prices w. e. f. 01.04.2024 specified in column (7) of the table herein below as ceiling prices exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE Ceiling Revised Ceiling price ceiling Price (wef price as Review Order Sl. Dosage form & under 1.4.2024 Existing SO Medicines Unit per number and No. Strength NLEM, with WPI number and date review date 2022 @ order (Rs.) 0.00551%) (in Rs.) (in Rs.) (1) (2) (3) (4) (5) (6) (7) (8) 9(a) 9(b) 31015/21/2023 Oral liquid 1574 1. Cefuroxime 1 ML 5.31 5.31 -Pricing dated 31-03-23 125mg/5mL(p) 5.28 (E) 08.02.2024 Tablet 5 mg 31015/12/2023 1 4663 2. Montelukast (including 12.01 12.01 -Pricing dated 25-10-23 Tablet 11.72 (E) chewable Tablet s) 19.02.2024 31015/13/2023 Mycophenol 1 4663 3. Tablet 500mg 74.59 74.59 -Pricing dated 25-10-23 ate mofetil Tablet 73.88 (E) 22.02.2024 Notes: - (a) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus Goods and Services Taxes as applicable) as fixed and notified by the Government as specified in column (6) of the above table, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (6) plus Goods and Services Taxes as applicable, if any. (b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price as specified in column (6) in the above table (plus Goods and Services Taxes as applicable, if any) shall continue to maintain the existing MRP in accordance with para 13(2) of DPCO,2013 till 31.03.2024. (c) The ceiling prices as specified in column (7) of the table are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). All the existing manufacturers of above-mentioned scheduled formulations having MRP lower or equal than the ceiling price as specified in column (6), as on 31.03.2024, in the above table (plus Goods and Services Taxes as applicable, if any) may revise the MRP on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (6) and/or (7) of the above said table. (e) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non-revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 71 (f) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (6) and/or (7) applicable of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (g) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (h) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (i) The manufacturers of above said scheduled formulations shall furnish quarterly return to NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (j) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (k) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director का. आ. 1551(अ).— , , . . , . . , . . , . . , . . . . @ 0.00551% , , 0.00551% I 01.04.2024 िे प्रभावी 10509.79 38267.1872 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] - 13(2) @ 0.00551% (4) [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक ORDER New Delhi, the 26th March, 2024 S.O. 1551(E).—In continuation of the notifications issued by National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Ministry of Chemical and Fertilizers vide S.O. 639(E) dated 12.02.2018, S.O. 1464(E) dated 02.04.2018, S.O. 1488(E) dated 29.03.2019, SO. 1217(E) dated 25.03.2020, S.O. 1334(E) dated 25.03.2021, 1502(E) dated 30.03.2022, 5249(E) dated 11.11.2022, 1572(E) dated 31.03.2023 and 4663(E) dated 25.10.2023 regarding the fixation of ceiling price of the Coronary Stents as specified in column no. (2) mentioned in the table below; after considering the Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022, it has been decided to revise the ceiling prices of Coronary Stents as mentioned in column no. (4) in the table below, exclusive of Goods and Services Tax as applicable,and unit specified in column (3) with effect from 01.04.2024, as under: TABLE Sl. No. Coronary Stents Unit Ceiling price (Sl. No. 28 in Schedule-I of the DPCO, 2013) (in Number) (wef 1.4.2024 with WPI @0.00551%) (in Rs.) (1) (2) (3) (4) 1 Bare Metal Stents 1 10509.79 Drug Eluting Stents (DES) including metallic DES and 2 Bioresorbable Vascular Scaffold (BVS)/ Biodegradable 1 38267.18 Stents Notes: - (a) All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of Coronary Stent, on the basis of WPI @ 0.00551% for the year 2023 over 2022 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 73 (b) The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (4) of the aforesaid table. (c) As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer/importers, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (d) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955 [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director नई दिल्ली, 26 मार्,च 2024 का. आ. 1552(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013] dk-vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;kas dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds 'kqf)&i= vkns'k dk- vk- 1500¼v½ fnukad 30 ekpZ] 2022, dk-vk- 4591¼v½ fnukad 29.09.2022, dk-vk- 1571¼v½ fnukad 31.03.2023, dk-vk- 4663¼v½ fnukda 25.10.2023, dk-vk- 4887¼v½ fnukad 10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02.02.2024 vkn's k ds vf/kØe.k es a tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d* esa fofufeZr iSd] uhps nh xbZ lkj.kh [k esa fofufnZ"V fuekZrk ds fo'ks”k mRikn ,o a iSsd vkdkj] mu ckrksa ds flok; vf/kØkUr djr s gq, ftUgsa ,ls s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la”kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LrHa k ¼5½ es a fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LrHa k ¼3½ vkSj ¼4½ es a dh xbZ Øe'k% rRLFkkuh izfof"V;ks a esa fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ es a dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;ks a es a ls izR;ds dh oLrq ,oa lsok dj] ;fn dksbZ gS] dk s NksMd+ j vf/kdre dher ds #i esa fu;r djrh gSA @ 0.00551% बढाकर @ 0.00551% (1) (2) (3) (4) (5) 1 Xywdkst batsD”ku 5% 1000 fefy xSj&dk¡p fo'ks"k 95.11 fo'ks’krkvks a lfgr 2 Xywdkst batsD”ku 5% 500 fefy xSj&dk¡p fo'ks"k 82.27 fo'ks’krkvks a lfgr 3 Xywdkst ¼,½$lksfM;e batsD”ku 5% ¼,½$0-9% 1000 fefy xSj&dk¡p fo'ks"k DyksjkbM ¼ch½ fo'ks’krkvks a lfgr 99.94 ¼ch½ 4 Xywdkst ¼,½$lksfM;e batsD”ku 5% ¼,½$ 0- 500 fefy xSj&dk¡p fo'ks"k DyksjkbM ¼ch½ fo'ks’krkvks a lfgr 85.52 9% ¼ch½ 5 lksfM;e DyksjkbM batsD”ku 0-9% 100 fefy xSj&dk¡p fo'ks"k 42.06 fo'ks’krkvks a lfgr 6 lksfM;e DyksjkbM batsD”ku 0-9% 250 fefy xSj&dk¡p fo'ks"k 62.10 fo'ks”krkvks a lfgr74 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 7 lksfM;e DyksjkbM batsD”ku 0-9% 500 fefy xSj&dk¡p fo'ks"k 87.94 fo'ks’krkvks a lfgr 8 lksfM;e DyksjkbM batsD”ku 0-9% 1000 fefy xSj&dk¡p fo'ks"k 98.51 fo'ks’krkvks a lfgr मैससच अससा पैरेंटल्स जलजमटेड यूरोहडे के साथ स्ट्टेरी जड्रप बोतल मैससच श्री कृष्णा केिव लेबोरेटरीि जलजमटेड यूरोहडे के साथ ईजीपोटच बोतल मैससच रुसोमा लेबोरेटरीि प्रा०जलजमटेड प् यरू ाड्रीप मैससच आर .के .लेबोरेटरीि प्रा०जलजमटेड यूरोहडे बाटल मैससच यूरोलाइफ हल्े थकेयर प्रा०जलजमटेड लाइफ पोट च मैससच ररयलकेड लाईफसाइंस प्रा०जलजमटेड यूरोहडे बाटल मैससच पुजनस्ट्का हल्े थकेयर प्रा०जलजमटेड (नीर् े नोन पीवीसी बेग मैससच अबैररस हल्े थकेयर प्रा० जलजमटेड डुओ पोटच मैससच जहलस हल्े थकेयर (नीर्े एिा जड्रप मैससच रूसोमा लेबोरेटरीि प्रा०जलजमटेड यूरोहडे बोटल ब्ांड नाम ड्यूजड्रप के साथ मैससच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड नीर्े यूरोहडे बोटल मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड नीर्े सेफ पोटच मैसस च बायोजसनिी लाइफकेयर प्राइवेट जलजमटेड जलजमटेड बायोपोटच नीर् े मैसस च प्रोजमया थेरेप्यूरटसस प्राइवेट जलजमटेड नीर् े एलडीपीई बोतल/नोन-ललास कंटेनर जविेि सुजवधाओं के साथ - यूरोहडे कैप[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 75 0.00551% र्के 5, 6, 7 औि 8 मे दशािई गई र्कीमते र्के वल मैससच पुजनस्ट्का हल्े थकेयर प्रा०जलजमटेड ( र्के 19) पर लागू होंगी. र्के 1, 2, 3, 4, 5, 7 औि 8 मे दशािई गई र्कीमते र्केवल मैससच जहलस हल्े थकेयर ( र्के 21) पर लागू होंगी. र्के 2, 4, 5 औि 7 मे दशािई गई र्कीमते र्केवल मैससच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड ( र्के 23) पर लागू होंगी. र्के 2, 4, 5, 6 औि 7 मे दशािई गई र्कीमते र्के वल मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड ( र्के 24) पर लागू होंगी. र्के 1, 2, 3, 4, 5, 7 औि 8 मे दशािई गई र्कीमते र्केवल मैिि ि बायोमिनजी लाइफर्के यि प्राइवेट मलममटेड ( र्के 25) पि लागू होंगी. र्के 2, 4, 5 औि 7 मे दशािई गई र्कीमते र्केवल मिै ि ि प्रोममया िेिेप्यूट्रटटि प्राइवेट मलममटेड ( र्के 26) पि लागू होंगी. (5) dk- vk- 1571¼v½ fnukad 31.03.2023, dk-vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4887¼v½ fnukda 10.11.2023 vkSj dk-vk- 424¼v½ fnukad 02.02.2024 0.00551% ञ (5) ट ठ यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे संिोधनों को दकए िाने के पंद्रह दिनों के भीतर की अवजध म ें प्रपत्र-।। के रूप म ें इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सूर्ना प्रस्ट्तुत नहीं दकए िाने को अजधकतम खुिरा मल्ू य म ेंसंिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लने े की जतजथ स े उस पर ब्याि सजहत पूवच-संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) स े अजधक की राजि िमा करन े के जलए उत्तरिायी होगा।76 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ड V (4) ण (1) u II I (त) II III II IV थ (द) [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक ORDER New Delhi, the 26th March, 2024 S.O. 1552(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1571(E) dated 31.03.2023, 4663(E) dated[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 77 25.10.2023, 4887(E) dated 10.11.2023 and 424(E) dated 02.02.2024 in so far as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase Sl. No. Medicines Dosage form and Unit Ceiling price Strength (w.e.f.01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Glucose Injection 5% 1000ml NonGlass with special 95.11 features 2 Glucose Injection 5% 500ml Non Glass with special 82.27 features 3 Glucose (A) + Sodium Injection 5% (A) + 1000ml Non Glass with special 99.94 Chloride (B) 0.9% (B) features 4 Glucose (A) + Sodium Injection 5% (A) + 500ml Non Glass with special 85.52 Chloride (B) 0.9% (B) features 5 Sodium Chloride Injection 0.9% 100ml Non Glass with special 42.06 features 6 Sodium Chloride Injection 0.9% 250ml Non Glass with special 62.10 features 7 Sodium Chloride Injection 0.9% 500ml Non Glass with special 87.94 features 8 Sodium Chloride Injection 0.9% 1000ml Non Glass with special 98.51 features TABLE B Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s B.Braun Medical (I) Pvt Ltd. Ecoflac Plus bottle with Eurohead 2 M/s Amanta Healthcare Ltd. Steriport bottle 3 M/s Aculife Healthcare Pvt Ltd. Aculife bottle with Eurohead 4 M/s Albert David Limited Albert David bottle with Eurohead 5 M/s Denis Chem Limited Aquapulse with Eurohead 6 M/s Claris Life Sciences Limited Claris bottle with Eurohead 7 M/s Fresenius Kabi India Pvt Limited Freeflex bags 8 M/s Otsuka Pharmaceutical India Private Ltd. Unibag (previously known as Claris Otsuka Private Limited) 9 M/s Aishwarya Lifesciences LifusionEurohead bottle 10 M/s Baxter (India) Pvt. Ltd. Viaflex bags 11 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle (previously known as Claris Otsuka Private Limited) 12 M/s Fresenius Kabi India Pvt Limited Eurohead bottle 13 M/s Axa Parenterals Ltd Steri Drip bottle with Eurohead 14 M/s Shree Krishna Keshav Laboratories Ltd Easyport bottle with Eurohead 15 M/s Rusoma Laboratories Pvt. Ltd. Puradrip 16 M/s R. K. Laboratories Pvt. Ltd. Eurohead bottle78 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 17 M/s Eurolife Healthcare Pvt. Ltd. Life port 18 M/s RealcadeLifesciencePvt. Ltd. Euro head bottle 19 M/s Puniska Healthcare Pvt. Ltd [Note (b) below] Non –PVC bag 20 M/s Abaris Healthcare Pvt. Ltd Duo Port 21 M/s Higgs Healthcare [Note (c) below] Aqua Drip 22 M/s Rusoma Laboratories Pvt. Ltd. Eurohead Bottles with Brand name “Dewdrip” 23 M/s Puerto life Sciences Private Limited [Note (d) Euro head bottle below] 24 M/s Sachin Parenteral Pvt. Ltd. [Note (e) below] “SAFE PORT” 25 M/s Biosynergy Lifecare Pvt. Ltd. [Note (f) below] “BIOPORT” 26. M/s Promea Therapeutics Pvt. Ltd. [Note (g) below] LDPE Bottle/ Non-Glass container with special features Euro head Cap Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In case of M/s Puniska Healthcare Pvt. Ltd.mentioned in Sl. No. 19 of Table B, only the prices of the formulations specified in Sl. No. 5, 6, 7 & 8 of Table A are applicable. (c) In case of M/s Higgs Healthcare mentioned in Sl. No. 21 of Table B, only the prices of the formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable. (d) In case of M/s Puerto life Sciences Private Limited mentioned in Sl. No. 23 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable. (e) In case of M/s Sachin Parenteral Pvt. Ltd. mentioned in Sl. No. 24 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5, 6 & 7 of Table A are applicable. (f) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 25 of Table B, only the prices of the formulations specified in Sl. No. 1, 2, 3, 4, 5, 7 & 8 of Table A are applicable. (g) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 26 of Table B, only the prices of the formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable. (h) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (i) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1571(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. No. 4887(E) dated 10.11.2023 and S.O. No. 424(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (j) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (k) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack alongwith documentation and demonstration. (l) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (m) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 79 from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (n) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (o) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (p) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (q) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (r) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director नई दिल्ली, 26 मार्,च 2024 का. आ. 1553(अ).—Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013] dk-vk- 1192¼v½ rkjh[k 22 ekpZ] 2016 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;kas dk iz;ksx djrs gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkns'k dk- vk- 1570¼v½ fnukad 31 ekpZ] 2023, dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½ fnukad 10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024, vkn's k ds vf/kØe.k esa tgk¡ rd, uhps nh xbZ lkj.kh [k es a fofufnZ"V fuekZrk ds fo'k”s k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djrs gq, ftUgas ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd ewY; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la”kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LrHa k ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ es a dh xbZ Øe'k% rRLFkkuh izfof"V;kas esa fofufnZ"V [kqjkd :i ,o a izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LrHa k ¼2½ esa dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;kas es a ls izR;ds dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NkMs +dj vf/kdre dher ds #i esa fu;r djrh gSA @ 0.00551% बढा @ 0.00551% (1) (2) (3) (4) (5) 1 ररंगर लैसटेट इंिेसिन 100 जमली प्रत्येक 100 जमलीलीटर पैक में 29.90 जविेि जविेिताएं ह ैं 2 ररंगर लैसटेट इंिेसिन 250 जमली प्रत्येक 250 जमलीलीटर पैक में 50.9980 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] जविेि जविेिताएं ह ैं 3 ररंगर लैसटेट इंिेसिन 500 जमली प्रत्यके 500 जमलीलीटर पैक में 64.96 जविेि जविेिताएं ह ैं 4 ररंगर लैसटेट इंिेसिन 1000 जमली प्रत्येक 1000 जमलीलीटर पैक में 114.21 जविेि जविेिताएं ह ैं (1) (2) 3 1 मिै ि ि अेबटि डवे वड मल. यिू ोहेड 2 मिै ि ि एटयलू ाइफ हेेिर्केयि प्रा. मलममटेड यिू ोहेड 3 मिै ि ि बी। ब्रौन मेडडर्कल प्रा (इंडडया). मलममटेड यिू ोहेड र्के िाि इर्कोफ्लर्कै प्लि बोतल 4 मिै ि ि फ्रेिेननयि र्काबी इंडडया प्रा. मलममटेड फ़्रीफ़्लटे ि बगै 5 मिै ि ि ओस्तर्कु ा फामािस्यट्रू टर्केि इंडडया प्रा. यिू ोहेड बोतल मलममटेड 6 मिै ि ि डने नि र्केम लेब मलममटेड यिू ोहेड प्रोपलीन बोतल 7 मिै ि ि अमान्ता हेेिर्केयि मलममटेड एफएफएि/बीएफएि 8 मिै ि ि श्री र्कृष्णा र्केशव लेबोिेटिीज मलममटेड यिू ोहेड 9 मिै ि ि अटिा पिै ेंटेि मलममटेड यिू ोहेड र्के िाि स्टेरिडडप 10 मिै ि ि रुिोमा लेबोिेटिीज मलममटेड यिू ोहेड एफएफएि बोतल 11 मिै ि ि आि. र्के. लेबोिेटिीज प्रा० मलममटेड यिू ोहेड बोतल 12 मिै ि ि रियलर्केड लाईफिाइिं प्रा० मलममटेड ववशषे िवु विाओं र्के िाि गिै -ललाि 13. मिै ि िअबरै िि हेेिर्केयि प्रा० मलममटेड (नीर्े ववशषे िवु विाओं र्के िाि गिै -ललाि 14. मिै ि िट्रहलि हेेिर्केयि (नीर्े ववशषे िवु विाओं र्के िाि गिै -ललाि 15. मिै ि ि रूिोमा लेबोिेटिीज प्रा०मलममटेड (नीर्े यिू ोहेड बोटल ड्यडू ड्रप र्के िाि 16. मसै सच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड (नीर्े यिू ोहेड बोतल 17. मसै सच सजर्न पैरेंटेरल प्रा .जलजमटेड (नीर्े "िेफ पोटि" मैससस बायोससनर्जी लाइफके यर प्राइवेट सलसमटेड "बायोपोटस" 18. (नीर्े मैससस प्रोसमया थेरेप्यूसटक्स प्राइवेट सलसमटेड (नीर्े प्रोकै प-आरएल 19.[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 81 0.00551% र्के 2, 3 औि 4 मे दशािई गई र्कीमते र्केवल मैससच मिै ि ि अबैरिि हेेिर्केयि प्रा० मलममटेड ( र्के 13) औि मैिि ि रूिोमा लेबोिेटिीज प्रा०मलममटेड ( र्के 15) पि लागू होंगी . र्के औि 4 मे दशािई गई र्कीमते र्केवल मैिि ि ट्रहलि हेेिर्केयि ( र्के 14) पर लागू होंगी. र्के 3 मे दशािई गई र्कीमते र्केवल मैससच प्यूटो लाइफ साइंसेि प्राइवेट जलजमटेड ( र्के 16), मैससच सजर्न पैरेंटेरल प्रा .जलजमटेड ( र्के 17) औि मैससस प्रोसमया थेरेप्यूसटक्स प्राइवेट सलसमटेड ( र्के 19) पि लागू होंगी . र्के औि 4 मे दशािई गई र्कीमते र्केवल मैससस बायोससनर्जी लाइफके यर प्राइवेट सलसमटेड ( र्के 18) पि लागू होंगी. (5) dk- vk- 1570¼v½ fnukad 31 ekpZ] 2023, dk- vk- 4663¼v½ fnukad 25.10.2023, dk- vk- 4888¼v½ fnukad 10.11.2023 vkSj dk- vk- 425¼v½ fnukad 02.02.2024 0.00551% (5) (ञ) यदि संिोधन दकया िाता ह ै तो, इसकी सूर्ना ऐसे संिोधनों को दकए िान े के पंद्रह दिनों के भीतर की अवजध में प्रपत्र-।। के रूप में इलेसरॉजनक अथवा वास्ट्तजवक दकसी भी तौर पर सरकार को अग्रेजित की िाएगी और इस उप-पैराग्राफ के तहत सर्ू ना प्रस्ट्तुत नहीं दकए िान े को अजधकतम खुिरा मूल्य में संिोधन नहीं दकया िाना माना िाएगा और संबंजधत जनमाचता अजधक िुल्क लेन े की जतजथ स े उस पर ब्याि सजहत पूव-च संिोजधत अजधकतम खुिरा मूल्य (एमआरपी) से अजधक की राजि िमा करने के जलए उत्तरिायी होगा। V82 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (4) ड (1) u II I ढ II III II IV ण त [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] यमिंवका पंवार, सह यक मनदेशक ORDER New Delhi, the 26th March, 2024 S.O. 1553(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. 4888(E) dated 10.11.2023 and S.O. 425(E) dated 02.02.2024 in so far as it relates to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. Medicines Dosage form and Unit Ceiling price No. Strength (w.e.f.01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Ringer lactate Injection100 ml Each 100 ml pack having special 29.90 features 2 Ringer lactate Injection 250 ml Each 250 ml pack having special 50.99 features[भाग II—खण् ड 3(ii)] भारत का रािपत्र : असाधारण 83 3 Ringer lactate Injection 500 ml Each 500 ml pack having special 64.96 features 4 Ringer lactate Injection 1000 ml Each 1000 ml pack having special 114.21 features TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s Albert David Ltd. Eurohead 2 M/s Aculife Healthcare Pvt. Ltd. Eurohead 3 M/s B. Braun Medical (India) Pvt. Ltd. Ecoflac Plus bottle with Eurohead 4 M/s Fresenius Kabi India Pvt. Ltd. Freeflex bags 5 M/s Ostuka Pharmaceuticals India Pvt. Ltd. Eurohead bottle 6 M/s Denis Chem lab Ltd. Eurohead Propylene Bottle 7 M/s Amanta Healthcare Ltd. FFS/BFS 8 M/s Shree Krishna Keshav Laboratories Ltd. Eurohead 9 M/s AxaParenterals Ltd. Steridip with Eurohead 10 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 11 M/s R. K. Laboratories Pvt. Ltd. Eurohead Bottle 12 M/s Realcade Lifescience Pvt. Ltd. Non-glass with special features 13 M/s Abaris Healthcare Pvt. Ltd (Note (b) below) Non-glass with special features 14 M/s Higgs Healthcare (Note (c) below) Non-glass with special features 15 M/s Rusoma Laboratories Pvt. Ltd. (Note (b) below) “Dewdrip” 16 M/s Puerto life Sciences Private Limited (Note (d) below) Eurohead bottle 17 M/s Sachin Parenteral Pvt. Ltd. (Note (d) below) “SAFE PORT” 18 M/s Biosynergy Lifecare Pvt. Ltd. (Note (e) below) “BIOPORT” 19 M/s Promea Therapeutics Pvt. Ltd. (Note (d) below) PROCAP-RL Notes: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) In case of M/s Abaris Healthcare Pvt. Ltd. (Sl. No. 13 of Table B) & M/s Rusoma Laboratories Pvt. Ltd. (Sl. No. 15 of Table B), only the prices of the formulations specified in Sl. No. 2, 3 & 4 of Table A are applicable. (c) In case of M/s Higgs Healthcare mentioned in Sl. No. 14 of Table B, only the prices of the formulations specified in Sl. No. 3 & 4 of Table A are applicable. (d) In case of M/s Puerto life Sciences Private Limited (Sl. No. 16 of Table B), M/s Sachin Parenteral Pvt. Ltd. (Sl. No. 17 of Table B) & M/s Promea Therapeutics Pvt. Ltd. (Sl. No. 19 of Table B), only the prices of the formulations specified in Sl. No. 3 of Table A are applicable. (e) In case of M/s Biosynergy Lifecare Pvt. Ltd. mentioned in Sl. No. 18 of Table B, only the prices of the formulations specified in Sl. No. 3 & 4 of Table A are applicable (f) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and84 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (g) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. 1570(E) dated 31.03.2023, S.O. 4663(E) dated 25.10.2023, S.O. 4888(E) dated 10.11.2023 and S.O. 425(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over the year 2022 in accordance with paragraph 16(2) of DPCO, 2013. (h) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (i) Any other manufacturer claiming separate ceiling price for ringer lactate injection in pack having special features shall apply to NPPA for separate ceiling price approval. (j) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (k) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (l) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (m) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (n) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (o) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (p) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 85 ubZ fnYyh] 26 ekpZ] 2024 ¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 नवम्बर] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkn's k] 2013 ds iSjk 11 ds mi&iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ds vkn's k dk-vk- 4077¼v½ fnukad 15.09.2023 vkn's k ds vf/kØe.k eas tgk¡ rd mldk lEcU/k uhp s dh lkj.kh ^d* esa fofufeZr से gSA uhp s nh xbZ lkj.kh [k eas fofufnZ"V fuekZrk ds fo"ks'k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djrs gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhp s dh lkj.kh ^d* ds LraHk ¼5½ esa fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LrHa k ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LraHk ¼2½ eas dh xbZ rRLFkkuh izfof"V eas fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds #i es a fu;r djrh gSA @ 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) 1 पििेरपसपिन (ए) + इजं ेक्शन के पिए िाउडर 2 ग्राम (ए) + प्रत्येक‍दोहरे‍चैम्बर‍बैग 250 पमिीग्राम(बी) fo'ks"k fo'ks’krkvks a lfgr 220.27 ताज़ोबैक्टम (बी) 2 पििेरपसपिन (ए) + इजं ेक्शन के पिए िाउडर 4 ग्राम (ए)+ प्रत्येक द़ोहरे चैम्बर बैग fo'ks"k 500 पमिीग्राम(बी) fo'ks’krkvks a lfgr 459.31 ताज़ोबैक्टम (बी) (3) मैससस गुपिक बाय़ोसाइसं ेज पिपमटेड टैज़ोपिक इजं ेक्शन (डीसीबी) 0.00551% 15.09.2023 0.00551%86 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍पैकेजों‍र्ें‍वपपेरवसवलि‍(ए)‍+‍ताजोबैक्टर्‍(बी)‍इंजेक्शि‍के‍वलए‍पाउडर‍ (i) 2‍ग्रार्‍(ए)‍+‍250‍वर्लीग्रार्‍(बी)‍(ii) 4‍ग्रार्‍(ए)+‍500‍वर्लीग्रार्(बी)‍प्रत्येक‍दोहरे‍चैम्बर‍बैग, के‍वलए‍अलग‍ अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍ह‍ैतो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के‍वलए‍एिपीपीए‍को‍आिेदि‍करेगा। यदद‍संशोधि‍दकया‍जाता‍है‍तो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के‍पंद्रह‍ददिों‍के‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-II‍ के‍रूप‍र्ें‍इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के‍तहत‍ सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्‍ेंसंशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ाता ा‍ अवधक‍शुल्क‍लेिे‍की‍वतवथ‍से‍उस‍पर‍ब्याज‍सवहत‍पूिा-संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍अवधक‍की‍रावश‍ जर्ा‍करिे‍के‍वलए‍उत्तरदायी‍होगा। u II I ञ II III II IV [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] युविका‍पंिार, सहायक‍विदशे क ORDER New Delhi, the 26th March, 2024 S.O. 1554(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 4077(E) dated 15.09.2023 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 87 scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. Medicines Dosage form and Strength Unit Ceiling price (wef No. 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Piperacillin (A) + Powder for Per Dual chamber bag with special feature Tazobactam (B) Injection 2 g (A) + 220.27 250 mg(B) 2 Piperacillin (A) + Powder for Per Dual chamber bag with special feature Tazobactam (B) Injection 4 g (A) + 459.31 500 mg(B) TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s Gufic Biosciences Limited Tazofic Injection (DCB) Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 4077(E) dated 15.09.2023 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Piperacillin (A) + Tazobactam (B) Injection (i) Powder for injection 2g (A) + 250gm (B) (ii) 4g (A) + 500gm (B) Per Dual chamber bag having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.88 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ] 2024 ¼v½.— 31.03.2023, 31.03.2023, 25.10.2023, 10.11.2023 02.02.2024 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) 1 र्ेरोविडाजोल गैर-ग्लास‍विशेष‍विशेषताएं‍पैकेज‍के‍वलए‍ प्रवत‍वर्ली 100वर्ली‍पैक‍र्ें‍इंजेक्शि‍(0.5%डब्लू/िी)/‍ 0.25 500‍वर्लीग्रार्/‍100वर्ली 1. र्ैससा‍ओत्सुका‍फार्ाास्यटु टकल‍इंवडया‍प्रा.‍वलवर्टेड यूरोहडे ‍बोतल 2. र्ैससा‍डेविस‍केर्‍लेब‍प्रा०वलवर्टेड‍‍ यूरोहडे ‍प्रोपलीि‍बोतल[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 89 3. र्ैससा‍रूसोर्ा‍लेबोरेटरीज‍प्रा०वलवर्टेड‍‍ यूरोहडे ‍एफएफएस‍बोतल 4. र्ेससा‍सवचि‍पैरेंटेरल‍प्रा.‍वलवर्टेड "सेफ‍पोटा" 5. र्ैससा‍बायोवसिजी‍लाइफकेयर‍प्राइिेट‍वलवर्टेड "बायोपोटा" 6. र्ैससा‍प्रोवर्या‍थेरेप्यूटटक्स‍प्राइिेट‍वलवर्टेड प्रोकैप-एर्टी 0.00551% 31.03.2023, 25.10.2023, 10.11.2023 02.02.2024 0.00551% कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍पैकेजों‍र्ें‍र्ेरोविडाजोल‍इंजेक्शि‍यूरो‍हेड‍के‍साथ‍प्लावस्टक‍बोतल‍र्ें‍ गैर-ग्लास‍कंटेिर‍र्ें‍पैकेज‍के‍वलए‍100वर्ली‍पैक‍र्ें‍इंजेक्शि‍(0.5%डब्लू/िी)/‍500‍वर्लीग्रार्/‍100वर्ली‍विशेष‍ विशेषताएं‍हैं, के‍वलए‍अलग‍अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍है‍तो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के‍वलए‍ एिपीपीए‍को‍आिेदि‍करेगा। यदद‍संशोधि‍दकया‍जाता‍है‍तो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के‍पंद्रह‍ददिों‍के‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-।।‍ के‍रूप‍र्ें‍इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के‍तहत‍ सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्‍ेंसंशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ााता‍ अवधक‍शुल्क‍लेिे‍की‍वतवथ‍से‍उस‍पर‍ब्याज‍सवहत‍पूिा-संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍अवधक‍की‍रावश‍ जर्ा‍करिे‍के‍वलए‍उत्तरदायी‍होगा। u II I90 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ञ II III II IV [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] युविका‍पंिार, सहयक‍विदशे क ORDER New Delhi, the 26th March, 2024 S.O. 1555(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11,14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1576(E) dated 31.03.2023, 1584(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated 10.11.2023 and 426(E) dated 02.02.2024 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index (WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. Medicines Dosage form and Strength Unit Ceiling price (wef No. 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Metronidazole Injection (0.5%w/v) /500mg/100ml Per ml in 100ml pack for packages in non- 0.25 glass with special features TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle 2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle 3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT”[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 91 5 M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT” 6 M/s Promea Therapeutics Pvt. Ltd. PROCAP-MT Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brand name of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1576(E) dated 31.03.2023, 4663(E) dated 25.10.2023, 4889(E) dated 10.11.2023 and 426(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Metronidazole Injection (0.5%w/v) /500mg/ 100ml in 100ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director92 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] ubZ fnYyh] 26 ] 2024 ¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 11 uoEcj] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi iSjk ¼3½ vkSj ¼4½ iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½ ds vkn's k dk- vk- 1575¼v½ fnukad 31.03.2023, dk-vk- 1583¼v½ fnukad 31.03.2023 vkSj dk-vk- 4890¼v½ fnukad 10.11.2023 vkn's k ds vf/kØe.k es a tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d* ls lacaf/kr gSA uhp s nh xbZ lkj.kh [k es a fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k dju s dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhps dh lkj.kh ^d* ds LraHk ¼5½ es a fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa dh xbZ Øe'k% rRLFkkuh izfof"V;ks a es a fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LrHa k ¼2½ eas dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dkbs Z gS] dk s NksM+dj vf/kdre dher ds #i eas fu;r djrh gSA 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) 1 र्ेंिीटोल‍‍ गैर-ग्लास‍विशेष‍विशेषताएं‍पैकेज‍के‍वलए‍ प्रवत‍वर्ली 0.40 100वर्ली‍पैक‍र्ें‍‍इंजेक्शि‍20% 1. र्ैससा‍ओत्सुका‍फार्ाास्यटु टकल‍इंवडया‍प्रा.‍वलवर्टेड यूरोहडे ‍बोतल 2. र्ैससा‍डेविस‍केर्‍लेब‍प्रा०वलवर्टेड‍‍ यूरोहडे ‍प्रोपलीि‍बोतल 3. र्ैससा‍रूसोर्ा‍लेबोरेटरीज‍प्रा०वलवर्टेड‍‍ यूरोहडे ‍एफएफएस‍बोतल 4. र्ेससा‍सवचि‍पैरेंटेरल‍प्रा.‍वलवर्टेड "सेफ‍पोटा" 5. र्ैससा‍बायोवसिजी‍लाइफकेयर‍प्राइिेट‍वलवर्टेड "बायोपोटा" @0.00551% 31.03.2023, 31.03.2023 10.11.2023[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 93 0.00551% कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍पैकेजों‍र्ें‍र्ेंिीटोल‍यूरो‍हेड‍के‍साथ‍प्लावस्टक‍बोतल‍र्ें‍गैर-ग्लास‍कंटेिर‍ र्ें‍पैकेज‍के‍वलए‍100‍वर्ली‍पैक‍र्ें‍इंजेक्शि‍20%‍की‍विशेष‍विशेषताएं‍ह,ैं के‍वलए‍अलग‍अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍ ह‍ैतो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के‍वलए‍एिपीपीए‍को‍आिेदि‍करेगा। यदद‍संशोधि‍दकया‍जाता‍ह‍ैतो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के‍पंद्रह‍ददिों‍के‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-।।‍के‍ रूप‍र्ें‍इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के‍तहत‍ सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्ें‍संशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ााता‍ अवधक‍शुल्क‍लेिे‍की‍वतवथ‍से‍उस‍पर‍ब्याज‍सवहत‍पूिा-संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍अवधक‍की‍रावश‍ जर्ा‍करिे‍के‍वलए‍उत्तरदायी‍होगा। u II I (ञ) II III II IV [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] युविका‍पंिार, सहायक‍विदशे क ORDER New Delhi, the 26th March, 2024 S.O. 1556(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. No. 1575(E) dated 31.03.2023, S. O. No. 1583(E) dated 31.03.2023 and S.O. No. 4890(E) dated94 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 10.11.2023 in so far as it relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: TABLE A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. No. Medicines Dosage form and Strength Unit Ceiling price (wef 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Mannitol Injection 20% in 100 ml pack for packages in Per ml 0.40 non-glass with special features TABLE ‘B’ Sl. No. Name of Manufacturer Product /Brand Name (1) (2) (3) 1 M/s. Otsuka Pharmaceutical India Private Ltd. Eurohead bottle 2 M/s. Denis Chem Lab Ltd. Eurohead Propylene Bottle 3 M/s. Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 4 M/s. Sachin Parenteral Pvt. Ltd. “SAFE PORT” 5 M/s. Biosynergy Lifecare Pvt. Ltd. “BIOPORT” Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brandnameof scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O. No. 1575(E) dated 31.03.2023, S.O. No. 1587(E) dated 31.03.2023 and S.O. No. 4890(E) dated 10.11.2023 read with corrigendum (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Mannitol Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 95 (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ] 2024 ¼v½.—Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky; }kjk tkjh dk-vk- 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk-vk- 5249¼v½ rkjh[k 22 uoEcj] 2022 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 11 ds mi&iSjk ¼3½ vkSj ¼4½, iSjk 14 vkSj 16 }kjk iznRr 'kfDr;ks a dk iz;ksx djr s gq, rFkk Hkkjr ljdkj ds jlk;u vkSj moZjd e=a ky;] ¼jk"Vªh; vkS"k/k eYw ; fu/kkZj.k izkf/kdj.k½ ds 'kqf)&i= vkn's k dk-vk- 1569¼v½ fnukad 31.03.2023, dk-vk- 4891¼v½ fnukad 10.11.2023 vkSj dk-vk- 427¼v½ fnukad 02.02.2024 vkns'k ds vf/kØe.k es a tgk¡ rd mldk lEcU/k uhps dh lkj.kh ^d*] uhp s nh xbZ lkj.kh [k eas fofufnZ"V fuekZrk ds fo'ks"k mRikn ,oa iSsd vkdkj] mu ckrks a ds flok; vf/kØkUr djr s gq, ftUgs a ,sl s vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k] ,rn~}kjk] Fkksd eYw ; lwpdkad ¼MCY;wihvkbZ½] 2023 ij vk/kkfjr la'kks/ku djrk gS] tSlk fd uhp s dh lkj.kh ^d* ds LraHk ¼5½ eas fofufnZ"V gS] vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ eas dh xbZ Øe'k% rRLFkkuh izfof"V;ks a eas fofufnZ"V [kqjkd :i ,oa izcyrk vkSj bdkbZ ¼;wfuV½@iSdsftax lfgr ml lkj.kh ds LrHa k ¼2½ eas dh xbZ rRLFkkuh izfof"V es a fofufnZ"V vuqlwfpr fofufeZfr;ks a eas ls izR;sd dh oLrq ,oa lsok dj] ;fn dkbs Z gS] dks NksM+dj vf/kdre dher ds #i es a fu;r djrh gSA 0.00551% (@ 0.00551% (1) (2) (3) (4) (5) 1 डेक्सरोज‍ गैर-ग्लास‍विशेष‍विशेषताएं‍पैकेज‍के‍वलए‍ प्रवत‍वर्ली 0.24 (ग्लूकोज) 100वर्ली‍पैक‍र्ें‍‍इंजेक्शि‍(25%‍डब्ल्यू‍/िी) 1. र्ैससा‍ओत्सुका‍फार्ाास्यटु टकल‍इंवडया‍प्रा.‍वलवर्टेड यूरोहडे ‍बोतल 2. र्ैससा‍डेविस‍केर्‍लेब‍प्रा०वलवर्टेड‍‍ यूरोहडे ‍प्रोपलीि‍बोतल96 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] 3. र्ैससा‍रूसोर्ा‍लेबोरेटरीज‍प्रा०वलवर्टेड‍‍ यूरोहडे ‍एफएफएस‍बोतल 4. र्ेससा‍सवचि‍पैरेंटेरल‍प्रा.‍वलवर्टेड "सेफ‍पोटा" 5. र्ैससा‍बायोवसिजी‍लाइफकेयर‍प्राइिेट‍वलवर्टेड "बायोपोटा" 6. र्ैससा‍प्रोवर्या‍थेरेप्यूटटक्स‍प्राइिेट‍वलवर्टेड प्रोकैप-डी25 0.00551% 31.03.2023, 10.11.2023 02.02.2024 0.00551% कोई‍अन्य‍विविर्ााता‍जो‍विशेष‍सुविधाओं‍िाले‍पैकेजों‍र्ें‍डेक्सरोज‍(ग्लूकोज)‍यूरो‍हेड‍के‍साथ‍प्लावस्टक‍बोतल‍र्ें‍गैर- ग्लास‍कंटेिर‍र्ें‍पैकेज‍के‍वलए‍100‍वर्ली‍पैक‍र्ें‍इंजेक्शि‍(25%‍डब्ल्यू‍/‍िी)‍की‍विशेष‍विशेषताएं‍ह‍ैं के‍वलए‍अलग‍ अवधकतर्‍र्ूल्य‍का‍दािा‍करता‍ह‍ैतो‍िह‍अलग‍अवधकतर्‍र्ूल्य‍अिुर्ोदि‍के‍वलए‍एिपीपीए‍को‍आिेदि‍करेगा। यदद‍संशोधि‍दकया‍जाता‍ह‍ैतो, इसकी‍सूचिा‍ऐसे‍संशोधिों‍को‍दकए‍जािे‍के‍पंद्रह‍ददिों‍के‍भीतर‍की‍अिवध‍र्ें‍प्रपत्र-।।‍के‍ रूप‍र्ें‍इलेक्रॉविक‍अथिा‍िास्तविक‍दकसी‍भी‍तौर‍पर‍सरकार‍को‍अग्रेवषत‍की‍जाएगी‍और‍इस‍उप-पैराग्राफ‍के‍तहत‍ सूचिा‍प्रस्तुत‍िहीं‍दकए‍जािे‍को‍अवधकतर्‍खुदरा‍र्ूल्य‍र्ें‍संशोधि‍िहीं‍दकया‍जािा‍र्ािा‍जाएगा‍और‍संबंवधत‍विर्ााता‍ अवधक‍शुल्क‍लेिे‍की‍वतवथ‍से‍उस‍पर‍ब्याज‍सवहत‍पूिा-संशोवधत‍अवधकतर्‍खुदरा‍र्ूल्य‍(एर्आरपी)‍से‍अवधक‍की‍रावश‍ जर्ा‍करिे‍के‍वलए‍उत्तरदायी‍होगा। V (ञ) u II I[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 97 II III II IV (ड) bl vkns’k eas mijksDr lkj.kh ds LraHk ¼2½ eas dh xbZ rRLFkkuh izfof"V es a fofufnZ"V ,slh fofufeZfr;ks a ds iSdks a dh vf/kdre dher fu;r gksus ds ifj.kkeLo#i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns’k] ;fn dkbs Z gks] tk s bl vkn’sk ls iwoZ tkjh gq, gSa] Lor% gh vf/kØe.k gks tk;sxa sA [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] युविका‍पंिार, सहायक‍विदशे क ORDER New Delhi, the 26th March, 2024 S.O. 1557(E).—In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11, 14 and 16 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated 02.02.2024 in so far as they relate to formulation packs mentioned in the Table A below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2023 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof: Table A Price Revision as per Annual Wholesale Price Index (WPI) @ 0.00551% increase. Sl. Medicines Dosage form and Strength Unit Ceiling price (wef No 01.04.2024 with WPI @ 0.00551%) (in Rs.) (1) (2) (3) (4) (5) 1 Dextrose Injection (25% w/v) in 100 ml pack for packages Per ml 0.24 (Glucose) in non-glass with special features TABLE ‘B’ Sl. Name of Manufacturer Product /Brand Name No. (1) (2) (3) 1 M/s Otsuka Pharmaceutical India Private Ltd. Eurohead bottle 2 M/s Denis Chem Lab Ltd. Eurohead Propylene Bottle 3 M/s Rusoma Laboratories Pvt. Ltd. Eurohead FFS Bottle 4 M/s Sachin Parenteral Pvt. Ltd. “SAFE PORT” 5. M/s Biosynergy Lifecare Pvt. Ltd. “BIOPORT” 6. M/s Promea Therapeutics Pvt. Ltd. PROCAP-D2598 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Note: (a) The ceiling prices are applicable with effect from 01.04.2024 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 0.00551% for the year 2023 over 2022). (b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled formulations at price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any. (c) The manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling price notified vide S.O.No. 1569(E) dated 31.03.2023, S.O. 4891(E) dated 10.11.2023 and S.O. 427(E) dated 02.02.2024 (plus Goods and Services Tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 0.00551% for year 2023 over 2022 in accordance with paragraph 16(2) of DPCO, 2013. (d) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table. (e) Any other manufacturer claiming separate ceiling price for Dextrose (Glucose) Injection (25% w/v) in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features shall apply to NPPA for separate ceiling price approval. (f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach NPPA for specific price approval for its formulation. (g) Information about the revision, if carried out, shall be forwarded to the Government in either electronic or physical form in Form-II within a period of fifteen days of such revision and non-submission of information under this sub-paragraph shall be construed as non revision of maximum retail price (MRP) and the concerned manufacturer shall be liable to deposit the amount charged over and above the pre-revised maximum retail price (MRP), alongwith interest thereon from the date of overcharging. (h) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (i) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (j) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013. (k) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation. (l) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955. (m) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 99 ubZ fnYyh] 26 ] 2024 ¼v½.—भारत‍सरकार‍के‍रसायि‍और‍उिारक‍र्ंत्रालय‍द्वारा‍जारी‍का.आ.‍1394(अ)‍तारीख‍30‍र्ई, 2013‍ और‍का.आ.‍5249(अ)‍तारीख‍11‍ििम्बर, 2022‍के‍साथ‍पटित‍औषध‍(कीर्त‍वियंत्रण)‍आदशे , 2013‍के‍पैरा‍5,11‍और‍15‍द्वारा‍ प्रदत्त‍शवियों‍का‍प्रयोग‍करते‍हुए, राष्ट्रीय‍औषध‍र्ूल्य‍विधाारण‍प्रावधकरण‍(वजसको‍संविप्त‍रूप‍र्ें‍एिपीपीए‍कहा‍जाता‍ह)ै , िीचे‍की‍ सारणी‍के‍स्तंभ‍(6)‍र्ें‍विविर्दष्टा ‍‍खुदरा‍र्ूल्य‍को‍उि‍सारणी‍के‍स्तंभ‍(3), (4)‍और‍(5)‍र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍विविर्दष्टा ‍प्रबलता, इकाई‍(यूविट)‍और‍विविर्ााता‍और‍विपणि‍कंपवियों‍के‍िार्‍सवहत‍स्तंभ(2)‍र्ें‍की‍तत्स्थािी‍प्रविवष्ट‍र्ें‍से‍प्रत्येक‍की, िस्तु‍एिं‍सेिा‍ कर, यदद‍कोई‍है, को‍छोड़कर‍अवधकतर्‍खुदरा‍र्ूल्य‍के‍रूप‍र्ें‍वियत‍करती‍है तावलका क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फेट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के‍बराबर एबॉट‍हल्े थकेयर‍प्राइिेट‍वलवर्टेड 1 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 14.00 (सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के‍बराबर र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा) वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फेट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के‍बराबर एबॉट‍हल्े थकेयर‍प्राइिेट‍वलवर्टेड 2 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 15.32 (सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के‍बराबर र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा) वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फेट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के‍बराबर र्ैिकाइंड‍फार्ाा‍वलवर्टेड 3 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 15.32 (सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के‍बराबर र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा) वसटावग्लवप्टि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ वपयोवग्लटाजोि‍ओर‍ वसटावग्लवप्टि‍फॉस्फेट‍र्ोिोहाइड्रेट‍आईपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ र्ेटफॉर्र्ाि‍ वसटावग्लवप्टि‍100‍वर्लीग्रार्‍के‍बराबर र्ैिकाइंड‍फार्ाा‍वलवर्टेड 4 हाइड्रोक्लोराइड‍ वपयोवग्लटाजोि‍हाइड्रोक्लोराइड‍आईपी‍ 1 गोली 14.00 (सस्टेंड‍टरलीज)‍गोली वपयोवग्लटाजोि‍15‍वर्लीग्रार्‍के‍बराबर र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वर्लीग्रार्‍(सस्टेंड‍टरलीज‍फॉर्ा) र्ेटोप्रोलोल‍सवक्सिेट‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेससा‍अजंता‍फार्ाा‍वलवर्टेड‍/‍ एक्सटेंडेड‍टरलीज, र्ेटोप्रोलोल‍सवक्सिेट‍आईपी‍47.50‍ र्ेससा‍सि‍फार्ाा‍लेबोरेटरीज‍ एम्लोवडपाइि‍और‍ वर्लीग्रार्‍ईक्यू।‍र्ेटोप्रोलोल‍टारेट‍50‍ वलवर्टेड 5 टेवल्र्सटाि‍गोवलयााँ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) 1 गोली 14.60 एम्लोवडपाइि‍बेवसलेट‍आईपी‍ईक्यू।‍ एम्लोवडपाइि‍5‍वर्.ग्रा. टेवल्र्सटाि‍आईपी‍40‍वर्लीग्रार्100 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) वलिावग्लवप्टि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ र्ेटफॉर्र्ाि‍ वलिावग्लवप्टि‍आईपी‍5‍वर्लीग्रार्‍ वलवर्टेड/र्ैससा‍ल्यूवपि‍वलवर्टेड 6 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ 1 गोली 13.03 (एक्स्टेंडेड‍टरलीज)‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ विटावर्ि‍डी3‍ प्रत्येक‍5‍वर्.ली.‍वसरप‍र्ें: र्ैससा‍रेिेिभेल‍हल्े थकेयर‍ (कोलेकैल्सीफेरोल)‍ कॉलेकैवल्सफेरॉल‍आईपी‍60000‍आईयू प्राइिेट.‍वलवर्टेड‍/‍र्ैससा‍ 7 1 वर्.ली. 12.53 ओरल‍सोल्यूसि एर्क्योर‍फार्ाास्यूटटकल्स‍ वलवर्टेड विटावर्ि‍डी3‍ प्रत्येक‍5‍वर्.ली.‍र्ें‍शावर्ल‍ह:ैं र्ैससा‍रेिेिभेल‍हल्े थकेयर‍प्राइिेट‍ 8 (कोलेकैल्सीफेरोल)‍ कोलेकैवल्सफेरॉल‍आईपी‍(िैिो‍ड्रॉपलेट‍रूप‍र्ें)‍ 1 वर्.ली. वलवर्टेड‍/‍र्ैससा‍इंटास‍ 13.60 ओरल‍सोल्यूसि 60000‍आईयू फार्ाास्यूटटकल्स‍वलवर्टेड वलिावग्लवप्टि‍‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेससा‍र्ोरपेि‍लैबोरेरीज‍ र्ेटफोर्र्ाि‍ वलिावग्लवप्टि‍2.5‍वर्.ग्रा. वलवर्टेड 9 1 गोली 8.97 हाइड्रोक्लोराइड‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ गोली वर्लीग्रार् दफिाइलफ्राइि‍ प्रत्येक‍5‍वर्.ली.‍र्ें: र्ेससा‍वतरुपवत‍र्ेवडकेयर‍ हाइड्रोक्लोराइड, दफिाइलफ्राइि‍हाइड्रोक्लोराइड‍आईपी‍5‍ वलवर्टेड‍/‍र्ेससा‍र्ैकवलयोड्स‍ क्लोरफेविरार्ाइि‍ वर्लीग्रार् फार्ाास्यूटटकल्स‍वलवर्टेड र्ैलेट, पैरावसटार्ोल, क्लोरफेविरार्ाइि‍र्ैलेट‍आईपी‍0.5‍ 10 1 ml 0.95 सोवडयर्‍साइरेट‍और‍ वर्लीग्रार् र्ेन्थॉल‍वसरप पेरावसटार्ोल‍आईपी‍125‍वर्लीग्रार् सोवडयर्‍साइरेट‍आईपी‍60‍वर्लीग्रार् र्ेन्थॉल‍आईपी‍1‍वर्लीग्रार् पैरावसटार्ोल, प्रत्येक‍अलेवपत‍गोवलयााँ‍र्ें: र्ेससा‍आज्ञा‍बायोटेक‍प्रा.‍ दफिाइलफ्राइि‍ पेरावसटार्ोल‍आईपी‍500‍वर्लीग्रार् वलवर्टेड/र्ैससा‍र्ैकवलयोड्स‍ हाइड्रोक्लोराइड, दफिाइलफ्राइि‍हाइड्रोक्लोराइड‍आईपी‍5‍ फार्ाास्यूटटकल्स‍वलवर्टेड 11 कैफीि‍और‍ वर्लीग्रार् 1 गोली 3.70 वडफेिहाइड्रार्ाइि‍ कैफीि‍(विजाल)‍आईपी‍30‍वर्लीग्रार् हाइड्रोक्लोराइड‍ वडफेिहाइड्रार्ाइि‍हाइड्रोक्लोराइड‍आईपी‍25‍ गोवलयााँ वर्लीग्रार् वलिावग्लवप्टि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ र्ेटफॉर्र्ाि‍ वलिावग्लवप्टि‍5‍वर्.ग्रा. वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 12 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍(एक्स्टेंडेड‍टरलीज‍ 1 गोली वलवर्टेड 11.60 (एक्स्टेंडेड‍टरलीज)‍ के‍रूप‍र्ें)‍आईपी‍500‍वर्लीग्रार् गोवलयााँ सेफपोडोक्साइर्‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍ब्ूक्स‍लैबोरेटरीज‍वलवर्टेड‍ पोटेवशयर्‍क्लैिुलैिेट‍ सेफपोडोक्साइर्‍प्रोक्सेटटल‍आईपी‍ /‍र्ैससा‍जर्ाि‍रेर्ेडीज‍ गोली अन्हाईड्रोअस‍सेफपोडोक्साइर्‍200‍वर्.ग्रा.‍के‍ फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड 13 1 गोली 28.49 बराबर पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍ क्लैिुलैिीक‍एवसड‍125‍वर्.ग्रा.‍के‍बराबर सेफपोडोक्साइर्‍ प्रत्येक‍5‍वर्.ली.‍रीकोंस्टीट्यूटेड‍सस्पशें ि‍र्ें: र्ैससा‍ब्ूक्स‍लैबोरेटरीज‍वलवर्टेड‍ 14 1 वर्.ली. 4.94 प्रोक्सेटटल‍और‍ सेफपोडोक्साइर्‍प्रोक्सेटटल‍आईपी‍ /‍र्ैससा‍जर्ाि‍रेर्ेडीज‍[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 101 क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) पोटेवशयर्‍क्लैिुलैिेट‍ अन्हाईड्रोअस‍सेफपोडोक्साइर्‍100‍वर्.ग्रा.‍के‍ फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड ओरल‍सस्पेंशि बराबर पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍ क्लैिुलैिीक‍एवसड‍62.50‍वर्.ग्रा.‍के‍बराबर वसवल्िवडवपि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍प्योर‍एंड‍क्योर‍हल्े थकेयर‍ 15 टेवल्र्सटाि‍गोवलयााँ वसल्िीवडपाइि‍आईपी‍10‍वर्लीग्रार् 1 गोली प्राइिेट‍वलवर्टेड‍वलवर्टेड/र्ैससा‍ 10.26 टेवल्र्सटाि‍आईपी‍40‍वर्लीग्रार् कैवडला‍फार्ाास्यूटटकल्स‍वलवर्टेड र्ेफेिैवर्क‍एवसड‍और‍ प्रत्येक‍अलेवपत‍गोवलयााँ‍र्ें: र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ 16 पेरावसटार्ोल‍ र्ेफेिैवर्क‍एवसड‍आईपी‍500‍वर्लीग्रार् 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 3.58 गोवलयााँ पेरावसटार्ोल‍आईपी‍325‍वर्लीग्रार् वलवर्टेड पैंटोप्राजोल‍और‍ प्रत्येक‍एंटटक‍लेवपत‍गॉली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ डोम्पेटरडोि‍गोली पैंटोप्राजोल‍सोवडयर्‍आईपी‍पैंटोप्राजोल‍40‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 17 1 गोली 7.04 वर्.ग्रा.‍के‍बराबर जुिेंटस‍हल्े थकेयर‍वलवर्टेड डोम्पेटरडोि‍आईपी‍10‍वर्लीग्रार् सेफपोडोक्साइर्‍और‍ प्रत्येक‍5‍वर्.ली.‍रीकोंस्टीट्यूटेड‍सस्पशें ि‍र्ें: र्ैससा‍ब्ूक्स‍लैबोरेटरीज‍वलवर्टेड‍ पोटेवशयर्‍क्लैिुलैिेट‍ सेफपोडोक्साइर्‍प्रोक्सेटटल‍आईपी‍ /‍र्ैससा‍जर्ाि‍रेर्ेडीज‍ ओरल‍सस्पेंशि अन्हाईड्रोअस‍सेफपोडोक्साइर्‍50‍वर्.ग्रा.‍के‍ फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड 18 1 वर्.ली. 3.17 बराबर पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍ क्लैिुलैिीक‍एवसड‍31.25‍वर्.ग्रा.‍के‍बराबर एर्ोवक्सवसवलि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍र्वलक‍लाइफसाइंसेज‍प्रा.‍ पोटेवशयर्‍क्लैिुलैिेट‍ एर्ोवक्सवसवलि‍राइहाइड्रेट‍आईपी‍ वलवर्टेड‍/‍र्ैससा‍थेवर्स‍र्ेवडकेयर‍ 19 गोली एर्ोवक्सवसवलि‍250‍वर्.ग्रा.‍के‍बराबर 1 गोली वलवर्टेड 17.46 पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍ क्लैिुलैिीक‍एवसड‍125‍वर्.ग्रा.‍के‍बराबर एर्ोवक्सवसवलि‍और‍ प्रत्येक‍5‍वर्.ली.‍रीकोंस्टीट्यूटेड‍सस्पशें ि‍र्ें: र्ैससा‍र्वलक‍लाइफसाइंसेज‍प्रा.‍ पोटेवशयर्‍क्लैिुलैिेट‍ एर्ोवक्सवसवलि‍राइहाइड्रेट‍आईपी‍ वलवर्टेड‍/‍र्ैससा‍थेवर्स‍र्ेवडकेयर‍ 20 ओरल‍सस्पेंशि एर्ोवक्सवसवलि‍600‍वर्.ग्रा.‍के‍बराबर 1 वर्.ली. वलवर्टेड 3.18 पोटेवशयर्‍क्लैिुलैिेट‍वडलुटेड‍आईपी‍ क्लैिुलैिीक‍एवसड‍42.9‍वर्.ग्रा.‍के‍बराबर एसेक्लोफेिाक, प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍वथओि‍फार्ाास्यूटटकल्स‍ पेरावसटार्ोल‍और‍ एसेक्लोफेिाक‍आईपी‍100‍वर्लीग्रार् वलवर्टेड‍/‍र्ैससा‍जे.बी.‍केवर्कल्स‍ 21 1 गोली 17.84 वथयोकोलवचकोसाइड‍ पेरावसटार्ोल‍आईपी‍325‍वर्लीग्रार् एंड‍फार्ाास्यूटटकल्स‍वलवर्टेड गोली वथयोकोलवचकोसाइड‍आईपी‍4‍वर्लीग्रार् वलिावग्लवप्टि‍‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेससा‍र्ोरपेि‍लैबोरेरीज‍ र्ेटफोर्र्ाि‍ वलिावग्लवप्टि‍2.5‍वर्.ग्रा. वलवर्टेड 22 1 गोली 7.92 हाइड्रोक्लोराइड‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍850‍ गोली वर्लीग्रार् वलिावग्लवप्टि‍‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेससा‍र्ोरपेि‍लैबोरेरीज‍ र्ेटफोर्र्ाि‍ वलिावग्लवप्टि‍2.5‍वर्.ग्रा. वलवर्टेड 23 1 गोली 9.60 हाइड्रोक्लोराइड‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ गोली वर्लीग्रार् रोसुिास्टेटटि‍और‍ प्रत्येक‍हाडा‍वजलेटटि‍कैप्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍ 24 1 कैप्सूल 17.03 क्लोवपडोग्रेल‍कैप्सूल रोसुिास्टेटटि‍कैवल्शयर्‍आईपी‍रोसुिास्टेटटि‍ /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍102 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) 10‍वर्लीग्रार्‍(हल्के‍िारंगी‍रंग‍की‍दफल्र्‍ वलवर्टेड लेवपत‍गोली‍के‍रूप‍र्ें)‍के‍बराबर‍ क्लोवपडोग्रेल‍वबसल्फेट‍आईपी‍क्लोवपडोग्रेल‍ 75‍वर्लीग्रार्‍(दो, हल्के‍भूरे‍रंग‍की‍दफल्र्‍ लेवपत‍गोवलयों‍के‍रूप‍र्ें, प्रत्येक‍र्ें‍ क्लोवपडोग्रेल‍37.5‍वर्लीग्रार्‍होता‍ह)ै‍के‍ बराबर रोसुिास्टेटटि‍और‍ प्रत्येक‍हाडा‍वजलेटटि‍कैप्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍ क्लोवपडोग्रेल‍कैप्सूल रोसुिास्टेटटि‍कैवल्शयर्‍आईपी‍रोसुिास्टेटटि‍ /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍ 20‍वर्लीग्रार्‍(हल्के‍िारंगी‍रंग‍की‍दफल्र्‍ वलवर्टेड लेवपत‍गोली‍के‍रूप‍र्ें)‍के‍बराबर‍ 25 क्लोवपडोग्रेल‍वबसल्फेट‍आईपी‍क्लोवपडोग्रेल‍ 1 कैप्सूल 19.46 75‍वर्लीग्रार्‍(दो, हल्के‍भूरे‍रंग‍की‍दफल्र्‍ लेवपत‍गोवलयों‍के‍रूप‍र्ें, प्रत्येक‍र्ें‍ क्लोवपडोग्रेल‍37.5‍वर्लीग्रार्‍होता‍ह)ै‍के‍ बराबर एटोरिास्टेटटि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ फेिोफाइब्ेट‍गोली एटोरिास्टेटटि‍कैवल्शयर्‍आईपी‍ वलवर्टेड/र्ैससा‍एटरस‍ 26 1 गोली 27.09 एटोरिास्टेटटि‍20‍वर्.ग्रा.‍के‍बराबर लाइफसाइंसेज‍वलवर्टेड फेिोफाइब्ेट‍आईपी‍160‍वर्लीग्रार् एटोरिास्टेटटि, प्रत्येक‍हाडा‍वजलेटटि‍कैप्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍ क्लोवपडोग्रेल‍और‍ एटोरिास्टेटटि‍कैवल्शयर्‍आईपी‍ /‍र्ैससा‍एटरस‍लाइफसाइंसेज‍ एवस्पटरि‍कैप्सूल एटोरिास्टेटटि‍40‍वर्लीग्रार्‍(हरे‍रंग‍की‍ वलवर्टेड पैलेट्स‍के‍रूप‍र्ें)‍के‍बराबर, क्लोवपडोग्रेल‍वबसल्फेट‍आईपी‍क्लोवपडोग्रेल‍ 27 75‍वर्लीग्रार्‍(दो‍लाल‍भूरे‍रंग‍की‍दफल्र्‍ 1 कैप्सूल 13.84 लेवपत‍गोवलयों‍के‍रूप‍र्ें, प्रत्येक‍र्ें‍37.5‍ वर्लीग्रार्‍क्लोवपडोग्रेल‍गोवलयां‍आईपी‍होती‍ ह)ैं‍के‍बराबर, एवस्पटरि‍आईपी‍75‍वर्लीग्रार्‍(एंटेटरक‍ लेवपत‍सफेद‍रंग‍के‍पैलेट्स‍के‍रूप‍र्ें) एटोरिास्टेटटि, और‍ प्रत्येक‍हाडा‍वजलेटटि‍कैप्सूल‍र्ें: र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍ क्लोवपडोग्रेल‍कैप्सूल एटोरिास्टेटटि‍कैवल्शयर्‍आईपी‍ /‍र्ैससा‍एटरस‍लाइफसाइंसेज‍ एटोरिास्टेटटि‍40‍वर्लीग्रार्‍(हरे‍रंग‍की‍ वलवर्टेड गोलाकार‍पैलेट्स‍के‍रूप‍र्ें)‍के‍बराबर, 28 क्लोवपडोग्रेल‍वबसल्फेट‍आईपी‍क्लोवपडोग्रेल‍ 1 कैप्सूल 26.88 75‍वर्लीग्रार्‍(दो‍लाल‍भूरे‍रंग‍की‍दफल्र्‍ लेवपत‍गोवलयों‍के‍रूप‍र्ें, प्रत्येक‍र्ें‍37.5‍ वर्लीग्रार्‍क्लोवपडोग्रेल‍गोवलयां‍आईपी‍होती‍ ह)ैं‍के‍बराबर, वग्लक्लाजाइड‍और‍ प्रत्येक‍अलेवपत‍गोवलयों‍र्ें: र्ैससा‍र्ेडीफोसा‍हल्े थकेयर‍प्राइिेट‍ र्ेटफॉर्र्ाि‍ वग्लक्लाजाइड‍आईपी‍40‍वर्लीग्रार् वलवर्टेड‍/‍र्ैससा‍र्ैिकाइंड‍फार्ाा‍ 29 1 गोली 7.35 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड गोवलयााँ वर्लीग्रार्[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 103 क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) विल्डावग्लवप्टि‍ प्रत्येक‍अलेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ (एसआर)‍और‍ विल्डावग्लवप्टि‍आईपी‍100‍वर्लीग्रार्‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड 30 र्ेटफॉर्र्ाि‍ (सस्टेंडेड‍टरलीज‍फॉर्ा‍के‍रूप‍र्ें) 1 गोली 9.67 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ (एसआर)‍गोवलयााँ वर्लीग्रार्‍(सस्टेंडेड‍टरलीज‍फॉर्ा‍के‍रूप‍र्ें) विल्डावग्लवप्टि‍ प्रत्येक‍अलेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ (एसआर)‍और‍ विल्डावग्लवप्टि‍आईपी‍100‍वर्लीग्रार्‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड 31 र्ेटफॉर्र्ाि‍ (सस्टेंडेड‍टरलीज‍फॉर्ा‍के‍रूप‍र्ें) 1 गोली 10.78 हाइड्रोक्लोराइड‍ र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ (एसआर)‍गोवलयााँ वर्लीग्रार्‍(सस्टेंडेड‍टरलीज‍फॉर्ा‍के‍रूप‍र्ें) डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 32 1 गोली वलवर्टेड/र्ैससा‍अल्केर्‍ 13.24 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ लेबोरेटरीज‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 33 1 गोली वलवर्टेड/र्ैससा‍एटरस‍ 13.24 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ लाइफसाइंसेज‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 34 1 गोली वलवर्टेड/र्ैससा‍एटरस‍ 14.92 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ लाइफसाइंसेज‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ 35 1 गोली 13.43 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ 36 1 गोली 15.11 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍यूएसिी‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्वेपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ 37 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ैिकाइंड‍फार्ाा‍ 15.11 हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर वलवर्टेड (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍104 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 38 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ैिकाइंड‍फार्ाा‍ 13.43 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 39 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 12.50 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 40 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 13.39 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 41 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ेडले‍ 13.43 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ फार्ाास्यूटटकल्स‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 42 1 गोली वलवर्टेड‍/‍र्ैससा‍र्ेडले‍ 15.11 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ फार्ाास्यूटटकल्स‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ 43 1 गोली 13.43 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍ल्यूवपि‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ 44 1 गोली 15.11 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड/र्ैससा‍ल्यूवपि‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार्[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 105 क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 45 1 गोली /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍ 14.44 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍विंडलास‍बायोटेक‍वलवर्टेड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 46 1 गोली /‍र्ैससा‍एर्क्योर‍फार्ाास्यूटटकल्स‍ 16.12 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 47 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 14.29 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍र्ैस्कॉट‍हल्े थ‍सीरीज‍प्रा.‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 48 1 गोली वलवर्टेड/र्ैससा‍र्ाइक्रो‍लैब्स‍ 15.18 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 49 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍डॉ.‍ 14.55 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ रेड्डीज‍लैबोरेटरीज‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 50 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍डॉ.‍ 16.23 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ रेड्डीज‍लैबोरेटरीज‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 51 1 गोली 13.39 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ ब्लू‍क्रॉस‍लेबोरेटरीज‍प्राइिेट‍ और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) वलवर्टेड गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ 52 1 गोली 14.29 र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍106 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर ब्लू‍क्रॉस‍लेबोरेटरीज‍प्राइिेट‍ (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 53 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 16.00 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ इंटास‍फार्ाास्यूटटकल्स‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् डापावग्लफ़्लोवजि, प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ेटफॉर्र्ाि‍ डापावग्लफ्लोवजि‍प्रोपेिेवडओल‍यूएसपी‍ र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ हाइड्रोक्लोराइड‍ डापावग्लफ्लोवजि‍10‍वर्.ग्रा.‍के‍बराबर 54 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 14.55 (एक्स्टेंडेड‍टरलीज)‍ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ इंटास‍फार्ाास्यूटटकल्स‍वलवर्टेड और‍वग्लर्ेपाइराइड‍ वर्लीग्रार्‍(एक्स्टेंडेड‍टरलीज‍के‍रूप‍र्ें) गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: डापावग्लफ्लोवजि, डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍ र्ेटफॉर्र्ाि‍ आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरेटरीज‍ 55 हाइड्रोक्लोराइड‍और‍ 1 गोली 12.98 र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड वग्लर्ेपाइराइड‍ वर्लीग्रार् गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: डापावग्लफ्लोवजि, डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍ र्ेटफॉर्र्ाि‍ आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरेटरीज‍ 56 हाइड्रोक्लोराइड‍और‍ 1 गोली 11.30 र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍1000‍ वलवर्टेड वग्लर्ेपाइराइड‍ वर्लीग्रार् गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: डापावग्लफ्लोवजि, डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍ र्ेटफॉर्र्ाि‍ आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरेटरीज‍ 57 हाइड्रोक्लोराइड‍और‍ 1 गोली 9.91 र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड वग्लर्ेपाइराइड‍ वर्लीग्रार् गोवलयााँ वग्लर्ेवपराइड‍आईपी‍1‍वर्लीग्रार् प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: डापावग्लफ्लोवजि, डैपावग्लफ्लोवजि‍प्रोपेिेवडओल‍र्ोिोहाइड्रेट‍ र्ेटफॉर्र्ाि‍ आईपी‍डैपावग्लफ्लोवजि‍5‍वर्.ग्रा.‍के‍बराबर र्ैससा‍सि‍फार्ाा‍लेबोरेटरीज‍ 58 हाइड्रोक्लोराइड‍और‍ 1 गोली 11.59 र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍500‍ वलवर्टेड वग्लर्ेपाइराइड‍ वर्लीग्रार् गोवलयााँ वग्लर्ेवपराइड‍आईपी‍2‍वर्लीग्रार् एजेलविवडवपि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ र्ेटोप्रोलोल‍सवक्सिेट‍ एजेलविवडपाइि‍आईपी‍16‍वर्लीग्रार् 59 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 15.92 (सस्टेन्ड‍टरलीज)‍ र्ेटोप्रोलोल‍सवक्सिेट‍आईपी‍र्ेटोप्रोलोल‍टारेट‍ टोरेंट‍फार्ाास्यूटटकल्स‍वलवर्टेड गोवलयााँ 25‍वर्लीग्रार्‍(सस्टेन्ड‍टरलीज‍के‍रूप‍र्ें)[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 107 क्रं.‍स.ं विविर्र्वात‍का‍ प्रबलता इकाई विविर्ाता ा‍और‍विपणि‍कंपिी खदु रा‍र्ल्ू य‍ िार्/ब्ाडं ‍का‍िार् (रू.) (1) (2) (3) (4) (5) (6) एजेलविवडवपि‍और‍ प्रत्येक‍दफल्र्‍लेवपत‍वबलायेडा‍गोली‍र्ें: र्ैससा‍एकम्स‍ड्रग्स‍एंड‍ र्ेटोप्रोलोल‍सवक्सिेट‍ एजेलविवडपाइि‍आईपी‍16‍वर्लीग्रार् 60 1 गोली फार्ाास्यूटटकल्स‍वलवर्टेड‍/‍र्ैससा‍ 17.23 (सस्टेन्ड‍टरलीज)‍ र्ेटोप्रोलोल‍सवक्सिेट‍आईपी‍र्ेटोप्रोलोल‍टारेट‍ टोरेंट‍फार्ाास्यूटटकल्स‍वलवर्टेड गोवलयााँ 50‍वर्लीग्रार्‍(सस्टेन्ड‍टरलीज‍के‍रूप‍र्ें) प्रत्येक‍दफल्र्‍लेवपत‍गोवलयााँ‍र्ें: र्ेकोबालावर्ि‍आईपी‍500‍एर्सीजी वजंक‍सल्फेट‍र्ोिोहाइड्रेट‍आईपी‍61.8‍ र्ेकोबालावर्ि, वजंक, वर्लीग्रार्‍(एलेम्नेटल‍वजंक‍22.5‍वर्लीग्रार्‍के‍ कैवल्शयर्‍पेंटोथेिेट, बराबर) र्ेससा‍प्योर‍एंड‍क्योर‍हल्े थकेयर‍ विटावर्ि‍बी6, कैवल्शयर्‍पेंटोथेिेट‍आईपी‍10‍वर्लीग्रार् 61 1 गोली प्रा.‍वलवर्टेड‍/‍र्ैससा‍ब्लू‍क्रॉस‍ 4.97 फोवलक‍एवसड, पाइटरडोवक्सि‍हाइड्रोक्लोराइड‍आईपी‍3‍ लेबोरेटरीज‍प्राइिेट‍वलवर्टेड वियावसिार्ाइड‍और‍ वर्लीग्रार् क्रोवर्यर्‍गोवलयााँ फोवलक‍एवसड‍आईपी‍1.5‍वर्लीग्रार् वियावसिर्ाइड‍आईपी‍50‍वर्लीग्रार् क्रोवर्यर्‍50‍एर्सीजी‍(क्रोवर्यर्‍वपकोवलिेट‍ आईपी‍के‍रूप‍र्ें) सेवफ्रएक्सोि‍और‍ प्रत्येक‍कॉवम्बपैक‍र्ें: र्ैससा‍ईस्ट‍अफ्रीकि‍(इंवडया)‍ सल्बैक्टर्‍इंजेक्शि भाग-‍I ओिरसीज‍/‍र्ैससा‍सॉफ्टडील‍ प्रत्येक‍िाईल‍र्ें: फार्ाास्यूटटकल्स‍प्राइिेट‍वलवर्टेड सेवफ्रएक्सोि‍सोवडयर्‍आईपी‍(स्टेराइल)‍ अन्हाईड्रोअस‍सेवफ्रएक्सोि‍1000‍वर्लीग्रार्‍ के‍बराबर, 62 1 िाईल 140.09 सल्बैक्टर्‍सोवडयर्‍आईपी‍(स्टेराइल)‍ सल्बैक्टर्‍500‍वर्.ग्रा.‍के‍बराबर भाग-‍II (फोर‍रीकोंस्टीट्यूसि) प्रत्येक‍एफएफएस‍एम्पाउल‍र्ें:‍ िाटर‍फोर‍इंजेक्शि‍आईपी‍10‍वर्.ली.108 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] तावलका‍के‍कॉलर्‍(3) और‍(5) र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍विर्दष्टा ‍विविर्ााण‍और‍विपणि‍ कंपवियों‍की‍स्रेंथ‍और‍िार्‍के‍साथ, उपरोि‍तावलका‍के‍कॉलर्‍(2) र्ें‍विर्दष्टा ‍ऐसे‍फॉर्ूालेशि‍के‍खुदरा‍र्ूल्य‍के‍ विधाारण‍के‍पटरणार्स्िरूप, कॉलर्‍(2), (3) और‍(5) र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍यथा‍विर्दष्टा ‍उस‍विविर्ााण‍और‍विपणि‍ कंपवियों‍के‍वलए‍विर्दष्टा ‍स्रेंथ‍के‍साथ‍फॉर्ूालेशि‍के‍खुदरा‍र्ूल्य‍को‍विधााटरत‍करिे‍िाले‍कोई‍र्ूल्य‍आदशे ‍यदद‍इस‍ अवधसूचिा‍से‍पहले‍जारी‍दकए‍गए‍हो, तो‍उसे‍इसका‍स्थाि‍वलया‍र्ािा‍जाएगा। [dk-a la-@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] युविका‍पंिार, सहायक‍विदशे क ORDER New Delhi, the 26th March, 2024 S.O. 1558(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Sitagliptin, Each film coated Bilayered M/s Akums Drugs & Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. / Metformin M/s Abbott Healthcare Sitagliptin Phosphate Hydrochloride Pvt. Ltd. Monohydrate IP eq. to (Sustained Released) 1 Tablet Sitagliptin 100mg 1 Tablet 14.00 Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) Sitagliptin, Each film coated Bilayered M/s Akums Drugs & Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. / Metformin M/s Abbott Healthcare Sitagliptin Phosphate Hydrochloride Pvt. Ltd. Monohydrate IP eq. to (Sustained Released) Sitagliptin 100mg Tablet 2 1 Tablet 15.32 Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form)[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 109 Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Sitagliptin, Each film coated Bilayered M/s Akums Drugs & Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. / Metformin M/s Mankind Pharma Sitagliptin Phosphate Hydrochloride Ltd. Monohydrate IP eq. to (Sustained Released) Sitagliptin 100mg Tablet 3 1 Tablet 15.32 Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 1000mg (Sustained Release Form) Sitagliptin, Each film coated Bilayered M/s Akums Drugs & Pioglitazone and Tablet Contain: Pharmaceuticals Ltd. / Metformin M/s Mankind Pharma Sitagliptin Phosphate Hydrochloride Ltd. Monohydrate IP eq. to (Sustained Released) 4 Tablet Sitagliptin 100mg 1 Tablet 14.00 Pioglitazone Hydrochloride IP eq. to Pioglitazone 15 mg Metformin Hydrochloride IP 500mg (Sustained Release Form) Metoprolol Each film coated bilayered tablet M/s Ajanta Pharma Succinate Extended contains: Limited / M/s Sun Release, Amlodipine Pharma Laboratories Metoprolol Succinate IP and Telmisartan Limited 47.50mg eq. to Metoprolol Tablet 5 Tartrate 50mg (As Extended 1 Tablet 14.60 release) Amlodipine Besilate IP eq. to Amlodipine 5mg Telmisartan IP 40mg Linagliptin & Each film coated bilayered tablet M/s Mascot Health Metformin contains: Series Pvt. Ltd. / M/s 6 Hydrochloride 1 Tablet Lupin Limited 13.03 Linagliptin IP 5mgMetformin (Extended Release) Hydrochloride IP 500mg (As Tablets Extended release) Vitamin D3 Each 5 ml syrup contains: M/s Ravenbhel (Cholecalciferol) Healthcare Pvt. Ltd. / 7 Cholecalciferol IP 60000IU 1 ml 12.53 Oral Solution M/s Emcure Pharmaceuticals Limited Cholecalciferol Each 5ml contains: M/s Ravenbhel (Vitamin D3) Oral Healthcare Pvt. Ltd. / 8 Cholecalciferol IP (In nano 1 ml 13.60 Solution 60000IU M/s Intas Droplet form) 60000IU Pharmaceuticals Ltd. Linagliptin + Each film coated tablet contains: M/s Morepen Metformin Laboratories Limited Linagliptin 2.5mg 9 Hydrochloride 1 Tablet 8.97 Tablet Metformin Hydrochloride IP 500mg 10 Phenylephrine Each 5 ml contains: 1 ml M/s Tirupati Medicare 0.95 Hydrochloride, Limited / M/s Macleods110 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Chlorpheniramine Phenylephrine Hydrochloride IP Pharmaceuticals Limited maleate, 5mg Paracetamol, Chlorpheniramine maleate IP Sodium Citrate & 0.5mg Menthol Syrup Paracetamol IP 125mg Sodium Citrate IP 60mg Menthol IP 1mg Paracetamol, Each uncoated tablet contains: M/s Aagya Biotech Pvt. Phenylephrine Ltd. / M/s Macleods Paracetamol IP 500mg Hydrochloride, Pharmaceuticals Limited Caffeine & Phenylephrine Hydrochloride IP 11 Diphenhydramine 5mg 1 Tablet 3.70 Hydrochloride Caffeine (Anhydrous) IP 30mg Tablet Diphenhydramine Hydrochloride IP 25mg Linagliptin & Each film coated bilayered tablet M/s Mascot Health Metformin contains: Series Pvt. Ltd. / M/s Hydrochloride Micro Labs Ltd. 12 Linagliptin 5mg 1 Tablet 11.60 (Extended Release) Tablets Metformin Hydrochloride (as Extended release) IP 500mg Cefpodoxime & Each film coated tablet contains: M/s Brooks Laboratories Potassium Ltd. / M/s German Cefpodoxime Proxetil IP eq. to Clavulanate Tablets Remedies 13 Anhydrous Cefpodoxime 200mg 1 Tablet 28.49 Pharmaceuticals Private Potassium Clavulanate Diluted Limited IP eq. to Clavulanic Acid 125mg Cefpodoxime Each 5ml reconstituted M/s Brooks Laboratories Proxetil & suspension contains: Ltd. / M/s German Potassium Remedies Cefpodoxime Proxetil IP eq. to Clavulanate Oral Pharmaceuticals Private 14 Anhydrous Cefpodoxime 100mg 1 ml 4.94 suspension Limited Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 62.50mg Cilnidipine and Each film coated tablet contains: M/s Pure and Cure Telmisartan Tablets Healthcare Pvt. Ltd. / 15 Cilnidipine IP 10mg 1 Tablet 10.26 M/s Cadila Telmisartan IP 40mg Pharmaceuticals Ltd. Mefenamic Acid & Each uncoated tablet contains: M/s Mascot Health Paracetamol Tablets Series Pvt. Ltd. / M/s 16 Mefenamic Acid IP 500mg 1 Tablet 3.58 Micro Labs Limited Paracetamol IP 325mg Pantoprazole & Each enteric coated tablet M/s Akums Drugs & Domperidone Tablet contains: Pharmaceuticals Ltd. / M/s Zuventus 17 Pantoprazole Sodium IP eq. to 1 Tablet 7.04 Healthcare Limited Pantoprazole 40mg Domperidone IP 10mg[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 111 Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Cefpodoxime & Each 5ml of reconstituted M/s Brooks Laboratories Potassium suspension contains: Ltd. / M/s German Clavulanate Oral Remedies Cefpodoxime Proxetil IP eq. to suspension Pharmaceuticals Private 18 Anhydrous Cefpodoxime 50mg 1 ml 3.17 Limited Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 31.25mg Amoxycillin and Each film coated tablet contains: M/s Malik Lifesciences Potassium Pvt. Ltd. / Themis Amoxycillin Trihydrate IP eq. to Clavulanate Tablets Medicare Ltd. 19 Amoxycillin 250mg 1 Tablet 17.46 IP Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 125mg Amoxycillin and Each 5ml of Reconstituted M/s Malik Lifesciences Potassium suspension contains: Pvt. Ltd. / Themis Clavulanate Oral Medicare Ltd. Amoxycillin Trihydrate IP eq. to 20 suspenssion 1 ml 3.18 Amoxycillin 600mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 42.9mg Aceclofenac, Each film coated tablet contains: M/s Theon Paracetamol & Pharmaceuticals Ltd. / Aceclofenac IP 100mg Thiocolchicoside M/s J.B. Chemicals & 21 1 Tablet 17.84 Tablets Paracetamol IP 325mg Pharmaceuticals Ltd. Thiocolchicoside IP 4mg Linagliptin + Each film coated tablet contains: M/s Morepen Metformin Laboratories Limited Linagliptin 2.5mg 22 Hydrochloride 1 Tablet 7.92 Tablet Metformin Hydrochloride IP 850mg Linagliptin + Each film coated tablet contains: M/s Morepen Metformin Laboratories Limited Linagliptin 2.5mg 23 Hydrochloride 1 Tablet 9.60 Tablet Metformin Hydrochloride IP 1000mg Rosuvastatin + Each hard gelatin capsule M/s Windlas Biotech Clopidogrel contains: Ltd. / M/s Emcue Capsules Pharmaceuticals Limited Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as light orange coloured film coated 1 24 tablet) 17.03 Capsule Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two, light brown coloured film coated tablets, each containing clopidogrel Tablet 37.5mg Rosuvastatin + Each hard gelatin capsule M/s Windlas Biotech Clopidogrel contains: 1 Ltd. / M/s Emcue 25 19.46 Capsules Capsule Pharmaceuticals Limited Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (as light112 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) orange coloured film coated tablet) Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two, light brown coloured film coated tablets, each containing clopidogrel Tablet 37.5mg Atorvastatin and Each film coated tablet contains: M/s Mascot Health Fenofibrate Tablets Series Pvt. Ltd. / M/s Atorvastatin Calcium IP eq. to 26 1 Tablet Eris Lifesciences 27.09 Atorvastatin 20mg Limited Fenofibrate IP 160mg Atorvastatin, Each hard gelatine capsule M/s Windlas Biotech Clopidogrel & contains: Limited / M/s Eris Aspirin Capsule Lifesciences Ltd. Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green coloured pellets), 1 27 Clopidogrel Bisulphate IP eq. to 13.84 Capsule Clopidogrel 75mg (As two reddish brown coloured film coated tablet, each containg 37.5mg Clopidogrel Tablets IP), Aspirin IP 75mg (As enteric coated white-coloured pellets) Atorvastatin & Each hard gelatine capsule M/s Windlas Biotech Clopidogrel Capsule contains: Limited / M/s Eris Lifesciences Ltd. Atorvastatin Calcium IP eq. to Atorvastatin 40mg (As green coloured spherical pellets), 1 28 26.88 Capsule Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two reddish brown coloured film coated tablet, each containg 37.5mg Clopidogrel Tablets IP), Gliclazide & Each uncoated tablets contains: M/s Mediforce Metformin Healthcare Pvt ltd / M/s Gliclazide IP 40mg 29 Hydrochloride 1 Tablet Mankind Pharma Ltd 7.35 Tablets Metformin Hydrochloride IP 500mg Vildagliptin (SR) & Each uncoated bilayered tablet M/s Mascot Health Metformin contains: Series Pvt. Ltd. / M/s Hydrochloride (SR) USV Private Limited Vildagliptin IP 100mg (As Tablets 30 Sustained release form) 1 Tablet 9.67 Metformin Hydrochloride IP 500mg (As Sustained release form) Vildagliptin (SR) & Each uncoated bilayered tablet M/s Mascot Health 31 Metformin contains: 1 Tablet Series Pvt. Ltd. / M/s 10.78 Hydrochloride (SR) USV Private Limited Vildagliptin IP 100mg (As[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 113 Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Tablets Sustained release form) Metformin Hydrochloride IP 1000mg (As Sustained release form) Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 32 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 13.24 (Extended Release) Alkem Laboratories and Glimepiride Metformin Hydrochloride IP Limited Tablets 500mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 33 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 13.24 (Extended Release) Eris Lifesciences and Glimepiride Metformin Hydrochloride IP Limited Tablets 500mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 34 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 14.92 (Extended Release) Eris Lifesciences and Glimepiride Metformin Hydrochloride IP Limited Tablets 500mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health Hydrochloride 35 eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 13.43 (Extended Release) USV Private Limited and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 36 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 15.11 (Extended Release) USV Private Limited and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release) Glimepiride IP 2 mg Dapagliflozin, Each film coated bilayered tablet Metformin contains: M/s Mascot Health Hydrochloride 37 1 Tablet Series Pvt. Ltd. / M/s 15.11 (Extended Release) Dapagliflozin Propanediol USP Mankind Pharma Ltd. and Glimepiride eq. to Dapagliflozin 10mg Tablets Metformin Hydrochloride IP114 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) 500mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet contains: Dapagliflozin, Metformin Dapagliflozin Propanediol USP M/s Mascot Health 38 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 13.43 (Extended Release) Mankind Pharma Ltd. and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 39 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 12.50 (Extended Release) Micro Labs Limited and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet contains: Dapagliflozin, Metformin Dapagliflozin Propanediol USP M/s Mascot Health 40 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 13.39 (Extended Release) Micro Labs Limited and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 41 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 13.43 (Extended Release) Medley Pharmaceuticals and Glimepiride Metformin Hydrochloride IP Ltd. Tablets 500mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 42 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 15.11 (Extended Release) Medley Pharmaceuticals and Glimepiride Metformin Hydrochloride IP Ltd. Tablets 500mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin M/s Mascot Health Hydrochloride Dapagliflozin Propanediol USP 43 1 Tablet Series Pvt. Ltd. / M/s 13.43 (Extended Release) eq. to Dapagliflozin 10mg Lupin Limited and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release)[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 115 Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 44 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 15.11 (Extended Release) Lupin Limited and Glimepiride Metformin Hydrochloride IP Tablets 500mg (As Extended release) Glimepiride IP 2 mg Each film coated tablet contains: Dapagliflozin, Metformin Dapagliflozin Propanediol USP Hydrochloride eq. to Dapagliflozin 10mg M/s Windlas Biotech 45 1 Tablet Limited / M/s Emcure 14.44 (Extended Release) Metformin Hydrochloride IP Pharmaceuticals Limited and Glimepiride 1000mg (As Extended release) Tablets Glimepiride IP 1 mg Each film coated tablet contains: Dapagliflozin, Metformin Dapagliflozin Propanediol USP Hydrochloride eq. to Dapagliflozin 10mg M/s Windlas Biotech 46 1 Tablet Limited / M/s Emcure 16.12 (Extended Release) Metformin Hydrochloride IP Pharmaceuticals Limited and Glimepiride 1000mg (As Extended release) Tablets Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 47 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 14.29 (Extended Release) Micro Labs Limited and Glimepiride Metformin Hydrochloride IP Tablets 1000mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Mascot Health 48 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Series Pvt. Ltd. / M/s 15.18 (Extended Release) Micro Labs Limited and Glimepiride Metformin Hydrochloride IP Tablets 1000mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol eq. to M/s Akums Drugs & 49 Hydrochloride Dapagliflozin 10mg 1 Tablet Pharmaceuticals Ltd. / 14.55 (Extended Release) Dr. Reddy's Laboratories and Glimepiride Metformin Hydrochloride IP Limited Tablets 1000mg (As Extended release) Glimepiride IP 1 mg Dapagliflozin, Each film coated bilayered tablet M/s Akums Drugs & 50 Metformin contains: 1 Tablet Pharmaceuticals Ltd. / 16.23 Hydrochloride Dr. Reddy's Laboratories116 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) (Extended Release) Dapagliflozin Propanediol eq. to Limited and Glimepiride Dapagliflozin 10mg Tablets Metformin Hydrochloride IP 1000mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin M/s Akums Drugs and Dapagliflozin Propanediol USP 51 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Pharmaceuticals Ltd. / 13.39 (Extended Release) M/s Blue Cross and Glimepiride Metformin Hydrochloride IP Laboratories Pvt. Ltd. Tablets 1000mg (As Extended release) Glimepiride IP 1 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and 52 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Pharmaceuticals Ltd. / 14.29 (Extended Release) M/s Blue Cross and Glimepiride Metformin Hydrochloride IP Laboratories Pvt. Ltd. Tablets 1000mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and 53 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Pharmaceuticals Ltd. / 16.00 (Extended Release) M/s Intas and Glimepiride Metformin Hydrochloride IP Pharmaceuticals Ltd. Tablets 1000mg (As Extended release) Glimepiride IP 2 mg Each film coated bilayered tablet Dapagliflozin, contains: Metformin Dapagliflozin Propanediol USP M/s Akums Drugs and 54 Hydrochloride eq. to Dapagliflozin 10mg 1 Tablet Pharmaceuticals Ltd. / 14.55 (Extended Release) M/s Intas and Glimepiride Metformin Hydrochloride IP Pharmaceuticals Ltd. Tablets 1000mg (As Extended release) Glimepiride IP 1 mg Each film coated tablet contains: Dapagliflozin Propanediol Dapagliflozin, Monohydrate IP eq. to 55 Metformin Dapagliflozin 5mg 1 Tablet M/s Sun Pharma 12.98 Hydrochloride and Laboratories Limited Glimepiride Tablets Metformin Hydrochloride IP 1000mg Glimepiride IP 2 mg Dapagliflozin, Each film coated tablet contains: Metformin M/s Sun Pharma 56 Dapagliflozin Propanediol 1 Tablet 11.30 Hydrochloride and Laboratories Limited Monohydrate IP eq. to Glimepiride Tablets Dapagliflozin 5mg[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 117 Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Metformin Hydrochloride IP 1000mg Glimepiride IP 1 mg Each film coated tablet contains: Dapagliflozin Propanediol Dapagliflozin, Monohydrate IP eq. to 57 Metformin Dapagliflozin 5mg 1 Tablet M/s Sun Pharma 9.91 Hydrochloride and Laboratories Limited Glimepiride Tablets Metformin Hydrochloride IP 500mg Glimepiride IP 1 mg Each film coated tablet contains: Dapagliflozin Propanediol Dapagliflozin, Monohydrate IP eq. to 58 Metformin Dapagliflozin 5mg 1 Tablet M/s Sun Pharma 11.59 Hydrochloride and Laboratories Limited Glimepiride Tablets Metformin Hydrochloride IP 500mg Glimepiride IP 2 mg Each film coated bilayered tablet contains: Azelnidipine and M/s Akums Drugs & Metoprolol Azelnidipine IP 16mg Pharmaceuticals Ltd. / 59 1 Tablet 15.92 Succinate (Sustained M/s Torrent Metoprolol Succinate IP eq. to Release) Tablet Pharmaceuticals Ltd. Metoprolol Tartrate 25mg (as Sustained release) Each film coated bilayered tablet contains: Azelnidipine and M/s Akums Drugs & Metoprolol Azelnidipine IP 16mg Pharmaceuticals Ltd. / 60 1 Tablet 17.23 Succinate (Sustained M/s Torrent Metoprolol Succinate IP eq. to Release) Tablet Pharmaceuticals Ltd. Metoprolol Tartrate 50mg (as Sustained release) Each film coated tablet contains: Mecobalamin IP 500mcg Zinc Sulphate Monohydrate IP Mecobalamin, Zinc, 61.8mg (eq. to elemental Zinc Calcium 22.5mg) M/s Pure and Cure Pantothenate, Calcium Pantothenate IP 10mg Healthcare Pvt. Ltd. / 61 Vitamin B6, Folic 1 Tablet M/s Blue Cross 4.97 Acid, Niacinamide Pyridoxine Hydrochloride IP Laboratories Private & Chromium 3mg Limited Tablets Folic Acid IP 1.5mg Niacinamide IP 50mg Chromium 50mcg (As Chromium Picolinate IP) Ceftriaxone and Each Combi pack Contains: M/s East African (India) 62 Sulbactam injection 1 Vial Overseas / M/s Softdeal 140.09 Part-I Each vial contains: Pharmaceuticals Private118 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] Sl. Name of the Strength Unit Manufacturer & Retail No. Formulation / Marketing Company Price Brand Name (Rs.) (1) (2) (3) (4) (5) (6) Ceftriaxone Sodium IP (Sterile) Limited eq. to anhydrous Ceftriaxone 1000mg, Sulbactam Sodium IP (Sterile) eq. to Sulbactam 500mg Part-II (For Reconstitution) Each FFS Ampoule contains: Sterile Water for Injection IP 10ml Note: (a) The manufacturer of above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove. (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director ubZ fnYyh] 26 ] 2024 ¼ .— का.आ.‍5249(अ)‍तारीख‍11‍ििम्बर,[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 119 (1) (2) (3) (4) (5) (6) कम्पोजीसि: रेर्ोवग्लफ़्लोवजि‍एटाबोिेट, रेर्ोवग्लफ़्लोवजि‍एटाबोिेट‍100‍ विल्डावग्लवप्टि‍और‍ वर्.ग्रा. र्ैससा‍ग्लेिर्ाका‍ 1. 1 गोली 8.76 र्ेटफॉर्र्ाि‍हाइड्रोक्लोराइड‍ विल्डावग्लवप्टि‍50‍वर्.ग्रा. फार्ाास्यूटटकल्स‍वलवर्टेड गोवलयााँ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍ 500‍वर्लीग्रार् कम्पोजीसि: रेर्ोवग्लफ़्लोवजि‍एटाबोिेट‍100‍ एटाबोिेट, विल्डावग्लवप्टि‍ वर्.ग्रा. र्ैससा‍ग्लेिर्ाका‍ 2. और‍र्ेटफॉर्र्ाि‍ 1 गोली 9.06 विल्डावग्लवप्टि‍50‍वर्.ग्रा. फार्ाास्यूटटकल्स‍वलवर्टेड हाइड्रोक्लोराइड‍गोवलयााँ र्ेटफोर्र्ाि‍हाइड्रोक्लोराइड‍आईपी‍ 1000‍वर्लीग्रार् प्रत्येक‍िाईल‍र्ें: र्ेससा‍बीडीआर‍ सेफ्टावजडाइर्‍और‍ सेफ्टावजडाइर्‍(सेफ्टावजडाइर्‍ फार्ाास्यूटटकल्स‍इंटरिेशिल‍ एविबैक्टर्‍पाउडर‍फोर‍ 3. पेंटाहाइड्रेट‍के‍रूप‍र्ें)‍आईपी‍2‍ग्रार् 1 िाईल प्राइिेट‍वलवर्टेड‍ 1696.43 कोंसंरेट‍फोर‍शोलूसि‍फोर‍ वलवर्टेड/र्ैससा‍िैटको‍फार्ाा‍ इंफ्यूजि एविबैक्टर्‍सोवडयर्‍एविबैक्टर्‍0.5‍ वलवर्टेड ग्रार्‍के‍बराबर I120 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)] तावलका‍के‍कॉलर्‍(3) और‍(5) र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍विर्दष्टा ‍विविर्ााण‍और‍विपणि‍ कंपवियों‍की‍स्रेंथ‍और‍िार्‍के‍साथ, उपरोि‍तावलका‍के‍कॉलर्‍(2) र्ें‍विर्दष्टा ‍ऐसे‍फॉर्ूालेशि‍के‍खुदरा‍र्ूल्य‍के‍ विधाारण‍के‍पटरणार्स्िरूप, कॉलर्‍(2), (3) और‍(5) र्ें‍तत्स्थािी‍प्रविवष्टयों‍र्ें‍यथा‍विर्दष्टा ‍उस‍विविर्ााण‍और‍विपणि‍ कंपवियों‍के‍वलए‍विर्दष्टा ‍स्रेंथ‍के‍साथ‍फॉर्ूालेशि‍के‍खुदरा‍र्ूल्य‍को‍विधााटरत‍करिे‍िाले‍कोई‍र्ूल्य‍आदशे ‍यदद‍इस‍ अवधसूचिा‍से‍पहले‍जारी‍दकए‍गए‍हो, तो‍उसे‍इसका‍स्थाि‍वलया‍र्ािा‍जाएगा। [dk-a l-a@254@122@2024@,Q@Qk- la- 8¼122½@2024@Mhih@,uihih,-&fMoh&II] युविका‍पंिार, सहायक‍विदशे क ORDER New Delhi, the 26th March, 2024 S.O. 1559E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof; TABLE Sl. Name of the Strength Unit Manufacturer & Retail Price No. Scheduled Marketing Company (Rs.) Formulation / Brand Name (1) (2) (3) (4) (5) (6) 1. Composition: Remogliflozin Remogliflozin Etabonate Etabonate, 100mg M/s Glenmark Vildagliptin & 1 Tablet Pharmaceuticals 8.76 Metformin Vildagliptin 50mg Limited Hydrochloride tablets Metformin Hydrochloride IP 500mg tablets 2. Composition: Remogliflozin Remogliflozin Etabonate Etabonate, M/s Glenmark 100mg Vildagliptin & 1 Tablet Pharmaceuticals 9.06 Metformin Vildagliptin 50 mg Limited Hydrochloride tablets Metformin Hydrochloride IP 1000 mg tablets 3. Each vial contains: M/s BDR Ceftazidime and Ceftazidime (As Pharmaceuticals Avibactam powder Ceftazidime pentahydrate) 1Vial Internation Pvt. Ltd. / 1696.43 for concentrate for IP 2gram M/s Natco Pharma solution for infusion Avibactam Sodium eq. to Limited Avibactam 0.5gm Note: (a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.[भाग II—खण्‍ड 3(ii)] भारत‍का‍राजपत्र‍:‍असाधारण 121 (b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table. (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers. (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same. (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies. (f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. (g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded. [PN/254/122/2024/F/F. No. 8(122)/2024/D.P./NPPA-Div.-II] YUVIKA PANWAR, Assistant Director Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064 and Published by the Controller of Publications, Delhi-110054.